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A B S T R A C T
Background
Many people with cancer experience moderate to severe pain that requires treatment with strong opioids, such as oxycodone and
morphine. Strong opioids are, however, not effective for pain in all people, neither are they well-tolerated by all people. The aim of this
review was to assess whether oxycodone is associated with better pain relief and tolerability than other analgesic options for adults with
cancer pain. This is an updated version of the original Cochrane review published in 2015, Issue 2 on oxycodone for cancer-related
pain.
Objectives
To assess the effectiveness and tolerability of oxycodone by any route of administration for pain in adults with cancer.
Search methods
For this update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE
andMEDLINE In-Process (Ovid), Embase (Ovid), Science Citation Index, Conference Proceedings Citation Index - Science (ISI Web
of Science), BIOSIS (ISI), and PsycINFO (Ovid) to November 2016. We also searched four trial registries, checked the bibliographic
references of relevant studies, and contacted the authors of the included studies. We applied no language, date, or publication status
restrictions.
Selection criteria
We included randomised controlled trials (parallel group or cross-over) comparing oxycodone (any formulation or route of adminis-
tration) with placebo or an active drug (including oxycodone) for cancer background pain in adults by examining pain intensity/relief,
adverse events, quality of life, and participant preference.
Data collection and analysis
Two review authors independently extracted data and assessed the included studies using standard Cochrane methodology. We meta-
analysed pain intensity data using the generic inverse variance method, and adverse events using the Mantel-Haenszel method, or
summarised these data narratively along with the quality of life and participant preference data. We assessed the overall quality of the
evidence using GRADE.
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Main results
For this update, we identified six new studies (1258 participants) for inclusion. In total, we included 23 studies which enrolled/
randomised 2648 participants, with 2144 of these analysed for efficacy and 2363 for safety. The studies examined a number of different
drug comparisons.
Pooled analysis of three of the four studies comparing controlled-release (CR) oxycodone to immediate-release (IR) oxycodone showed
that the ability of CR and IR oxycodone to provide pain relief were similar (standardised mean difference (SMD) 0.1, 95% confidence
interval (CI) -0.06 to 0.26; low quality evidence). Pooled analyses of adverse events showed no significant differences between CR and
IR oxycodone for asthenia (risk ratio (RR) 0.58, 95% CI 0.2 to 1.68), confusion (RR 0.78, 95% CI 0.2 to 3.02), constipation (RR
0.71, 95% CI 0.45 to 1.13), dizziness/lightheadedness (RR 0.74, 95% CI 0.4 to 1.37), drowsiness/somnolence (RR 1.03, 95% CI
0.69 to 1.54), dry mouth (RR 1.14, 95% CI 0.48 to 2.75), insomnia (RR 1.04, 95% CI 0.31 to 3.53), nausea (RR 0.85, 95% CI 0.56
to 1.28), nervousness (RR 0.57, 95% CI 0.2 to 1.64), pruritus (RR 1.46, 95% CI 0.65 to 3.25), vomiting (RR 0.66, 95% CI 0.38 to
1.15), and discontinuation due to adverse events (RR 0.6, 95% CI 0.29 to 1.22). The quality of the evidence was very low for all these
adverse events. Three of the four studies found similar results for treatment acceptability.
Pooled analysis of seven of the nine studies comparing CR oxycodone to CRmorphine indicated that pain relief was significantly better
after treatment with CR morphine than CR oxycodone (SMD 0.14, 95% CI 0.01 to 0.27; low quality evidence). However, sensitivity
analysis did not corroborate this result (SMD 0.12, 95% CI -0.02 to 0.26).
Pooled analyses of adverse events showed no significant differences between CR oxycodone and CR morphine for confusion (RR 1.01
95% CI 0.78 to 1.31), constipation (RR 0.98, 95% CI 0.82 to 1.16), dizziness/lightheadedness (RR 0.76, 95% CI 0.33 to 1.76),
drowsiness/somnolence (RR 0.9, 95% CI 0.75 to 1.08), dry mouth (RR 1.01, 95% CI 0.8 to 1.26), dysuria (RR 0.71, 95% CI 0.4 to
1.26), nausea (RR 1.02, 95% CI 0.82 to 1.26), pruritus (RR 0.81, 95% CI 0.51 to 1.29), vomiting (RR 0.94, 95% CI 0.68 to 1.29),
and discontinuation due to adverse events (RR 1.06, 95% CI 0.43 to 2.6). However, the RR for hallucinations was significantly lower
after treatment with CR oxycodone compared to CR morphine (RR 0.52, 95% CI 0.28 to 0.97). The quality of the evidence was very
low for all these adverse events. There were no marked differences in treatment acceptability or quality of life ratings.
The remaining studies either compared oxycodone in various formulations or compared oxycodone to different alternative opioids.
None found any clear superiority or inferiority of oxycodone for cancer pain, neither as an analgesic agent nor in terms of adverse event
rates and treatment acceptability.
The quality of this evidence base was limited by the high or unclear risk of bias of the studies and by imprecision due to low or very
low event rates or participant numbers for many outcomes.
Authors’ conclusions
The conclusions have not changed since the previous version of this review. The data suggest that oxycodone offers similar levels of pain
relief and overall adverse events to other strong opioids including morphine. Although we identified a clinically insignificant benefit on
pain relief in favour of CR morphine over CR oxycodone, this did not persist following sensitivity analysis and so we do not consider
this important. However, in this updated analysis, we found that hallucinations occurred less often with CR oxycodone than with CR
morphine, but the quality of this evidence was very low so this finding should be treated with utmost caution. Our conclusions are
consistent with other reviews and suggest that while the reliability of the evidence base is low, given the absence of important differences
within this analysis it seems unlikely that larger head to head studies of oxycodone versus morphine are justified, although well-designed
trials comparing oxycodone to other strong analgesics may well be useful. For clinical purposes, oxycodone or morphine can be used
as first-line oral opioids for relief of cancer pain in adults.
P L A I N L A N G U A G E S U M M A R Y
Oxycodone for cancer-related pain in adults
Background
Many people with cancer experience moderate to severe pain that requires treatment with strong painkillers that are classified as opioids.
Oxycodone and morphine are examples of these opioids that are used for the relief of cancer pain. However, strong painkillers are not
effective for pain in all people neither are they well-tolerated by all people. The aim of this review was to assess whether oxycodone is
associated with better pain relief and tolerability than other strong painkillers for adults with cancer pain.
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Study characteristics
For this update, in November 2016, we found six more relevant studies. In total, we included 23 studies with 2648 participants. These
studies compared the painkilling ability (benefit) and side effects (harms) of different types of oxycodone to each other or to other
strong painkillers.
Key results
Generally, the studies showed that oxycodone is an equally effective strong painkiller whether taken every six or every 12 hours, and
equally effective as other strong pain killers, such as morphine.
All the strong painkillers examined in the studies were also associated with a number of unwanted effects, such as vomiting, constipation,
anddrowsiness.Overall, these donot differ betweenoxycodone and the other strongpainkillers.Hallucinations (where people experience
imaginary things, e.g. hearing voices) are much less common as a side effect but we found that they were less likely with oxycodone
than within morphine.
Overall, we found that the current evidence is comprised of studies that contained small numbers of participants of which many (19%)
did not complete the studies. However, since there was very little difference between oxycodone and morphine, more research in this
area is unlikely. Studies looking at oxycodone compared to other strong pain killers may be useful.
Quality of the evidence
We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low quality evidence means
that we are very uncertain about the results. High quality evidence means that we are very confident in the results. Overall the quality
of the evidence was low or very low, downgraded because of issues with study quality and size.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
CR oxycodone compared with IR oxycodone for cancer- related pain in adults
Patient or population: adults with cancer-related pain
Settings: in- or outpat ients
Intervention: CR oxycodone
Comparison: IR oxycodone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
IR oxycodone CR oxycodone
Pain intensity
(various pain intensity
scales; SMD)
The mean pain intensity in the CR oxycodone
group was
0.1 standard deviations higher (0.06 lower to 0.
26 higher) than in the IR oxycodone group
SMD 0.1 (-0.06 to 0.26) 578
(3 studies)
⊕⊕©©
low1
-
Const ipat ion
(Event rate)
224 per 1000 159 per 1000
(101 to 253)
RR 0.71
(0.45 to 1.13)
317
(3 studies)
⊕©©©
very low2,3
-
Drowsiness/
somnolence
(Event rate)
224 per 1000 230 per 1000
(154 to 344)
RR 1.03
(0.69 to 1.54)
317
(3 studies)
⊕©©©
very low2,3
-
Nausea
(Event rate)
242 per 1000 206 per 1000
(136 to 310)
RR 0.85
(0.56 to 1.28)
317
(3 studies)
⊕©©©
very low2,3
-
Vomit ing
(Event rate)
174 per 1000 115 per 1000
(66 to 200)
RR 0.66
(0.38 to 1.15)
317
(3 studies)
⊕©©©
very low2,3
-
Quality of lif e No data available, but there appeared to be no dif ferences in treatment acceptability between the treatment groups (measured on various scales, not
pooled); 578 part icipants (3 studies); quality of the evidence low.1
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Part icipant preference No data available. - - - -
* The assumed risk is reported as the observed risk in the control group across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; CR: controlled release; IR: immediate-release; RR: risk rat io; SMD: standardised mean dif ference.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded twice for very serious lim itat ions to study quality due to risk of bias (attrit ion bias and under-report ing of the
domain of select ion bias).
2 Downgraded twice for imprecision due to very low event rates.
3 Downgraded twice for very serious lim itat ions to study quality due to risk of bias (performance/ detect ion bias, and
inadequate t it rat ion and under-report ing of the domains of select ion, performance, detect ion and attrit ion bias, and whether
the part icipants were adequately t it rated).
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B A C K G R O U N D
This review is an update of a previously published review in The
Cochrane Database of Systematic Reviews, 2015, Issue 2 on oxy-
codone for cancer-related pain.
Description of the condition
Pain from cancer can be caused by direct invasion of a tumour into
soft tissue or bone and is often a presenting symptom at the time
of diagnosis of cancer. One European survey published in 2009
found that, of 5000 people with cancer (including 617 commu-
nity-based National Health Service (NHS) patients in the UK),
72% experienced pain (77% of UK patients) which was of mod-
erate to severe intensity in 90% of this group (Breivik 2009). This
is consistent with a systematic review that demonstrated cancer
pain prevalence of up to 75% in advanced disease, and that at least
30% of people with cancer are undertreated (Greco 2014). Recent
research has also shown that less than half of all people with cancer
that die are prescribed a strong opioid, and that median treatment
duration is only nine weeks before death (Ziegler 2016). Pain in
people with cancer may also be caused by cancer treatments and
by comorbid conditions. In this review, we define cancer pain as
pain arising as a direct consequence of the cancer, and not from
other aetiologies.
Description of the intervention
Oxycodone is a strong opioid analgesic indicated for the treat-
ment of moderate to severe chronic pain, including cancer pain.
It is available orally as immediate-release (IR) solution and tablets
(for four-hourly dosing) and as sustained (controlled (CR)) release
tablets (for 12-hourly dosing). It is also available as a parenteral in-
jection. In some countries, oxycodone is available as a compound
with paracetamol (acetaminophen) or ibuprofen.
How the intervention might work
Oxycodone works primarily as an agonist of mu-opioid receptors
in the spinal cord and brain. It has some activity at kappa-opi-
oid receptors (which are also involved in nociception or analgesia)
though the importance of this mechanism in the overall analgesic
effect of oxycodone is unclear. Despite animal studies suggesting
differences in pharmacodynamics, these have not been demon-
strated in clinical studies to date. Therefore, the sharedmechanism
of action to other strong opioids (i.e. agonist activity at mu-opioid
receptors) means that clinical benefits and adverse effects are likely
to be similar. However, important differences exist in the phar-
macokinetics of strong opioids (e.g. morphine undergoes second-
phase elimination via glucuronidation, while oxycodone under-
goes extensive first-phase metabolism via CYP2D6 and CYP3A4
pathways) so clinical equivalence cannot be inferred (Gudin 2012;
Leppert 2010).
Why it is important to do this review
The World Health Organization (WHO) published the Method
for Cancer Pain Relief (WHO analgesic ladder) in 1986 (WHO
1986), which advocates a stepwise approach to analgesia for cancer
pain and revolutionised the use of oral opioids. It recommended
thatmorphine be used first line for moderate to severe cancer pain.
Observational studies have suggested that this approach results
in pain control for 73% of people (Bennett 2008) with a mean
reduction in pain intensity of 65% (Ventafridda 1987).
Many people with cancer experience moderate to severe pain that
requires treatment with strong analgesics. Oxycodone and mor-
phine are examples of strong opioids that are used for the relief of
cancer pain. However, strong opioids are not effective for pain in
all people, neither are they well tolerated by all people. Guidance
by the European Association for Palliative Care on the use of opi-
oids in cancer pain suggests that oxycodone could be used as first-
line treatment of moderate to severe cancer pain as an alternative
to morphine (Caraceni 2012). The aim of this review is to assess
whether oxycodone is associated with better pain relief and toler-
ability than other analgesic options for people with cancer pain.
The protocol for this review was updated from Reid 2010.
O B J E C T I V E S
To assess the effectiveness and tolerability of oxycodone by any
route of administration for pain in adults with cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), with parallel-group or cross-
over design, comparing oxycodone (any formulation and any route
of administration) with placebo or an active drug (including oxy-
codone) for cancer background pain. We did not examine studies
on breakthrough pain.
Types of participants
Adults (aged ≥ 18 years) with cancer pain.
6Oxycodone for cancer-related pain (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of interventions
Oxycodone (any dose, formulation, and route of administration)
versus oxycodone (any dose, formulation, and route of adminis-
tration).
Oxycodone (any dose, formulation, and route of administration)
versus other active drug (any dose, formulation, and route of ad-
ministration).
Oxycodone (any dose, formulation, and route of administration)
versus placebo.
Types of outcome measures
Primary outcomes
• Pain intensity and pain relief, which we have treated as
measures of essentially the same thing, albeit from opposite
starting points (i.e. effectiveness is demonstrated by pain
intensity going down and by pain relief going up). The majority
of the included studies reported pain intensity, with much fewer
studies reporting pain relief. We therefore meta-analysed pain
intensity (see also Measures of treatment effect; Data synthesis)
and not pain relief, but also reported narratively any analyses of
pain relief reported by the included studies.
Both these outcomes had to be participant-reported and could be
reported in any transparent manner (e.g. by using numerical or
verbal rating scales). We did not consider these outcomes when
reported by physicians, nurses, or carers. If possible, we aimed
to distinguish between nociceptive and neuropathic pain, but the
data were not presented in a manner that made this possible.
Secondary outcomes
• Adverse events (e.g. constipation, nausea, vomiting,
drowsiness, confusion, respiratory depression).
• Quality of life (or treatment acceptability as a proxy).
• Participant preference.
We considered all these outcomes as they were reported in the
included studies.
Search methods for identification of studies
We applied no language, date, or publication status (published in
full, published as abstract, unpublished) restrictions to the search.
Electronic searches
For this update, we identified relevant trials by searching the fol-
lowing databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (Issue 10 of 12, 2016);
• MEDLINE and MEDLINE In-Process (Ovid) (1946 to 29
November 2016);
• Embase (Ovid) (1947 to 29 November 2016);
• Science Citation Index (Web of Science) (1899 to 29
November 2016);
• Conference Proceedings Citation Index - Science (Web of
Science) (1990 to 29 November 2016);
• BIOSIS (Web of Science) (1926 to 29 November 2016);
• PsycINFO (Ovid) (1806 to November week 3 2016).
We applied the Cochrane highly sensitive search strategy for iden-
tifying RCTs to this search (Lefebvre 2011). These searches were
run for the original review in March 2014 when PubMed was also
searched. We did not search PubMed for this update as it did not
yield any records that were not found by the other databases in
the original review. The search strategies used can be found in
Appendix 1.
Searching other resources
We
also searched Clinicaltrials.gov (13March 2014), metaRegister of
Controlled Trials (mRCT) (3 March 2014), EU Clinical Trials
Register (3 March 2014), and WHO International Clinical Trials
Registry Platform (ICTRP) (3 March 2014) as complementary
sources for related studies. In an update search run on 6December
2016, we searched Clinicaltrials.gov, EU Clinical Trials Register,
WHO International Clinical Trials Registry Platform (ICTRP),
and UKClinical Trials Gateway (UKCTG), but not metaRegister
of Controlled Trials (mRCT) as this is no longer available, but
rather signposted to EU Clinical Trials Register and UK Clinical
Trials Gateway (UKCTG). For both the previous review and the
update, we checked the bibliographic references of relevant identi-
fied studies to find additional trials not identified by the electronic
searches and contacted authors of the included studies to ask if
they knew of any other relevant studies.
Data collection and analysis
Selection of studies
Two review authors (MSH, NB) assessed the titles and abstracts
of all the studies identified by the search for potential inclusion.
We independently considered the full records of all potentially
relevant studies for inclusion by applying the selection criteria
outlined in the Criteria for considering studies for this review
section. We resolved any disagreements by discussion. We did
not restrict the inclusion criteria by date, language, or publication
status (published in full, published as abstract, unpublished).
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Data extraction and management
Using a standardised data extraction form, two review authors
(MSH, JSH) extracted data pertaining to study design, participant
details (including age, cancer characteristics, previous analgesic
medication, and setting), interventions (including details about
titration), and outcomes. We resolved any disagreements by dis-
cussion. If there were studies for which only a subgroup of the
participants met the inclusion criteria for the current review, we
would have only extracted data on this subgroup provided ran-
domisation had not been broken; however, no such studies were
identified for inclusion.
Assessment of risk of bias in included studies
Two review authors (MSH and JSH or NB) independently as-
sessed the methodological quality of each of the included stud-
ies by using the ’Risk of bias’ assessment method outlined in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). For each study, we assessed the risk of bias for the follow-
ing domains: selection bias (study level; two items; random se-
quence generation and allocation concealment), performance bias
(outcome level; two items; blinding of participants and blinding
of treating personnel), detection bias (outcome level; one item;
blinding of outcome assessment), attrition bias (outcome level;
one item; incomplete outcome data), and reporting bias (study
level; one item; selective reporting). For the question on alloca-
tion concealment, in the absence of explicit explanation about al-
location concealment, we accepted ’central randomisation’ as suf-
ficient indication of adequate allocation concealment and conse-
quently rated such studies as low risk of bias for this item. We
also included an item that assessed the adequacy of titration (with
judgements made based on any available relevant information, in-
cluding design features, inclusion criteria, and interim pain assess-
ments) and another item that captured whether data were available
for both time periods in cross-over trials. Each of the ’Risk of bias’
items required a ’low risk,’ ’high risk,’ or ’unclear risk’ response.
We also documented the reasons for each response in accordance
with Higgins 2011, and resolved any disagreements on the ’Risk
of bias’ ratings through discussion. For the item assessing whether
data were available for both time periods in cross-over trials, we
inputted ’unclear’ and ’not applicable’ as the rating and reason for
parallel-group trials.
Measures of treatment effect
For pain intensity, we extracted themeans and standard deviations
(SD) and we used these to estimate the standardised mean differ-
ence (SMD) between the treatments along with the 95% confi-
dence interval (CI), as the outcome was not measured on the same
scale across studies. For adverse events, we extracted event rates to
calculate risk ratios (RR) with 95% CIs as the summary estimates
(see also Data synthesis).
Unit of analysis issues
The participant was the unit of analysis, but in a number of cases
the data reported in the included cross-over trials could not other-
wise be incorporated into the analyses (see Dealing with missing
data), sowe included them as if the design had been parallel-group.
Higgins 2011 (in Chapter 16) pointed out that this approach,
while giving rise to unit of analysis error, is nevertheless conser-
vative as it results in an underweighting of the data. However,
in order to assess the impact of this strategy, we also performed
sensitivity analyses when we included cross-over trial data in this
manner by excluding the cross-over trials from the meta-analyses.
Dealing with missing data
In cases where data were missing, we contacted the authors to
request the missing data. This strategy did not result in any ad-
ditional data. We limited imputation of missing data to the im-
putation of missing SDs, either by calculating the SD if enough
information was available or by using SDs from similar samples or
studies, both according to the methods outlined byHiggins 2011.
We only imputed SDs for pain intensity for Lux 2014, which were
not reported for the subgroup of participants withmalignant pain,
by using the reported SDs for the whole sample of participants
with either malignant (n = 31) or non-malignant pain (n = 15),
and for Yu 2014 for the primary outcome of the study “mean pain
at its worst in the past 24 hours” by using the standard deviations
for the same outcome measured at baseline in the full analysis set.
We recorded the dropout/missing data rates in the ’Risk of bias’
tables under the items on attrition bias and in the ’Participants’
section of the Characteristics of included studies table, and we
addressed the potential effect of the missing data on the results in
the Discussion. It was not possible to assess the impact of miss-
ing data in sensitivity analyses due to the low number of included
studies within each comparison. In all cases, we aimed to perform
intention-to-treat (ITT) analyses.
Assessment of heterogeneity
We assessed heterogeneity by using the I2 statistic. We considered
I2 values above 50% to represent substantial heterogeneity in line
with Higgins 2011, and we planned to assess potential sources of
heterogeneity through subgroup analyses as outlined in Subgroup
analysis and investigation of heterogeneity.
Assessment of reporting biases
In addition to implementing the comprehensive search strategy
outlined in the Searchmethods for identification of studies section,
the risk of outcome reporting bias was illustrated in the ’Risk of
bias’ summary figures that we constructed for each study and each
type of assessed bias.
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Data synthesis
We entered the data extracted from the included studies into Re-
view Manager 5 (RevMan 2014), which was used for data syn-
thesis. We analysed pain intensity using the generic inverse vari-
ance method in accordance with Higgins 2011. As the I2 statistic
was not above 50%, we used a fixed-effect model. However, given
the limitations of this analysis strategy as outlined in the Unit of
analysis issues section, we also considered the results of the individ-
ual studies. We meta-analysed the adverse events data by using the
Mantel-Haenszel method; however, as this method is not suitable
for cross-over trial data, we only included the data from parallel-
group trials in these analyses. In addition, we have also presented
all reported adverse events from the included studies in tables.
Quality of the evidence
We used the GRADE system to rank the quality of the evidence
using the GRADEprofiler Guideline Development Tool software
(GRADEproGDT 2015), and the guidelines provided inChapter
12.2 of the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011).
TheGRADE approach uses five considerations (study limitations,
consistency of effect, imprecision, indirectness, and publication
bias) to assess the quality of the body of evidence for each outcome.
The GRADE system uses the following criteria for assigning grade
of evidence:
• high: we are very confident that the true effect lies close to
that of the estimate of the effect;
• moderate: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially different;
• low: our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of the
effect;
• very low: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
We decreased the grade rating by one (-1) or two (-2) if we iden-
tified:
• serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
• imprecise (-1) or very imprecise data (-2);
• high probability of reporting bias (-1).
’Summary of findings’ tables
We included two ’Summary of findings’ tables to present the main
findings in a transparent and simple tabular format. In particu-
lar, we included key information concerning the quality of evi-
dence, the magnitude of effect of the interventions examined, and
the sum of available data on the outcomes pain intensity, adverse
events (constipation, drowsiness/somnolence, nausea, and vom-
iting), quality of life (or treatment acceptability as a proxy) and
participant preference.
Subgroup analysis and investigation of heterogeneity
Different aspects of the trials are likely to contribute heterogeneity
to the proposed main analyses. If there were sufficient data, we
therefore planned to perform subgroup analyses based on doses,
titration, formulations (e.g. IR, sustained-release), routes of ad-
ministration (e.g. oral, rectal), length of the trials, and populations
(e.g. opioid-naive participants). We grouped the studies by formu-
lation and route of administration, but as there were insufficient
data, we were unable to perform any further subgroup analyses.
Sensitivity analysis
If sufficient data had been available, we planned to examine the
robustness of the meta-analyses by conducting sensitivity analyses
using different components of the ’Risk of bias’ assessment, partic-
ularly those relating to whether allocation concealment and blind-
ing were adequate. We also planned to conduct further sensitivity
analyses to examine the impact of missing data on the results if a
large proportion of the studies were at an ’unknown’ or ’high risk’
of attrition bias and, finally, we planned to use sensitivity analyses
to examine whether publication status and trial size influenced
the results. Unfortunately, we were unable to perform any such
sensitivity analyses due to the low number of studies within each
comparison.
R E S U L T S
Description of studies
Results of the search
The updated searches of the electronic databases retrieved 345
records (see Electronic searches). Our searches of the trials registers
identified 23 further studies. Our screening of the reference lists
of the included publications did not reveal any additional RCTs.
We therefore had a total of 368 records.
Once duplicates had been removed, we had 267 records. We ex-
cluded 257 records based on titles and abstracts. We obtained the
full text of the remaining 10 records. We excluded five studies for
this update (see Characteristics of excluded studies table). We did
not identify any ongoing studies for this update.
From the search, we included five studies reported in five refer-
ences (Corli 2016; Lux 2014; Su 2015; Yu 2014; Zhang 2014), of
which three had originally been included under ’ongoing studies.’
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Another of the ongoing studies was published in full after the up-
date search, but before the publication of the updated review, and
we also included this study (Zecca 2016), so in total there were
six new studies. For a further description of our screening process,
see the study flow diagram (Figure 1).
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Figure 1. Study flow diagram. PICO: P = patient, problem, or population; I = intervention; C = comparison,
control, or comparator; O = outcome.
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In total, we included 23 studies and excluded 63 studies in this
review. There are six studies awaiting classification, and nine on-
going studies.
Included studies
The six new studies included an additional 1258 randomised par-
ticipants, such that the 23 included studies enrolled/randomised
2648 participants (1347 men, 1109 women; for the remaining
192 participants gender was not specified) with 2144 of these
analysed for efficacy and 2363 for safety. The reported mean/
median ages of the participant populations in the studies ranged
from 45 years to 68.8 years. Eleven of the studies were cross-over
trials (Beaver 1978a; Beaver 1978b; Bruera 1998; Gabrail 2004;
Hagen 1997; Heiskanen 1997; Kalso 1990; Lauretti 2003; Leow
1995; Lux 2014; Stambaugh 2001), and 12 were parallel-group
trials (Corli 2016; Imanaka 2013;Kaplan1998;Mercadante 2010;
Mucci-LoRusso 1998; Parris 1998; Riley 2015; Salzman 1999; Su
2015; Yu 2014; Zecca 2016; Zhang 2014), with eight of the stud-
ies conducted in the USA (Beaver 1978a; Beaver 1978b; Gabrail
2004; Kaplan 1998; Mucci-LoRusso 1998; Parris 1998; Salzman
1999; Stambaugh 2001); two in Canada (Bruera 1998; Hagen
1997); two in Finland (Heiskanen 1997; Kalso 1990); three in
China (Su 2015; Yu 2014; Zhang 2014); three in Italy (Corli
2016; Mercadante 2010; Zecca 2016); and one each in Germany/
Poland/Switzerland (Lux 2014), Australia (Leow 1995), Brazil
(Lauretti 2003), the UK (Riley 2015), and Japan/Korea (Imanaka
2013). The length of the trials ranged from single-dose treatment
to one year, and the studies reported the following comparisons:
• CR oxycodone versus IR oxycodone (Kaplan 1998; Parris
1998; Salzman 1999; Stambaugh 2001);
• CR oxycodone versus extended-release (ER) oxycodone
(Lux 2014);
• CR oxycodone versus CR morphine (Bruera 1998; Corli
2016; Heiskanen 1997; Lauretti 2003; Mercadante 2010;
Mucci-LoRusso 1998; Riley 2015; Zecca 2016; Zhang 2014),
with one of these studies including a further two arms of
transdermal (TD) buprenorphine and TD fentanyl (Corli 2016);
and one of the studies comparing two different brands of slow-
release morphine to CR oxycodone (Zhang 2014);
• CR oxycodone versus CR hydromorphone (Hagen 1997);
• CR oxycodone versus ER hydromorphone (Yu 2014);
• CR oxycodone versus ER oxymorphone (Gabrail 2004);
• CR oxycodone versus ER tapentadol (Imanaka 2013);
• CR oxycodone versus TD fentanyl (Corli 2016; Su 2015);
• CR oxycodone versus TD buprenorphine (Corli 2016);
• intravenous (IV) oxycodone versus rectal oxycodone (Leow
1995);
• IV oxycodone followed by IR oxycodone versus IV
morphine followed by IR morphine (Kalso 1990);
• intramuscular (IM) oxycodone versus oral oxycodone
(Beaver 1978a);
• IM oxycodone versus IM morphine versus IM codeine
(Beaver 1978b).
See also Characteristics of included studies table for further details
about the studies.
Excluded studies
For this update, we excluded five studies. Of the records identified
by the original and the update search, altogether we excluded 63
studies. A number of the studies identified in the searches com-
pared oxycodone in combination with another drug (e.g. nalox-
one or acetaminophen) against oxycodone alone or placebo. Such
studies were not included as they would not answer our primary
question, which concerned the effectiveness of oxycodone for can-
cer pain. The majority of the 63 studies were excluded because
they did not include the population or comparison of interest (36
studies), while others were excluded because they were system-
atic (11) or narrative reviews (six), not RCTs/RCT-based analyses
(seven), letters to the editor (two), or case reports (one). See also
Characteristics of excluded studies table.
Studies awaiting classification
Six studies are awaiting classification because they are either ongo-
ing but of unclear relevance, or published in such a way that not
enough information is available to ascertain whether theymeet the
inclusion criteria (e.g. as an abstract only). In some cases, we have
attempted to contact the authors, but have not successfully ob-
tained a response. We await further information, including study
completion and publication, before we can ascertain their rele-
vance to the current review and classify them accordingly. See also
Characteristics of studies awaiting classification table.
Ongoing studies
Nine studies are ongoing. These studies examine some new drug
comparisons involving oxycodone compared to those reported in
this review, and some comparisons that have already been included.
Upon their completion and publication, we hope to be able to
include data from all of them in future updates of this review. See
also Characteristics of ongoing studies table.
Risk of bias in included studies
See Figure 2 and Figure 3 for summaries of the ’risk of bias’ judge-
ments made for the included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
In all but seven studies, not enough information was reported to
assess whether the methods employed to generate the randomi-
sation sequence and to ensure allocation concealment were ad-
equate. Six of these seven studies were considered to be at low
risk of bias for both items (Corli 2016; Heiskanen 1997; Imanaka
2013; Lux 2014; Yu 2014; Zecca 2016), while the seventh study
was considered at low risk of bias for randomisation sequence but
at unclear risk of bias for allocation concealment (Riley 2015).
Only seven studies reported enough information for us to make a
judgement that the treatment groups were comparable at baseline
(Corli 2016; Imanaka 2013; Kaplan 1998; Riley 2015; Salzman
1999; Su 2015; Zhang 2014). Two further studies reported that
the groups were comparable at baseline apart from there being
more participants with bone metastasis and an Eastern Cooper-
ative Oncology Group (ECOG) performance status of 3 in the
hydromorphone group than in the oxycodone group (Yu 2014),
or there being more participants with a Karnofsky Performance
Status (from 0 to 100) ≤ 70 in the CR oxycodone group than in
the CRmorphine group (Zecca 2016). In the remaining studies, it
was unclear whether the participant selection methods employed
had resulted in comparable, balanced groups at the start of the
study.
Blinding
The problem of under-reporting was also an issue when assign-
ing risk of bias estimates to the items assessing performance and
detection bias, that is, blinding. In no instance was it directly
and unequivocally reported who was blinded, so we had to infer,
on the basis of supplementary information, whether we were rea-
sonably certain that blinding had been adequately executed for a
given individual (that is, participant, treating personnel, outcome
assessors, or a combination of these, where not the participants
themselves). On this basis, the risk of performance bias was con-
sidered to be low for the primary outcome of pain in 13 of the
studies (Beaver 1978a; Beaver 1978b; Bruera 1998; Hagen 1997;
Heiskanen 1997; Imanaka 2013; Kaplan 1998; Lauretti 2003; Lux
2014; Mucci-LoRusso 1998; Parris 1998; Stambaugh 2001; Yu
2014), unclear in four studies (Gabrail 2004;Kalso 1990; Su 2015;
Zhang 2014), and high in six of the studies that were all described
as open-label (Corli 2016; Leow 1995; Mercadante 2010; Riley
2015; Salzman 1999; Zecca 2016). For adverse events, the risk
of performance bias was low in 11 studies (Beaver 1978a; Beaver
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1978b; Bruera 1998; Hagen 1997; Imanaka 2013; Kaplan 1998;
Lauretti 2003; Lux 2014;Mucci-LoRusso 1998; Stambaugh 2001;
Yu 2014), unclear in six studies (Gabrail 2004; Heiskanen 1997;
Kalso 1990; Parris 1998; Su 2015; Zhang 2014), and high in the
same six open-label studies as was the case for pain (Corli 2016;
Leow 1995; Mercadante 2010; Riley 2015; Salzman 1999; Zecca
2016). The pattern of judgements was identical for detection bias,
for both outcomes. This was the case for the primary outcome of
pain because, according to our criteria, this outcome had to be
participant reported. It was therefore at risk of detection bias to
the same extent that it was at risk of performance bias since both
depend on participant blinding. As is also evident from the bias
judgements (see Characteristics of included studies table), when a
study was described as double-blind but did not describe who was
blinded, additional information in the studies generally led us to
the conclusion that at least the participants seemed to be blinded,
although we did not feel able to gauge with sufficient confidence
who else might have been blinded. Given that it was not always
clear who assessed the adverse events, this accounts for the similar
judgements for performance and detection bias for this outcome.
Incomplete outcome data
Overall the data from only 81% of the total number of enrolled/
randomised participants were analysed for pain and 89.2% for
adverse events, which indicates that attrition bias was a substan-
tial problem in this data set, with only seven studies consid-
ered at low risk (Corli 2016; Kalso 1990; Kaplan 1998; Leow
1995; Parris 1998; Su 2015; Zecca 2016), and 12 studies con-
sidered at high risk (Bruera 1998; Gabrail 2004; Hagen 1997;
Heiskanen 1997; Imanaka 2013; Lux 2014; Mercadante 2010;
Mucci-LoRusso 1998; Riley 2015; Salzman 1999; Stambaugh
2001; Yu 2014), while four studies were at unclear risk (Beaver
1978a; Beaver 1978b; Lauretti 2003; Zhang 2014) for the pri-
mary outcome of pain. For adverse events, the risk of attrition
bias was slightly less with 11 studies considered at low risk (Corli
2016; Kalso 1990; Kaplan 1998; Imanaka 2013; Leow 1995;
Mucci-LoRusso 1998; Parris 1998; Salzman 1999; Su 2015; Yu
2014; Zecca 2016), and six studies considered at high risk (Bruera
1998; Hagen 1997; Heiskanen 1997; Mercadante 2010; Riley
2015; Stambaugh 2001), while six studies were at unclear risk
(Beaver 1978a; Beaver 1978b; Gabrail 2004; Lauretti 2003; Lux
2014; Zhang 2014).
Selective reporting
Seventeen of the included studies were not considered to be at
risk of selective reporting bias, whereas five of the studies either
did not report adverse events or did not report them in a manner
so they could be scrutinised for (and potentially included in) an
evidence synthesis (Beaver 1978a; Beaver 1978b; Bruera 1998;
Lauretti 2003; Lux 2014); these studies were therefore judged
at high risk. One study only reported four adverse events in a
transparent manner and was therefore considered at unclear risk
of reporting bias (Hagen 1997).
Other potential sources of bias
The participants appeared to be adequately titrated in the major-
ity of the studies (Bruera 1998; Corli 2016; Gabrail 2004; Hagen
1997; Heiskanen 1997; Imanaka 2013; Kalso 1990; Lauretti
2003; Lux 2014; Mucci-LoRusso 1998; Parris 1998; Riley 2015;
Stambaugh 2001; Su 2015; Yu 2014; Zecca 2016; Zhang 2014),
although this was unclear in four studies (Beaver 1978a; Beaver
1978b; Leow 1995; Mercadante 2010), and not the case in one
study (Kaplan 1998). One study examined titration as its main
objective (Salzman 1999). For all 11 cross-over trials, data were
available for all cross-over phases. Only four studies undertook
ITT analyses for both efficacy and safety (Leow 1995; Parris 1998;
Stambaugh 2001; Zhang 2014), with a further three studies per-
forming these analyses for safety only (Kalso 1990; Salzman 1999)
or for efficacy only (Corli 2016; Riley 2015). In one study, it was
unclear whether ITT analyses had been undertaken (Su 2015).
The remaining studies did not perform ITT for any of the out-
comes. The vastmajority of the included studies had received com-
mercial funding or had authors who were employees of the drug
manufacturers, or both (Beaver 1978a; Beaver 1978b; Gabrail
2004; Hagen 1997; Heiskanen 1997; Imanaka 2013; Kaplan
1998; Leow 1995; Lux 2014; Mucci-LoRusso 1998; Parris 1998;
Salzman 1999; Stambaugh 2001; Yu 2014; Zecca 2016). Only
three studies were considered free from the potential influence of
commercial funding (Corli 2016; Kalso 1990; Riley 2015), with
a further five studies having unclear status (Bruera 1998; Lauretti
2003; Mercadante 2010; Su 2015; Zhang 2014). All the included
studies were considered at low risk of any other biases (e.g. carry-
over effects in the cross-over trials) with the exception of four stud-
ies which were judged to be at unclear risk of other bias due to the
manner in which the trials were reported (Beaver 1978a; Beaver
1978b; Su 2015; Zhang 2014).
Effects of interventions
See: Summary of findings for the main comparison CR
oxycodone compared with IR oxycodone for cancer-related pain
in adults; Summary of findings 2 CR oxycodone compared with
CR morphine for cancer-related pain in adults
Analysis 1.1 and Figure 4 shows the pain intensity scores for each
of the listed treatment groups, subgrouped according to overall
treatment comparisons. We felt that presenting the pain intensity
data this way for the studies where it was possible gave a compre-
hensive overview of the pain intensity data for the majority of the
included studies, although the actual analyses should be treated
with some caution as outlined in theUnit of analysis issues section.
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Figure 4. Forest plot of comparison: 1 Pain, outcome: 1.1 Pain intensity and pain relief.
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Controlled-release oxycodone versus immediate-
release oxycodone
Four studies compared CR oxycodone to IR oxycodone (Kaplan
1998; Parris 1998; Salzman 1999; Stambaugh 2001).
Pain intensity and pain relief
Pooled analysis showed that there was no statistically significant
difference in pain intensity after treatment with either CR or IR
oxycodone (SMD 0.1, 95% CI -0.06 to 0.26, I2 = 35%) (Analysis
1.1; Figure 4), which was also in line with the finding that none
of the included studies reported that pain intensity differed be-
tween the treatment groups. Salzman 1999 could not be included
in the pooled analysis due to the design of the study, so is instead
summarised narratively below. Sensitivity analysis excluding the
cross-over trial (Stambaugh 2001) did not change the overall re-
sults (SMD 0.12, 95% CI -0.06 to 0.29).
Salzman 1999 examined in a parallel-group trial lasting up to
21 days whether CR oxycodone could be used as readily as IR
oxycodone for titration to stable pain control and found that 22/
24 and 19/24 participants in the CR and IR groups, respectively,
achieved stable pain control within a mean time of 1.6 days (SE =
0.4) and 1.7 days (SE = 0.6), respectively.
We judged the quality of evidence for this outcome to be low. We
downgraded the quality of evidence by two levels for very serious
limitations to study quality due to risk of bias (arising from under-
reporting and attrition bias). See Summary of findings for themain
comparison.
Adverse events
Pooled analyses of adverse events showed no significant difference
between treatment with CR oxycodone and IR oxycodone for
asthenia (RR 0.58, 95% CI 0.2 to 1.68, I2 = 30%; Analysis 2.2),
confusion (RR 0.78, 95% CI 0.2 to 3.02, I2 = 25%; Analysis 2.3),
constipation (RR 0.71, 95% CI 0.45 to 1.13, I2 = 38%; Analysis
2.4), dizziness/lightheadedness (RR 0.74, 95% CI 0.4 to 1.37, I2
= 15%; Analysis 2.5), drowsiness/somnolence (RR 1.03, 95% CI
0.69 to 1.54, I2 = 0%; Analysis 2.6), dry mouth (RR 1.14, 95%CI
0.48 to 2.75, I2 = 0%; Analysis 2.7), insomnia (RR 1.04, 95% CI
0.31 to 3.53, I2 = 35%; Analysis 2.11), nausea (RR 0.85, 95% CI
0.56 to 1.28, I2 = 0%; Analysis 2.12), nervousness (RR 0.57, 95%
CI 0.2 to 1.64, I2 = 0%; Analysis 2.13), pruritus (RR1.46, 95%CI
0.65 to 3.25, I2 = 33%; Analysis 2.14), vomiting (RR 0.66, 95%
CI 0.38 to 1.15, I2 = 18%; Analysis 2.16), and discontinuation
due to adverse events (RR 0.6, 95% CI 0.29 to 1.22, I2 = 0%;
Analysis 2.17). The I2 statistic was 61% for headache and 55%
for sweating so the results reported for these two adverse events
in Analysis 2.10 and Analysis 2.15 should be disregarded. Parris
1998 analysed 109 participants for safety evaluation; however, it
is unclear which group had 55 and which had 54 participants. In
the meta-analyses of adverse events, we allocated 54 participants
to the CR oxycodone group and 55 to the IR oxycodone group.
Sensitivity analyses showed that allocating 55 participants to the
CR oxycodone group and 54 participants to the IR oxycodone
group made no difference to the conclusions.
In a parallel-group trial lasting five days, Parris 1998 reported
that all the adverse events observed during the study resolved.
Stambaugh 2001 conducted a cross-over study with a duration of
three to seven days per phase, and stated that: “The study showed
similar incidences and numbers of reports of individual adverse
events considered related to the IR and CR drug” (page 505), but
did not report any formal statistical comparisons of the adverse
event rates between the study groups. Table 1 contains all the
adverse events reported by the included studies comparing CR
oxycodone and IR oxycodone.
We judged the quality of evidence for adverse events to be very
low in all cases. We downgraded the quality of evidence by two
levels for very serious limitations to study quality due to risk of
bias (arising from under-reporting, performance/detection bias,
inadequate titration, attrition bias, or a combination of these); and
we downgraded the quality of the evidence by one or two levels
due to imprecision (arising from low or very low event rates).
Quality of life
There were no data for quality of life, but Kaplan 1998 reported
in a parallel-group study lasting six days that there was no differ-
ence in treatment acceptability between the study groups (mean at
study end 3.2, SE 0.1, in both groups), and Parris 1998 found no
significant differences in acceptability of treatment between the
study groups. In Stambaugh 2001, 30/30 and 29/30 participants
rated IR and CR oxycodone, respectively, as of ’fair’, ’good’ or
’excellent’ acceptability during the last 24 hours of the treatment
phases, with 24/30 and 22/30 participants rating the drugs ’good’
or ’excellent’, respectively. We judged the quality of evidence for
this outcome to be low. We downgraded the quality of evidence
by two levels for very serious limitations to study quality due to
risk of bias (arising from under-reporting and attrition bias)
Participant preference
None of the studies reported data for participant preference.
See also Summary of findings for the main comparison.
Controlled-release oxycodone versus extended-
release oxycodone
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One study comparedCRoxycodone toERoxycodone (Lux 2014).
Pain intensity and pain relief
Lux 2014 found no difference in pain intensity between CR and
ER oxycodone in a cross-over trial with each of the two phases
lasting 10 days (Analysis 1.1; Figure 4). We judged the quality of
evidence for this outcome to be low. We downgraded the quality
of evidence by one level for serious limitations to study quality due
to risk of bias (arising from attrition bias) and by one level due to
imprecision (arising from low participant numbers).
Adverse events
Lux 2014 also included participants with non-malignant pain and
only reported adverse events for the whole sample. Therefore, we
have not reported results for adverse events.
Quality of life
The study did not report quality of life.
Participant preference
The study did not report participant preference.
Controlled-release oxycodone versus controlled-
release morphine
Nine studies compared CR oxycodone to CR morphine (Bruera
1998; Corli 2016; Heiskanen 1997; Lauretti 2003; Mercadante
2010; Mucci-LoRusso 1998; Riley 2015; Zecca 2016; Zhang
2014).
Pain intensity and pain relief
Pooled analysis including Bruera 1998; Corli 2016; Heiskanen
1997, Mercadante 2010; Mucci-LoRusso 1998; Riley 2015; and
Zecca 2016 showed that the pain intensity scores were significantly
lower after treatment with CRmorphine thanwith CR oxycodone
(SMD 0.14, 95% CI 0.01 to 0.27, I2 = 7%) (Analysis 1.1; Figure
4) (Bruera 1998; Corli 2016; Heiskanen 1997;Mercadante 2010;
Mucci-LoRusso 1998; Riley 2015; Zecca 2016). Using the SD of
the baseline average pain score of the full sample (200 participants;
SD 1.94) in Riley 2015 to express this SMD as a difference in
Brief Pain Inventory scores (0 to 10 numerical rating scale from
no pain to worst pain imaginable) between the treatments gave an
estimated difference of 0.27 between the treatments, which was
not clinically significant. Moreover, sensitivity analysis excluding
the two cross-over trials (Bruera 1998, Heiskanen 1997) did not
find a significant difference between CR oxycodone and CR mor-
phine (SMD 0.12, 95% CI -0.02 to 0.26, I2 = 24%). Two studies
could not be included in the pooled analysis due to the design of
the study (Lauretti 2003) or because pain intensity was not re-
ported (Zhang 2014), and the results of these studies are therefore
summarised narratively.
Lauretti 2003 conducted a two-phase (each lasting 14 days) cross-
over study to examine IR morphine consumption (which was the
main outcome) during treatment with CR oxycodone and CR
morphine, keeping the ratio of CR oxycodone and CR morphine
constant (1:1.8). IR morphine was used as rescue medication and
the participants were allowed to take as much as necessary to keep
visual analogue scale (VAS) pain score below 4. The participants
consumed 38% more IR morphine during treatment with CR
morphine than with CR oxycodone. Lauretti 2003 concluded that
the results indicated that CR oxycodone combined with IR mor-
phine was associated with superior analgesia and lower, or similar,
rates of adverse events (see ’Adverse events’ below) than a combi-
nation of CR and IR morphine.
In a four-arm parallel-group trial lasting 28 days, Corli 2016 com-
pared CR oxycodone with CRmorphine (and also included a TD
fentanyl and a TD buprenorphine arm), and found that the CR
oxycodone and CR morphine treatment groups did not differ sig-
nificantly in terms of requirement for additional opioids (CR oxy-
codone 33/125 participants; CR morphine 36/122 participants;
P = 0.59), the opioid escalation index > 5% (CR oxycodone 24/
125 participants; CR morphine 13/122 participants; P = 0.06),
or premature discontinuations for pain-related reasons (CR oxy-
codone 19/125 participants; CR morphine 33/122 participants;
P = 0.05); however, the proportion of participants requiring adju-
vant drugs were significantly higher in the CR oxycodone group
(CR oxycodone 102/125 participants; CR morphine 84/122 par-
ticipants; P = 0.02), were significantly higher in theCR oxycodone
group whereas the proportion of participants requiring switches
(CR oxycodone 15/125 participants; CR morphine 27/122 par-
ticipants; P = 0.03) were significantly lower in the CR oxycodone
group compared to the CR morphine group.
Mucci-LoRusso 1998 conducted a parallel-group trial lasting up
to 12 days and found that 40/48 and 42/52 participants achieved
stable pain control after receiving CR oxycodone and CR mor-
phine, respectively, within a median of 2 days for both groups
(ranges were 1 to 10 and 1 to 9 days, respectively).
In an open-label, parallel-group trial of one-year duration, Riley
2015 compared CR oxycodone to CR morphine and found that
67% and 62% of the participants achieved a response to first line
oxycodone and morphine, respectively, and that this was not a
significant difference. Moreover, in the participants who achieved
a response to their assigned first line treatment none of the five pain
indices studied (that is ’worst pain’, ’least pain’, ’average pain’, ’pain
right now’, and ’percentage relief ’) differed significantly between
the treatment groups.
Zecca 2016, in a parallel-group trial lasting two weeks and com-
paring CR oxycodone to CRmorphine, reported that opioid dose
escalation did not differ significantly between treatments (CR oxy-
codone 8.3%; CR morphine 6.5%).
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Zhang 2014 conducted a three-arm parallel-group trial of un-
known duration comparing CR oxycodone to CR morphine and
CR MS Contin and found that pain relief rates (i.e. participants
experiencing at least moderate pain relief ) of the three groups did
not differ significantly (CR oxycodone 53/57 participants; CR
morphine 51/57 participants; CRMS Contin 52/57 participants;
P = 0.62).
We judged the quality of evidence for this outcome to be low.
We downgraded the quality of evidence by two levels for very
serious limitations to study quality due to risk of bias (arising from
under-reporting, performance/detection bias, and attrition bias).
See Summary of findings 2.
Adverse events
Pooled analyses of adverse events showed no significant difference
between treatmentwithCRoxycodone andCRmorphine for con-
fusion (RR 1.01, 95% CI 0.78 to 1.31, I2 = 16%; Analysis 2.3),
constipation (RR 0.98, 95% CI 0.82 to 1.16, I2 = 33%; Analysis
2.4), dizziness/lightheadedness (RR 0.76, 95% CI 0.33 to 1.76, I
2 = 0%; Analysis 2.5), drowsiness/somnolence (RR 0.9, 95% CI
0.75 to 1.08, I2 = 0%; Analysis 2.6), dry mouth (RR 1.01, 95%
CI 0.8 to 1.26, I2 = 32%; Analysis 2.7), dysuria (RR 0.71, 95%
CI 0.4 to 1.26, I2 = 0%; Analysis 2.8), nausea (RR 1.02, 95% CI
0.82 to 1.26, I2 = 0%; Analysis 2.12), pruritus (RR 0.81, 95% CI
0.51 to 1.29, I2 = 0%; Analysis 2.14), vomiting (RR 0.94, 95%CI
0.68 to 1.29, I2 = 2%; Analysis 2.16), and discontinuation due to
adverse events (RR 1.06, 95% CI 0.43 to 2.6, I2 = 48%; Analysis
2.17). However, the RR for hallucinations was significantly lower
after treatment with CR oxycodone than after CR morphine (RR
0.52, 95% CI 0.28 to 0.97, I2 = 0%; Analysis 2.9). The I2 statistic
was 53% for ’any adverse events’ so the results reported for this
outcome (Analysis 2.1) should be disregarded. Zhang 2014 com-
pared CR oxycodone to both CR morphine and CR MS Contin.
In the meta-analyses of adverse events, we included CR morphine
as the comparison group. Sensitivity analyses substituting the CR
morphine data with the CRMSContin data showed that whether
the comparison group was CRmorphine or CRMS Contin made
no difference to the conclusions.
Bruera 1998 reported that: “There were no statistically significant
differences by treatment inmean severity for any of the elicited ad-
verse events or in the frequency of reporting of unelicited events”
(page 3225), but presented only data on sedation and nausea VAS
ratings. Corli 2016 found no significant differences between the
two treatment groups in the incidences of gastralgia and breath-
lessness, whether they were ’any degree’ or ’severe.’ Severe but not
’any degree’ muscle spasm myoclonus occurred significantly more
often in theCRmorphine group than in theCR oxycodone group.
Heiskanen 1997 conducted a cross-over trial lasting three to six
days per phase and found that vomiting was significantly more
common during morphine treatment while constipation was sig-
nificantly more common during oxycodone treatment; and re-
ported no other significant differences in adverse event rates be-
tween the drugs. In a parallel-group trial lasting four weeks (with
an extension of another four weeks), Mercadante 2010 found no
significant differences in the reported adverse events between the
groups. Lauretti 2003 found that CR and IR morphine were as-
sociated with more nausea and vomiting compared to the combi-
nation of CR oxycodone and IR morphine. Riley 2015 reported
that there were no significant differences in adverse event reaction
scores between oxycodone and morphine, either in first-line re-
sponders or non-responders. Table 2 contains all the adverse events
reported by the included studies comparing CR oxycodone and
CR morphine.
We judged the quality of evidence for this outcome to be very
low in all cases. We downgraded the quality of evidence by two
levels for very serious limitations to study quality due to risk of
bias (arising from under-reporting, performance/detection bias,
attrition bias, or a combination of these), and we downgraded the
quality of the evidence by one or two levels due to imprecision
(arising from low or very low event rates).
Quality of life
Mucci-LoRusso 1998 reported no clinically significant changes in
quality of life for either treatment group, but did not show results
or analyses. The authors also found that 74% and 77% of the CR
oxycodone and CR morphine participants, respectively, rated the
acceptability of treatment as good to excellent (non-significant)
and that the mean acceptability ratings at the study end did not
differ significantly between the CR oxycodone (mean 4, SE = 0.1)
and CR morphine (mean 3.9, SE = 0.1) participants. Heiskanen
1997 found that the mean daily acceptability of treatment rat-
ings were significantly higher for morphine (3.49/5; SE = 0.12)
than for oxycodone (3.19/5; SE = 0.11), but Lauretti 2003 also
found that CR and IR morphine were associated with a similar
acceptance to the study drugs compared to the combination of CR
oxycodone and IR morphine. We judged the quality of evidence
for this outcome to be very low. We downgraded the quality of
evidence by two levels for very serious limitations to study qual-
ity due to risk of bias (arising from under-reporting and attrition
bias), and we downgraded one level for imprecision (arising from
low participant numbers).
Participant preference
In a cross-over trial with each phase lasting seven days, Bruera 1998
reported that 8/23 participants preferredCRoxycodone treatment
while 11/23 participants preferred treatment with CR morphine
(non-significant difference). We judged the quality of evidence
for this outcome to be very low. We downgraded the quality of
evidence by two levels for very serious limitations to study quality
due to risk of bias (arising fromunder-reporting and attrition bias),
and we downgraded the quality of the evidence by two levels due
to imprecision (arising from very low participant numbers).
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See also Summary of findings 2.
Controlled-release oxycodone versus controlled-
release hydromorphone
One study compared CR oxycodone to CR hydromorphone (
Hagen 1997).
Pain intensity and pain relief
In a cross-over trial lasting seven days per phase, Hagen 1997
found no difference in pain intensity between treatment with CR
oxycodone and CR hydromorphone (Analysis 1.1; Figure 4). We
judged the quality of evidence for this outcome to be very low.
We downgraded the quality of evidence by two levels for very
serious limitations to study quality due to risk of bias (arising from
under-reporting and attrition bias), and two levels for imprecision
(arising from very low participant numbers).
Adverse events
Hagen 1997 observed no differences in frequency of adverse events
between treatment groups with the exception of drowsiness, which
occurred more frequently during treatment with oxycodone (see
Table 3). We judged the quality of evidence for this outcome to
be very low. We downgraded the quality of evidence by two levels
for very serious limitations to study quality due to risk of bias
(arising from under-reporting and attrition bias), and two levels
for imprecision (arising from very low participant numbers).
Quality of life
The study did not report quality of life.
Participant preference
Hagen 1997 found that 25.8% of participants had no treatment
preference with approximately half of the remaining participants
preferring oxycodone (35.5%) while the other half preferred hy-
dromorphone (38.7%). We judged the quality of evidence for this
outcome to be very low. We downgraded the quality of evidence
by two levels for very serious limitations to study quality due to
risk of bias (arising from under-reporting and attrition bias), and
two levels for imprecision (arising from very low participant num-
bers).
Controlled-release oxycodone versus extended
release hydromorphone
One study compared CR oxycodone to ER hydromorphone (Yu
2014).
Pain intensity and pain relief
In a 28-day parallel-group trial, Yu 2014 found no differences in
pain intensity or pain relief between treatmentwithCRoxycodone
and ER hydromorphone on any of the following pain measures:
mean pain at its worst in past 24 hours (CR oxycodone 5.1; ER
hydromorphone 4.9; Analysis 1.1; Figure 4), mean pain on av-
erage (CR oxycodone 3.3; ER hydromorphone 2.9), mean pain
at its least in past 24 hours (CR oxycodone 1.9; ER hydromor-
phone 1.6), mean pain ’right now’ (CR oxycodone 2.8; ER hy-
dromorphone 2.7), mean pain relief in past 24 hours (CR oxy-
codone 62.2%; ER hydromorphone 64.5%), and the number of
rescue medication doses taken during overall maintenance phase
(CR oxycodone 29.3; ER hydromorphone 24.2). We judged the
quality of evidence for this outcome to be very low. We down-
graded the quality of evidence by one level for serious limitations
to study quality due to risk of bias (arising from attrition bias),
and two levels for imprecision (arising from very low participant
numbers).
Adverse events
Yu 2014 reported that the observed adverse events were similar
between the treatment groups, and that they did not differ sig-
nificantly in duration of persistence for vomiting, constipation,
nausea, dizziness, pyrexia, and decreased appetite, but presented
no further formal statistical analyses (see Table 3). We judged the
quality of evidence for this outcome to be low. We downgraded
the quality of evidence by two levels for imprecision (arising from
very low participant numbers).
Quality of life
The study did not report quality of life.
Participant preference
The study did not report participant preference.
Controlled-release oxycodone versus extended
release oxymorphone
One study comparedCRoxycodone to ERoxymorphone (Gabrail
2004).
Pain intensity and pain relief
Gabrail 2004, in a cross-over trial with each phase lasting seven to
10 days, found clinically indistinguishable mean 24-hour average
daily pain intensity ratings between the two treatments (Analysis
1.1 and Figure 4). We judged the quality of evidence for this
outcome to be very low. We downgraded the quality of evidence
by two levels for very serious limitations to study quality due to
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risk of bias (arising from under-reporting and attrition bias), and
by two levels for imprecision (arising from very low participant
numbers).
Adverse events
Gabrail 2004 reported that the adverse event rates were similar
between the drugs, although no formal statistical analyses were
presented (see Table 3), and no participants withdrew due to ab-
normal laboratory values, insufficient analgesia, or loss to follow-
up. We judged the quality of evidence for this outcome to be very
low. We downgraded the quality of evidence by two levels for very
serious limitations to study quality due to risk of bias (arising from
under-reporting of the domains of selection, performance, detec-
tion, and attrition bias), and by two levels for imprecision (arising
from very low participant numbers).
Quality of life
Gabrail 2004 reported that no differences were observed in quality
of life (general activity, mood, walking ability, normal work, rela-
tionships with others, sleep, and enjoyment of life) between the
drugs. We judged the quality of evidence for this outcome to be
very low. We downgraded the quality of evidence by two levels for
very serious limitations to study quality due to risk of bias (arising
from under-reporting of the domains of selection, performance,
detection, and attrition bias), and by two levels for imprecision
(arising from very low participant numbers).
Participant preference
The study reported no data for participant preference, but Gabrail
2004 found that 78.3% of participants rated oxycodone as ’excel-
lent,’ ’very good,’ or ’good’ with 86.4% of the participants giving
oxymorphone such ratings. We judged the quality of evidence for
this outcome to be very low. We downgraded the quality of ev-
idence by two levels for very serious limitations to study quality
due to risk of bias (arising from under-reporting of the domains
of selection, performance, and detection bias), and by two levels
for imprecision (arising from very low participant numbers).
Controlled-release oxycodone versus extended
release tapentadol
One study compared CR oxycodone to ER tapentadol (Imanaka
2013).
Pain intensity and pain relief
Imanaka 2013, in a parallel-group trial of four weeks’ duration,
found equal analgesia between the study groups (see Analysis 1.1;
Figure 4) with 82/139 CR oxycodone participants and 80/126 ER
tapentadol participants reporting ≥ 30% improvement in pain
intensity during the last three days of treatment, and 59/139 CR
oxycodone participants and ER 63/126 tapentadol participants
reporting ≥ 50% improvement in pain intensity during the last
three days of treatment. We judged the quality of evidence for
this outcome to be low. We downgraded the quality of evidence
by one level for serious limitations to study quality due to risk of
bias (arising from attrition bias), and by one level for imprecision
(arising from low participant numbers).
Adverse events
Inspection of Table 3 suggested that the adverse event rates were
comparable between the treatment groups, but Imanaka 2013 did
not present any formal statistical analyses of this apparent equality.
We judged the quality of evidence for this outcome to be moderate
or low, depending on the event rates of the individual adverse
events. We downgraded the quality of evidence by one or two
levels for imprecision (arising from low or very low event rates).
Quality of life
The study did not report quality of life.
Participant preference
The study did not report participant preference.
Controlled-release oxycodone versus transdermal
fentanyl
Two studies comparedCRoxycodone to TD fentanyl (Corli 2016;
Su 2015).
Pain intensity and pain relief
Pooled analysis including Corli 2016 and Su 2015 showed that
the pain intensity scores after treatment with CR oxycodone and
TD fentanyl did not differ significantly (SMD 0.02, 95% CI -
0.19 to 0.24, I2 = 0%) (Analysis 1.1; Figure 4).
Corli 2016 compared CR oxycodone with TD fentanyl in a
four-arm trial of 28 days’ duration, which also included a TD
buprenorphine and a CR morphine group, and found that the
CR oxycodone and TD fentanyl groups did not differ signifi-
cantly in terms of the requirement for additional opioids (CR oxy-
codone 33/125 participants; TD fentanyl 46/124 participants; P
= 0.08), premature discontinuations for pain-related reasons (CR
oxycodone 19/125 participants; TD fentanyl 18/124 participants;
P = 1), proportion of participants requiring adjuvant drugs (CR
oxycodone 102/125 participants; TD fentanyl 100/124 partici-
pants; P = 0.87), or proportion of participants requiring switches
(CR oxycodone 15/125 participants; TD fentanyl 16/124 partic-
ipants; P = 0.85). However, a significantly higher proportion of
participants in the CR fentanyl group required a mean increase
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in the opioid daily dose > 5% according to the opioid escalation
index compared to the oxycodone group (CR oxycodone 24/125
participants; TD fentanyl 45/124 participants; P = 0.003). In a
parallel-group trial lasting two weeks, Su 2015 reported no differ-
ences between groups treated with CR oxycodone or TD fentanyl
in pain relief (CR oxycodone 90.48%; TD fentanyl 92.11%) or
pain intensity measured by response categories (CR oxycodone 15
complete response, 21 partial response, 2 minor response, 4 no
response; TD fentanyl: 13 complete response, 20 partial response,
2 minor response, 3 no response).
We judged the quality of evidence for this outcome to be very
low. We downgraded the quality of evidence by two levels for very
serious limitations to study quality due to risk of bias (arising from
under-reporting, performance bias, and detection bias), and by
one level for imprecision (arising from low participant numbers).
Adverse events
Pooled analysis of the event rates for constipation and dysuria re-
vealed that the I2 statistic was 83% for constipation, so the results
listed in Analysis 2.4 for this treatment subgroup should be ig-
nored, and that there was no significant difference between treat-
ment groups for dysuria (RR 1.15, 95% CI 0.62 to 2.16, I2 =
0%).
Corli 2016 found no significant differences between the two treat-
ment groups in the incidences of the following adverse events,
whether they were ’any degree’ or ’severe’: drowsiness, confusion,
nausea, vomiting, constipation, dry mouth, hallucinations, gas-
tralgia, muscle spasm myoclonus, breathlessness, and itching. Su
2015 reported that the rates of nausea and vomiting (P = 0.026)
and constipation (P = 0.022) were significantly higher in the CR
oxycodone group than in the TD fentanyl group, and that the rates
of dizziness and lethargy did not differ significantly between the
groups (all P > 0.65). We judged the quality of evidence for this
outcome to be very low. We downgraded the quality of evidence
by two levels for very serious limitations to study quality due to
risk of bias (arising from under-reporting, performance bias, and
detection bias), and by one or two levels (depending on the event
rates of the individual adverse events) for imprecision (arising from
low or very low event rates). See Table 4.
Quality of life
Su 2015 found no differences in quality of life as measured by the
Karnofsky Performance Status (from 0 to 100) (CR oxycodone
mean 75.79; TD fentanyl mean 74.05). We judged the quality
of evidence for this outcome to be very low. We downgraded the
quality of evidence by two levels for very serious limitations to
study quality due to risk of bias (arising from under-reporting of
the domains of selection, performance, and detection bias), and
by two levels for imprecision (arising from very low participant
numbers).
Participant preference
Neither study reported participant preference.
Controlled-release oxycodone versus transdermal
buprenorphine
Pain intensity and pain relief
Corli 2016 compared CR oxycodone with TD buprenorphine in
a four-arm trial of 28 days’ duration, which also included a TD
fentanyl and a CR morphine group, and found no significant dif-
ference between CR oxycodone and TD buprenorphine groups
in terms of pain intensity (Analysis 1.1; Figure 4). Corli 2016
found no significant differences between the groups in terms of
requirement for additional opioids (CR oxycodone 33/125 partic-
ipants; TD buprenorphine 48/127 participants; P = 0.06), opioid
escalation index > 5% (CR oxycodone 24/125 participants; TD
buprenorphine 18/127 participants; P = 0.31), premature discon-
tinuations for pain-related reasons (CR oxycodone 19/125 partic-
ipants; TD buprenorphine 26/127 participants; P = 0.32), pro-
portion of participants requiring adjuvant drugs (CR oxycodone
102/125 participants; TD buprenorphine 100/127 participants;
P = 0.64), or proportion of participants requiring switches (CR
oxycodone 15/125 participants; TD buprenorphine 21/127 par-
ticipants; P = 0.37). We judged the quality of evidence for this
outcome to be very low.We downgraded the quality of evidence by
two levels for very serious limitations to study quality due to risk
of bias (arising from performance bias and detection bias), and by
one level for imprecision (arising from low participant numbers).
Adverse events
Corli 2016 found no significant differences between the two treat-
ment groups in the incidences of the following adverse events,
whether they were ’any degree’ or ’severe:’ drowsiness, confusion,
nausea, vomiting, constipation, dry mouth, hallucinations, gas-
tralgia, dysuria, muscle spasm myoclonus, and itching. ’Any de-
gree,’ but not severe, breathlessness occurred more often in the
TD buprenorphine group than in the CR oxycodone group. We
judged the quality of evidence for this outcome to be very low. We
downgraded the quality of evidence by two levels for very serious
limitations to study quality due to risk of bias (arising from per-
formance bias and detection bias), and by one or two levels (de-
pending on the event rates for the individual adverse events) for
imprecision (arising from low or very low event rates). See Table
4.
Quality of life
Neither study reported quality of life.
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Participant preference
Neither study reported participant preference.
Intravenous oxycodone versus rectal oxycodone
One study compared IV oxycodone to rectal oxycodone (Leow
1995).
Pain intensity and pain relief
Leow 1995 conducted a single-dose cross-over study in 12 par-
ticipants, with each phase lasting 24 hours, and found that while
IV oxycodone was associated with faster onset of pain relief rel-
ative to rectal oxycodone, rectal oxycodone was associated with
a longer duration of pain relief compared to IV oxycodone. We
judged the quality of evidence for this outcome to be very low. We
downgraded the quality of evidence by two levels for very serious
limitations to study quality due to risk of bias (arising from under-
reporting and performance bias and detection bias), and by two
levels for imprecision (arising from very low participant numbers).
Adverse events
Leow 1995 reported no significant differences in the adverse event
profiles for the two study arms (see Table 3). We judged the qual-
ity of evidence for this outcome to be very low. We downgraded
the quality of evidence by two levels for very serious limitations
to study quality due to risk of bias (arising from under-reporting,
performance bias and detection bias), and by two levels for impre-
cision (arising from very low participant numbers).
Quality of life
The study did not report quality of life.
Participant preference
The study did not report participant preference.
Intravenous oxycodone followed by immediate-
release oxycodone versus intravenous morphine
followed by immediate-release morphine
One study compared IV oxycodone followed by IR oxycodone to
IV morphine followed by IR morphine (Kalso 1990).
Pain intensity and pain relief
In a cross-over study comparing IV oxycodone titration (two days)
followed by IR oxycodone titration (two days) with IV morphine
titration (two days) followed by IR morphine titration (two days)
in 19 analysed participants, Kalso 1990 found that the participants
achieved equal analgesia with both drugs, but around 30% more
IV oxycodone was needed compared to IV morphine and around
25% less IR oxycodone was needed than IR morphine to achieve
this. We judged the quality of evidence for this outcome to be
very low. We downgraded the quality of evidence by two levels for
very serious limitations to study quality due to risk of bias (arising
from under-reporting of the domains of selection, performance,
and detection bias), and by two levels for imprecision (arising from
very low participant numbers).
Adverse events
Kalso 1990 found that nausea was significantly more common
with oral morphine treatment compared to the other three treat-
ment modalities (see also Table 3). We judged the quality of evi-
dence for this outcome to be very low. We downgraded the quality
of evidence by two levels for very serious limitations to study qual-
ity due to risk of bias (arising from under-reporting of the domains
of selection, performance, and detection bias), and by two levels
for imprecision (arising from very low participant numbers).
Quality of life
The study did not report quality of life.
Participant preference
Kalso 1990 reported that 10 participants expressed no treatment
preference while five participants preferred oxycodone while an-
other five participants preferred treatment with morphine. We
judged the quality of evidence for this outcome to be very low. We
downgraded the quality of evidence by two levels for very serious
limitations to study quality due to risk of bias (arising from under-
reporting of the domains of selection, performance, and detection
bias), and by two levels for imprecision (arising from very low
participant numbers).
Intramuscular oxycodone versus oral oxycodone
One study compared IM oxycodone to oral oxycodone (Beaver
1978a).
Pain intensity and pain relief
In a single-dose, cross-over study, Beaver 1978a compared 5 mg
and 15 mg IM oxycodone to 10 mg and 30 mg oral oxycodone
in 17 participants of whom 13 completed at least one cross-over
round of the study medications. Beaver 1978a reported that oral
oxycodone was 0.57 (95% CI 0.22 to 1.84) times as potent as IM
oxycodone for pain relief and 0.78 (95% CI 0.3 to 8.82) times
as potent for change in pain intensity. We judged the quality of
evidence for this outcome to be very low. We downgraded the
quality of evidence by two levels for very serious limitations to
study quality due to risk of bias (arising from under-reporting of
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the domains of selection and attrition bias), and by two levels for
imprecision (arising from very low participant numbers).
Adverse events
Beaver 1978a reported that the adverse effects for both oral and
IM oxycodone, although infrequent, were related to dose, but oth-
erwise provided no further details on the observed adverse effects.
We judged the quality of evidence for this outcome to be very
low. We downgraded the quality of evidence by two levels for very
serious limitations to study quality due to risk of bias (arising from
under-reporting of the domains of selection and attrition bias),
and by two levels for imprecision (arising from very low partici-
pant numbers).
Quality of life
The study did not report quality of life.
Participant preference
The study did not report participant preference.
Intramuscular oxycodone versus intramuscular
morphine versus intramuscular codeine
Two studies (reported in one publication) compared IM oxy-
codone, IM morphine and IM codeine (Beaver 1978b).
Pain intensity and pain relief
In another single-dose, cross-over study Beaver 1978b compared
7.5 mg, 15 mg and 30 mg IM oxycodone to 8 mg, 16 mg and
32 mg IM morphine in 34 participants of whom 28 completed at
least one round of the study drugs. In this study, IM oxycodone
was found to be 0.74 (95% CI 0.36 to 1.2) times as potent as IM
morphine for pain relief and 0.68 (95% CI 0.32 to 1.07) times as
potent as IM morphine for change in pain intensity. In a further
study of similar designBeaver 1978b compared 7.5mg, 15mg and
30 mg IM oxycodone to 90 mg and 180 mg IM codeine and to
16 mg IM morphine in 30 participants of whom 26 completed at
least one cross-over round of the study medications. Beaver 1978b
reported that IM oxycodone was 10.72 (95% CI not reported)
times as potent as IM codeine for pain relief and 8.44 (95% CI
2.13 to 44.69) times as potent as IM codeine for change in pain
intensity.We judged the quality of evidence for this outcome to be
very low. We downgraded the quality of evidence by two levels for
very serious limitations to study quality due to risk of bias (arising
from under-reporting of the domains of selection and attrition
bias), and by two levels for imprecision (arising from very low
participant numbers).
Adverse events
Beaver 1978b noted that in both studies side effects typical of nar-
cotic analgesics were observed, although not in sufficient numbers
to allow meaningful analysis, and they reported no further details
on adverse events. We judged the quality of evidence for this out-
come to be very low. We downgraded the quality of evidence by
two levels for very serious limitations to study quality due to risk
of bias (arising from under-reporting of the domains of selection
and attrition bias), and by two levels for imprecision (arising from
very low participant numbers).
Quality of life
The studies did not report quality of life.
Participant preference
The studies did not report participant preference.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
CR oxycodone compared with CR morphine for cancer- related pain in adults
Patient or population: adults with cancer-related pain
Settings: in- or outpat ients
Intervention: CR oxycodone
Comparison: CR morphine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
CR morphine CR oxycodone
Pain intensity
(various pain intensity
scales; SMD)
The mean pain intensity in the CR oxycodone
group was 0.14 standard deviations higher (0.
01 lower to 0.27 higher) than in the CR morphine
group
SMD 0.14 (0.01 to 0.27) 882
(7 studies)
⊕⊕©©
low1
-
Const ipat ion
(Event rate)
355 per 1000 348 per 1000
(291 to 412)
RR 0.98
(0.82 to 1.16)
797
(5 studies)
⊕©©©
very low2,4
-
Drowsiness/
somnolence
(Event rate)
337 per 1000 303 per 1000
(253 to 364)
RR 0.9
(0.75 to 1.08)
798
(5 studies)
⊕©©©
very low2,4
-
Nausea
(Event rate)
266 per 1000 272 per 1000
(218 to 336)
RR 1.02
(0.82 to 1.26)
798
(5 studies)
⊕©©©
very low2,4
-
Vomit ing
(Event rate)
161 per 1000 151 per 1000
(109 to 207)
RR 0.94
(0.68 to 1.29)
798
(5 studies)
⊕©©©
very low3,4
-
Quality of lif e No data available, but CRoxycodone appears to be associated with sim ilar or lower treatment acceptability than CRmorphine
(measured on various scales, not pooled); 149 part icipants (3 studies); quality of the evidence very low.3,5
-
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Part icipant preference 8/ 23 part icipants preferred CR oxycodone while
11/ 23 part icipants preferred treatment with CR
morphine (non-signif icant dif f erence)
- 23
(1 study)
⊕©©©
very low3,5
-
* The assumed risk is reported as the observed risk in the control group across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; CR: controlled release; RR: risk rat io; SMD: standardised mean dif ference.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded twice for very serious lim itat ions to study quality due to risk of bias (performance/ detect ion bias and attrit ion
bias and under-report ing of the domain of select ion bias).
2 Downgraded once for imprecision due to low event rates/ part icipant numbers.
3 Downgraded twice for imprecision due to very low event rates/ part icipant numbers.
4 Downgraded twice for very serious lim itat ions to study quality due to risk of bias (performance/ detect ion bias and/ or
attrit ion bias and under-report ing of the domains of select ion and attrit ion bias).
5 Downgraded twice for very serious lim itat ions to study quality due to risk of bias (attrit ion bias and under-report ing of the
domain of select ion bias).
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D I S C U S S I O N
For the current update, we identified six additional studies for in-
clusion, which allowed us to perform further meta-analyses, prin-
cipally on the adverse event data. We were also able to examine
four new treatment comparisons with oxycodone, and assess the
robustness of our primary pain intensity meta-analyses by per-
forming sensitivity analyses. Although these analyses found that
CR oxycodone was associated with a higher pain intensity, and
therefore less pain relief, and a lower risk of hallucinations com-
pared to CR morphine, the updated results and conclusions are
broadly speaking the same as the original review because the (cur-
rent) finding of inferior pain relief by CR oxycodone compared to
CRmorphine was only statistically and not clinically significant as
the effect size was very small. It was also not supported by sensitiv-
ity analyses, and the finding of a lower risk of hallucinations with
treatment with CR oxycodone compared to CR morphine was
based on very low event rates (see ’For clinicians’ in Implications
for practice).
Summary of main results
Overall, we included 23 studies which enrolled/randomised 2648
participants, with 2144 of these analysed for efficacy and 2363 for
safety. The studies examined a number of different drug compar-
isons.
Four studies compared CR oxycodone to IR oxycodone, and
pooled analysis of three of these studies showed that there was no
difference in pain intensity after treatment with either CR or IR
oxycodone (SMD 0.1, 95% CI -0.06 to 0.26). This is also in line
with the finding that none of the included studies reported that
the pain intensity differed between the treatment groups. Pooled
analyses of the adverse event data from three of the studies found
no differences between the treatments in RRs for any of the ad-
verse events, and the fourth study, which could not be included
in the pooled analyses, reported no differences in adverse events
either. Three of the four studies also found no difference in treat-
ment acceptability between the comparisons. We noted that IR
oxycodone was given every six hours rather than every four hours
in these studies. This might have biased the efficacy data in favour
of CR oxycodone; however, the adverse effect data suggest that
giving IR oxycodone every four hours (more frequently) would
have resulted in greater adverse effects, which would have miti-
gated advantages in efficacy.
Nine studies compared CR oxycodone to CR morphine and
pooled analysis of seven of these nine studies suggested that pain
intensity did differ significantly between the treatments (SMD
0.14, 95% CI 0.01 to 0.27). However, this result was not corrob-
orated by a sensitivity analysis that excluded the two cross-over
trials included in the overall analysis (SMD 0.12, 95% CI -0.02
to 0.26). There were no marked differences in terms of treatment
acceptability or quality of life ratings observed between the treat-
ments. Zhang 2014 also found no significant differences in pain
relief rates between CR oxycodone, CR morphine and CR MS
Contin. Pooled analyses of the adverse event rates also found no
differences between the treatments for any of the adverse events,
with the exception of hallucinations, which participants treated
with CR morphine were at almost double the risk of experiencing
compared to participants treated with CR oxycodone. However,
these findings contrast somewhat with those reported in Lauretti
2003, which was different in design to the other four studies and
examined IR morphine consumption during treatment with CR
oxycodone and CR morphine while keeping the ratio of CR oxy-
codone and CRmorphine constant. Lauretti 2003 found that the
participants consumed 38% more IR morphine during treatment
with CR morphine than with CR oxycodone, and that CR and
IR morphine was associated with more nausea and vomiting and
a similar acceptance to the study drugs compared to the combina-
tion of CR oxycodone and IR morphine, and therefore concluded
that CRoxycodone combinedwith IRmorphine is associated with
superior analgesia and lower or similar rates of adverse events than
a combination of CR and IR morphine.
Two studies compared CR oxycodone to TD fentanyl and pooled
analysis of them found that the pain intensity scores after treat-
ment with CR oxycodone and TD fentanyl did not differ signifi-
cantly (SMD 0.02, 95% CI -0.19 to 0.24). One of the studies also
found that quality of life did not differ between the treatments, but
there was some disagreement between the study results in terms
of adverse events with one of the studies finding that the rates of
nausea and vomiting, and constipation were significantly higher in
the CR oxycodone group than in the TD fentanyl group, whereas
the other study reported no treatment group differences in (these
and other) adverse event rates.
The remaining studies all compared either oxycodone in differ-
ent formulations or oxycodone to different alternative opioids and
none of them found any clear superiority or inferiority of oxy-
codone for cancer pain, neither as an analgesic agent nor in terms
of adverse event rates or treatment acceptability.
Overall completeness and applicability of
evidence
Although the findings of this review are applicable to the popula-
tion and comparisons defined for this review, that is, adults with
cancer who need treatment with strong opioids for cancer pain,
they should be taken in the context that this review found 23
studies that were eligible for inclusion and these studies reported
on 13 different comparisons involving oxycodone and included
only 2648 participants. Moreover, for some of the outcomes (par-
ticipant preference and quality of life) there were extremely few
data available. To somewhat mitigate this shortfall, we reported
treatment acceptability as a proxy. However, that does not change
the fact that the evidence base for the effectiveness and tolerability
of oxycodone (relative or absolute) for pain in adults with cancer
was very limited and it did not allow us to examine the effective-
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ness and tolerability of oxycodone in detail through participant
or treatment subgroup analyses. The current evidence base would
therefore benefit from more well-designed, large RCTs.
Quality of the evidence
The quality of the evidence for all the outcomes was low or very
low, meaning we have little confidence in the effect estimate and
the true effect may be substantially different from the estimate of
the effect. This is due to imprecision (low participant numbers) in
some cases, and serious or very serious study limitations in all cases.
In general, the assessment of the quality of the included studies
was limited by a great extent of under-reporting in the studies, es-
pecially for the participant selection items (random sequence gen-
eration and allocation concealment), while blinding appeared to
be reasonably well undertaken overall, both in terms of treatment
performance and outcome assessment. However, as is not unusual
for pain research, the results were substantially compromised by
attrition, with data missing from just under 20% of the enrolled/
randomised participants for efficacy, and frommore than 10% for
safety. These are substantial proportions and, while it did not ap-
pear to be selective attrition, the results must be interpreted with
caution.
Potential biases in the review process
We undertook the review according to the methods specified in
our protocol, which were all in line with the recommendations
of Cochrane as outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011), and included a thorough
search strategy designed to maximise the chances of identifying
all relevant studies. Contacting authors resulted in no additional
studies being identified, that is, the review therefore only contains
data from published studies, some of which have not reported all
the outcome data despite having apparently collected these data.
The review may therefore be at some risk of publication bias,
although publication bias is usually associatedwith positive results,
and the majority of the included studies did not find significant
differences between their treatment groups in terms of efficacy and
safety. Although, our meta-analyses of pain intensity included data
from cross-over studies that were analysed as if they were parallel-
group studies, which as outlined in Unit of analysis issues results
in unit of analysis error (although, in turn, this leads to an under-
weighting rather than over-weighting of the data), the results were
also subjected to sensitivity analyses that excluded the cross-over
trials, and that needed to confirm the results in order for them to
be accepted as true results.
Agreements and disagreements with other
studies or reviews
King 2011 conducted a systematic review without meta-analy-
sis that also included observational studies and concluded that,
“There is no evidence from the included trials of a significant
difference in analgesia or adverse effects between oxycodone and
morphine or hydromorphone” (page 454). Caraceni 2011 reached
a similar conclusion in their systematic review without meta-anal-
ysis. Bekkering 2011 and Reid 2006 both included meta-analyses
in their systematic reviews and they also concluded that the effec-
tiveness of oxycodone and morphine did not significantly differ,
although the inclusion criteria employed by Bekkering 2011 dif-
fered from ours, with Bekkering 2011 excluding cross-over trials
and including trials of chronic non-malignant pain, whereas the
publication of Reid 2006 before the trial of Mercadante 2010 pre-
cluded its inclusion. That said, the conclusions of all these reviews
are all in agreement with those that we have reached in this review
dealing with the same comparisons as the aforementioned reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Since the last versionof this review, none of the new relevant studies
have provided additional information to change the conclusions.
For adults with cancer pain
We found low quality evidence that oxycodone offers similar lev-
els of pain relief and overall adverse effects as morphine for adults
with cancer. Although we identified a clinically insignificant ben-
efit on pain relief in favour of controlled-release (CR) morphine
compared to CR oxycodone, this did not persist following sensi-
tivity analysis and so we do not consider this important. We did
find an increased frequency of hallucinations after treatment with
CR morphine (7.8%) compared to CR oxycodone (4%).
For clinicians
We found low quality evidence that oxycodone offers similar levels
of cancer pain relief and adverse events to other strong opioids in-
cluding morphine, which is commonly considered the gold stan-
dard strong opioid. Although we identified a clinically insignifi-
cant benefit on pain relief in favour of CR morphine compared to
CR oxycodone, this did not persist following sensitivity analysis
and so we do not consider this important. We found an increased
risk of hallucinations with CR morphine but we also found a nu-
merically higher frequency of myoclonus (another excitatory opi-
oid adverse effect) with CR oxycodone and we did not find any
differences in reported drowsiness or confusion. The interpreta-
tion of increased relative risk of hallucinations should therefore be
treated with caution given the low quality of evidence.
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For policy makers
The findings of this review are consistent with current interna-
tional guidance on using oxycodone or morphine as first-line opi-
oids for adults with cancer-related pain.
For funders of the intervention
We did not undertake cost-effectiveness analysis.
Implications for research
General
We found that the current evidence base is comprised of studies
that contained small numbers of participants in which there was
a significant (19%) dropout rate. For example, the direct compar-
ison meta-analysis between oxycodone and morphine was based
on fewer than 450 cancer participants in each treatment group;
this was a very small evidence base. However, given the absence of
important differences within this analysis, it seems unlikely that
larger head to head studies of oxycodone versus morphine will be
justified.
Design
There were no implications for the design of future clinical studies.
Measurement (endpoints)
For future cancer pain studies, developing a single outcome that
combines good pain control (no more thanmild on a verbal rating
scale) with acceptable adverse effects (perhaps no more than mild
severity on any adverse event) would enable a clearer comparison
between any analgesics used in this context.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beaver 1978a
Methods Design: randomised, double-blind, cross-over trial.
Year: not reported.
Country: USA.
Participants Participants: 17 participants entered, “13 patients completed at least one round” (see
’Interventions’ below) and were analysed for efficacy (“The 4 patients who failed to
complete a single round did so for reasons extraneous to the drugs under study”); 5 men/
8 women, mean (range) age 51 (23-68) years. “One of these patients appeared twice in
the study, and 5 completed a second round, yielding 19 cross-over comparisons.”
Inclusion criteria: “The subjects were patients with a variety of malignant tumours on the
wards of James Ewing Hospital. Each patient was first examined to ascertain the nature
and location of his or her pain, the extent of disease, prior experience with narcotics and
analgesic drugs and ability to communicate meaningful information about pain. At this
time, the patient was also told how the studies were to be conducted and that, while
all test medications might appear the same, they would actually include a number of
different drugs, some probably more effective than others in relieving pain. Many of the
patients had had some prior experience with oral or parenteral narcotics, and several had
a history of sufficient recent narcotic use to warrant the assumption that they possessed
some tolerance to narcotics. Patients were placed on a routine analgesic other than those
included in the study during nonstudy hours, and, insofar as was possible, concomitant
administration of psychoactive drugs was avoided.”
Exclusion criteria: see ’Inclusion criteria.’ No other information provided.
Interventions Oxycodone arm
- Drug: oxycodone + oral placebo.
- Dose/dosing: 5 mg.
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: appears to be single dose.
- Titration schedule: no titration.
- Rescue medication: assessed by participant “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr [hours] had elapsed since administration of
the study medication).” No further information reported
- Other medication: see ’Rescue medication’ and ’Inclusion criteria.’
Comparison arm 1
- Drug: oxycodone + oral placebo.
- Dose or dosing: 15 mg.
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: appears to be single dose.
- Titration schedule: no titration.
- Rescue medication: assessed by participant “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
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analgesic was administered (if at least 3 hr [hours] had elapsed since administration of
the study medication).” No further information reported
- Other medication: see ’Rescue medication’ and ’Inclusion criteria.’
Comparison arm 2
- Drug: oxycodone + intramuscular placebo
- Dose or dosing: 10 mg
- Formulation: Immediate-release?
- Route of administration: oral.
- Length of treatment: appears to be single dose.
- Titration schedule: no titration.
- Rescue medication: assessed by participant “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr [hours] had elapsed since administration of
the study medication).” No further information reported
- Other medication: see ’Rescue medication’ and ’Inclusion criteria.’
Comparison arm 3
- Drug: oxycodone + intramuscular placebo
- Dose or dosing: 30 mg
- Formulation: Immediate-release?
- Route of administration: oral.
- Length of treatment: appeared to be single dose.
- Titration schedule: no titration.
- Rescue medication: assessed by participant “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr [hours] had elapsed since administration of
the study medication).” No further information reported
- Other medication: see ’Rescue medication’ and ’Inclusion criteria.’
- For cross-over trials, cross-over schedule: “Treatments were assigned to patients ac-
cording to a series of randomly chosen Latin squares, and each study medication was
administered on a separate day. Each patient received a low and a high dose of both the
”standard“ and the ”test drug,“ chosen at equilog intervals. Unless a patient completed
all doses of the crossover comparison or ”round,“ his data were excluded from the relative
potency analysis. After completing the first round, some patients were able to repeat the
course, allowing for comparison of replicate rounds within the same individual.”
Outcomes - Pain intensity: assessed by participant “hourly for 6 hours after administration of the
studymedication or until pain returned to the premedication level and a routine analgesic
was administered (if at least 3 hr [hours] had elapsed since administration of the study
medication);” using a 4-point categorical scale (0 = none, 1 = slight, 2 = moderate, 3 =
severe)
- Pain relief: assessed by participant hourly for 6 hours after administration of the study
medication or until pain returned to the premedication level and a routine analgesic was
administered (if at least 3 hours had elapsed since administration of the studymedication)
; using a 5-point categorical scale (0 = none, 1 = slight, 2 = moderate, 3 = lots, 4 =
complete)
“Patients who were remedicated before 6 hr [hours] elapsed after administration of a
study medication were assigned scores of zero (0) for change in pain intensity and pain
relief for the remaining observation points of the 6-hr observation period.”
- Adverse effects: “The observer also recorded apparent and volunteered side-effects, but
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leading questions were avoided.”
Notes - Study free of commercial funding? No: “This work was supported by grants awarded
by the Committee on Problems of Drug Dependence, National Academy of Sciences,
National Research Council, from funds contributed by a group of interested pharma-
ceutical manufacturers, and by National Cancer Institute Grant CA-08748.”
- Groups comparable at baseline? No participant details reported by initial treatment
allocation
- ITT analyses undertaken? No: “Unless a patient completed all doses of the crossover
comparison or ”round,“ his data were excluded from the relative potency analysis.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Treatments were assigned to patients ac-
cording to a series of randomly chosen
Latin squares.” No further information re-
ported
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “Neither the patient nor the observer was
aware of the identity of the medications,
which were physically indistinguishable
and identified only by a numerical code on
individual dosage envelopes. To maintain
double-blind conditions, both capsules and
an injection, one of which was a dummy,
were administered each time a patient was
given a study medication.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk Participant reported. See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Participant reported. See cell above
Incomplete outcome data (attrition bias)
Pain
Unclear risk Data from 13/17 participants reported.
“One of these patients appeared twice in
the study, and 5 completed a second round,
yielding 19 crossover comparisons.”
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Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Data from 13/17 participants reported.
“One of these patients appeared twice in
the study, and 5 completed a second round,
yielding 19 crossover comparisons.”
Selective reporting (reporting bias) High risk No side effects or adverse events reported in
detail: “The side-effects are both intramus-
cular and oral oxycodone were dose-related
and qualitatively similar to those noted in
the codeine study.” (which were also not
reported in any detail at all: “While a dose-
response regression was generally evident,
side-effects did not occur with sufficient
frequency to allow meaningful analysis.”)
Other bias Unclear risk It is unclear if this study is subject to a high
risk of other biases
Were the participants adequately titrated? Unclear risk Not enough information provided
For cross-over trials: are data available for
both time periods?
Low risk Yes, data are available from all the cross-
over periods
Beaver 1978b
Methods Design: randomised, double-blind, cross-over trial.
Year: not reported.
Country: USA.
Participants ”The patient population and method of evaluating analgesic efficacy were similar to
those employed in the oral/parenteral analgesic relative potency assays of codeine and
oxycodone described in the previous paper“ (Beaver 1978a).
Paper contained 2 studies:
’Intramuscular morphine and oxycodone’ and ’intramuscular codeine, oxycodone and
morphine’
’Intramuscular morphine and oxycodone’
Participants: 34 participants entered, ”28 patients completed at least one round“ (see
’Interventions’ below) and were analysed for efficacy (”All of the patients who failed to
complete a single round did so for reasons extraneous to the drugs under study“); 14
men/14 women, mean (range) age 46 (23-68) years. ”Of the 28 patients participating in
the study, 4 appeared twice in a single series, and 2 appeared in each of two series. Twenty-
four patients completed a second round, yielding a total of 58 crossover comparisons.“
’Intramuscular codeine, oxycodone and morphine’
Participants: 30 participants entered, ”26 completed at least one round“ (see ’Interven-
tions’ below) and were analysed for efficacy (”The 4 who failed to complete a single
round did so for reasons extraneous to the drugs under study“); 14 men/12 women,
mean (range) age 45 (23-80) years. ”Series I was carried out in 11 patients, one of whom
appeared twice in the series and 10 of whom completed a second round, yielding 22
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cross-over comparisons of 90 and 180 mg of codeine, 7.5 and 15 mg of oxycodone and
16 mg of morphine. Series II consisted of 27 cross-over comparisons in 16 patients of
90 and 180 mg codeine, 15 and 30 mg of oxycodone, and 16 mg of morphine. One
patient appeared in both Series I and Series II.“
Inclusion criteria: see above.
Exclusion criteria: see above.
Interventions ’Intramuscular morphine and oxycodone’:
”This assay consisted of three series, each comparing two doses of morphine sulfate (the
standard) with two doses of oxycodone hydrochloride (the test drug) by intramuscular
injection.“ ”The distribution of patients and doses in the various series is presented in
table 1. In general, the more obviously tolerant patients were given series II treatments,
which consisted of double the dosage in series I.“
Oxycodone arm
- Drug: oxycodone hydrochloride.
- Dose or dosing: series I: 7.5 mg and 15 mg; series II and III: 15 mg and 30 mg
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: appears to be single dose.
- Titration schedule: no titration.
- Rescue medication: ”Assessed by patient “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr [hours] had elapsed since administration of
the study medication).” No further information reported
- Other medication: see ’Rescue medication’ and ’Inclusion criteria.’
Comparison arm
- Drug: morphine sulphate.
- Dose or dosing: series I and III: 8 mg and 16 mg; series II: 16 mg and 32 mg
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: appeared to be single dose.
- Titration schedule: no titration.
- Rescue medication: “Assessed by patient ”hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr [hours] had elapsed since administration of
the study medication).“ No further information reported
- Other medication: see ’Rescue medication’ and ’Inclusion criteria.’
’Intramuscular codeine, oxycodone and morphine’:
”This assay consisted of two series, each comparing 90 and 180 mg codeine phosphate
(the standard) with two doses of oxycodone hydrochloride (the test drug) and a single
16 mg dose of morphine sulfate.“
Oxycodone arm
- Drug: oxycodone hydrochloride.
- Dose or dosing: series I: 7.5 mg and 15 mg; series II: 15 mg and 30 mg
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: appeared to be single dose.
- Titration schedule: no titration.
- Rescue medication: ”Assessed by patient “hourly for 6 hours after administration of
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the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr [hours] had elapsed since administration of
the study medication).” No further information reported
- Other medication: see ’Rescue medication’ and ’Inclusion criteria.’
Comparison arm 1
- Drug: morphine sulphate.
- Dose or dosing: series I and II: 16 mg.
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: appeared to be single dose.
- Titration schedule: no titration.
- Rescue medication: “Assessed by patient ”hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr [hours] had elapsed since administration of
the study medication).“ No further information reported
- Other medication: see ’Rescue medication’ and ’Inclusion criteria.’
Comparison arm 2
- Drug: codeine phosphate.
- Dose/dosing: series I and II: 90 mg and 180 mg.
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: appeared to be single dose.
- Titration schedule: no titration.
- Rescue medication: ”Assessed by patient “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr [hours] had elapsed since administration of
the study medication).” No further information reported
- Other medication: see ’Rescue medication’ and ’Inclusion criteria.’
- For cross-over trials, cross-over schedule: “Treatments were assigned to patients ac-
cording to a series of randomly chosen Latin squares, and each study medication was
administered on a separate day. Each patient received a low and a high dose of both the
”standard“ and the ”test drug,“ chosen at equilog intervals. Unless a patient completed all
doses of the cross-over comparison or ”round,“ his data were excluded from the relative
potency analysis. After completing the first round, some patients were able to repeat the
course, allowing for comparison of replicate rounds within the same individual.”
Outcomes - Pain intensity: assessed by participant “hourly for 6 hours after administration of the
studymedication or until pain returned to the premedication level and a routine analgesic
was administered (if at least 3 hr [hours] had elapsed since administration of the study
medication);” using a 4-point categorical scale (0 = none, 1 = slight, 2 = moderate, 3 =
severe)
- Pain relief: assessed by participant hourly for 6 hours after administration of the study
medication or until pain returned to the premedication level and a routine analgesic was
administered (if at least 3 hr had elapsed since administration of the study medication)
; using a 5-point categorical scale (0 = none, 1 = slight, 2 = moderate, 3 = lots, 4 =
complete)
“Patients who were remedicated before 6 hr elapsed after administration of a study
medication were assigned scores of zero (0) for change in pain intensity and pain relief
for the remaining observation points of the 6-hr observation period.”
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- Adverse effects: “The observer also recorded apparent and volunteered side-effects, but
leading questions were avoided.”
Notes - Study free of commercial funding? No: “This work was supported in part by grants
awarded by the Committee on Problems of Drug Dependence, National Academy of
Sciences, National Research Council, from funds contributed by a group of interested
pharmaceutical manufacturers, and by National Cancer Institute Grant CA-08748.”
- Groups comparable at baseline? No participant details reported by initial treatment
allocation
- ITT analyses undertaken? No: “Unless a patient completed all doses of the crossover
comparison or “round,” his data were excluded from the relative potency analysis.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Treatments were assigned to patients ac-
cording to a series of randomly chosen
Latin squares”. No further information re-
ported
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “Neither the patient nor the observer was
aware of the identity of the medications,
which were physically indistinguishable
and identified only by a numerical code on
individual dosage envelopes. To maintain
double-blind conditions, both capsules and
an injection, one of which was a dummy,
were administered each time a patient was
given a study medication.” From Beaver
1978a
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk Participant reported. See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Participant reported. See cell above
Incomplete outcome data (attrition bias)
Pain
Unclear risk Data included from 28/34 and 26/30 par-
ticipants in the two studies, respectively
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Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Data included from 28/34 and 26/30 par-
ticipants in the two studies, respectively
Selective reporting (reporting bias) High risk No side effects or adverse events reported
in detail: Study 1: “While side-effects ob-
served after both morphine and oxycodone
were typical of the narcotic analgesics, they
did not occur with sufficient frequency to
allow ameaningful comparison of the side-
effect liability of the two drugs. Notewor-
thy was the virtual absence of side-effects
in patients in series II, an observation con-
sistent with these patients’ substantial tol-
erance to narcotics.” Study 2: “Side-effects
were qualitatively similar to those noted in
the oxycodone-morphine comparison, but
they did not occurwith sufficient frequency
to allow a meaningful comparison among
treatments.”
Other bias Unclear risk It is unclear if this study is subject to a high
risk of other biases
Were the participants adequately titrated? Unclear risk Not enough information provided
For cross-over trials: are data available for
both time periods?
Low risk Yes, data are available from all the cross-
over periods
Bruera 1998
Methods Design: randomised, double-blind, cross-over trial.
Year: not reported.
Country: Canada.
Participants Participants: 32 participants entered, 23 participants analysed for efficacy and VAS vari-
ables (5 participants dropped out during the CR morphine phase: 3 in phase 1, 2 in
phase 2; 1 due to lack of pain control and adverse event, 1 due to protocol violation, 3
due to adverse events; 4 participants dropped out during the CR oxycodone phase: 2 in
phase 1, 2 in phase 2; 1 due to lack of pain control, 2 due to adverse events, 1 was lost
to follow-up); 13 women, 10 men; age not reported; cancer type: lung (7), breast (7),
prostate (1), other (8): cancer stage not reported; type of pain not reported; setting: pal-
liative care programme; previous analgesic medication: IR morphine (8), CR morphine
(10), IR oxycodone ± acetaminophen (11), CR hydromorphone (1), CR codeine (1),
IR codeine + acetaminophen (1); duration of opioid use: 6.6 (± 10) months; duration
of chronic pain: 8 (± 13) months
Inclusion criteria: “The study included 32 patients from the Palliative Care Program at
the Cross Cancer Institute and Grey Nuns Hospital in Edmonton, Canada. All patients
were≥ 18 years of age, gave written informed consent, had pain due to cancer, and were
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receiving treatment with an oral opioid analgesic at study entry. Life expectancy for all
patients was estimated by the treating physician to be at least 4 months.”
Exclusion criteria: use of active anticancer therapy, with the exception of hormones,
within 2 weeks of study entry; physical or mental inability to answer questions and com-
ply with the treatment protocol; history of intolerance of oxycodone or any related com-
pound; impaired renal or hepatic function; significantly impaired ventilatory function
(clinically present dyspnoea at rest); current use of an investigational drug; pregnancy
or lactation; unwillingness or inability to co-operate or give written, informed consent;
and inability to take oral medications
Interventions Oxycodone arm
- Drug: oxycodone + placebo morphine.
- Dose and dosing: mean dose 46.5 (± 57) mg every 12 hours
- Formulation: Controlled-release (CR)
- Route of administration: oral.
- Length of treatment: 7 days.
- Titration schedule: “≥ 3 day prestudy history of stable analgesia (defined as a daily
rescue opioid consumption ≤ 20% of the scheduled daily opioid dose).”
- Rescue medication: Immediate-release oxycodone hydrocloride, at doses of ca 10% of
daily scheduled opioid dose. Mean daily number of doses 2.3 (± 2.3)
- Other medication: no other analgesic agents. All other prestudy medications were
maintained with no changes allowed later than 72 hours before randomisation
Comparison arm
- Drug: morphine + placebo oxycodone.
- Dose and dosing: mean dose = 72.6 (± 102) mg every 12 hours
- Formulation: Controlled-release (CR)
- Route of administration: oral.
- Length of treatment: 7 days.
- Titration schedule: “≥ 3 day prestudy history of stable analgesia (defined as a daily
rescue opioid consumption ≤ 20% of the scheduled daily opioid dose).”
- Rescue medication: Immediate-release (IR) morphine, at doses of ca 10% of daily
scheduled opioid dose. Mean daily number of doses 1.7 (± 2.1)
- Other medication: no other analgesic agents, all other prestudy medications were
maintained with no changes allowed later than 72 hours before randomisation
“Patients who had been receiving narcotic analgesics other thanmorphine or single-entity
oxycodone before the start of the study were transferred to an equianalgesic oral dose of
controlled-release oxycodone or controlled-release morphine at the start of phase 1. The
initial dose of controlled-release oxycodone was determined busing a 1:1.5 conversion
ratio between controlled-release oxycodone and controlled-release morphine.”
- For cross-over trials, cross-over schedule: on day 8 participants crossed over to receive
the alternative drug and placebo at a dose equivalent to that received at the start of
phase 1. During both study phases, blind-labelled dose adjustments were permitted if
participants required more than 3 rescue analgesic doses over 24 hours
Outcomes - Pain intensity: assessed by participant 4 times per day before dosing and at the end
of each phase; 100-mm VAS (0 = no pain to 100 = worst possible pain) and 5-point
categorical scale (0 = no pain to 4 = worst possible pain)
- Overall effectiveness of the study medication: assessed by participant on days 8 and 15;
verbal rating scale (0 = not effective to 3 = highly effective)
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- Nausea and sedation: days 8 and 15; 100-mm VAS (0 = no nausea or sedation to 100
extreme nausea or sedation)
- Adverse events: recorded by participants; checklist (nausea, vomiting, constipation, dry
mouth, drowsiness, dizziness, difficulty concentrating, fatigue, poor sleep, vivid dreams,
hallucinations, headache, agitation, twitching, itching, sweating (from 0 = none to 4 =
intolerable) and non-directed adverse events questionnaire
- Treatment preference: assessed by participants and investigators at the end of study
Notes - Study free of commercial funding? Unclear. No information provided
- Groups comparable at baseline? No participant details reported by initial treatment
allocation
- ITT analyses undertaken? No for efficacy or VAS variables where the analyses restricted
to the 23/32participantswho completed both study phases. Safety variableswere analysed
for all enrolled participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised. No further
information provided
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “Blinding was maintained by the double-
dummy technique using matching place-
bos of controlled release oxycodone and
controlled-release morphine. The immedi-
ate-release oxycodone and morphine for-
mulations were also blinded.”
Trial labelled as ’double-blind’
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk “Blinding was maintained by the double-
dummy technique using matching place-
bos of controlled release oxycodone and
controlled-release morphine. The immedi-
ate-release oxycodone and morphine for-
mulations were also blinded.”
Trial labelled as ’double-blind’
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above. Outcome was participant-
reported
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above. Outcome was participant-
reported
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Incomplete outcome data (attrition bias)
Pain
High risk 23/32 participants analysed.
Incomplete outcome data (attrition bias)
Adverse events
High risk The only safety data analyses that are re-
ported analysed 23/32 participants
Selective reporting (reporting bias) High risk The majority of the adverse events are not
reported beyond the sentence “There were
no statistically significant differences by
treatment in mean severity for any of the
elicited adverse events or in frequency of
reporting of unelicited events.”
Other bias Low risk The authors report that “There was no ev-
idence of period or sequence (carry-over)
effect.” No other biases were identified
Were the participants adequately titrated? Low risk The participants were probably adequately
titrated
For cross-over trials: are data available for
both time periods?
Low risk Yes. Data only analysed if available from
both time periods
Corli 2016
Methods Design: randomised, parallel group, open-label, superiority, phase IV clinical trial
Year: 2011-2014.
Country: Italy.
Participants Participants: of 520 randomised participants, 515 included in safety analyses and 498
included in ITT analyses
- Morphine: 122 participants, 67 men, 55 women; mean (SD) age 67.5 (± 11.7) years;
cancer type: lung/pleura (34), colon/rectum (11), breast (17), prostate (6), pancreas (14)
, genitourinary (10), oesophagus/stomach/duodenum (3), head/neck (9), gynaecological
(11), myeloma (1), sarcoma (0), other (6); tumour metastatic: yes (101); ongoing cancer
therapy (53); previous administration of weak opioids for the background pain (88);
type of pain: only nociceptive (98), only neuropathic (0), nociceptive and neuropathic
(23), insufficient information to classify (1), missing (0)
- Oxycodone: 125 participants, 72 men, 53 women; mean (SD) age 66.9 (± 11.1) years;
cancer type: lung/pleura (31), colon/rectum (14), breast (16), prostate (13), pancreas (8)
, genitourinary (8), oesophagus/stomach/duodenum (8), head/neck (8), gynaecological
(6), myeloma (4), sarcoma (2), other (7); tumour metastatic: yes (112); ongoing cancer
therapy (48); previous administration of weak opioids for the background pain (81);
type of pain: only nociceptive (106), only neuropathic (0), nociceptive and neuropathic
(18), insufficient information to classify (1), missing (0)
- Buprenorphine: 127 participants, 68 men, 59 women; mean (SD) age 65.2 (± 13.
5) years; cancer type: lung/pleura (39), colon/rectum (15), breast (22), prostate (4),
pancreas (13), genitourinary (3), oesophagus/stomach/duodenum (1), head/neck (13),
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gynaecological (8), myeloma (2), sarcoma (3), other (4); tumour metastatic: yes (107);
ongoing cancer therapy (48); previous administration of weak opioids for the background
pain (89); type of pain: only nociceptive (102), only neuropathic (1), nociceptive and
neuropathic (23), insufficient information to classify (1), missing (0)
- Fentanyl: 124 participants, 70 men, 54 women; mean (SD) age 68 (± 10.6) years;
cancer type: lung/pleura (37), colon/rectum (17), breast (10), prostate (6), pancreas (4),
genitourinary (10), oesophagus/stomach/duodenum (6), head/neck (12), gynaecological
(9), myeloma (5), sarcoma (3), other (5); tumour metastatic: yes (104); ongoing cancer
therapy (42); previous administration of weak opioids for the background pain (85);
type of pain: only nociceptive (106), only neuropathic (0), nociceptive and neuropathic
(15), insufficient information to classify (2), missing (1)
Inclusion criteria: Participants with diagnostic (histological or cytological) evidence of
locally advanced or metastatic solid tumour; with persistent moderate to severe cancer
pain (average pain intensity ≥ 4, measured on a 0-10 numerical rating scale (NRS) and
related to the last 24 hours); requiring for the first time an analgesic treatment with third
step WHO sopioids; aged > 18 years
Exclusion criteria: Participants with a diagnosis of primary brain tumour or leukaemia,
or undergoing concurrent radiotherapy, first-line chemotherapy started 7 days before
randomisation, or on any nonpharmacological analgesic treatment or with preexisting
renal failure
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose and dosing: ”The initial dose of opioid was based on the recommendations of the
European Association for Palliative care.“ ”The suggested initial daily dose was 60 mg
of oral M[orphine] for participant with previous WHO step II treatment or half of this
(30 mg/day) for opioid-naïve participants. The doses of the other opioids were regulated
on the basis of the oral M equivalent dose ratio.“ Protocol lists 40 mg/24 hours. Mean
(± SD) initial dose (as oral morphine equivalent daily dose) 44.6 (± 16) mg/day. Mean
(± SD) final dose (as oral morphine equivalent daily dose) 71.1 (± 60.8) mg/day
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 28 days.
- Titration schedule: ”During the follow-up [active treatment phase], any adjustments
necessary for better control of pain was allowed for clinical and ethical reasons. Physicians
could change the dose, add another opioid or adjuvant drug or change the opioid (switch)
. In case of constantly unsatisfactory analgesia or severe toxicity, the opioid could be
discontinued.“
- Rescue medication: not reported.
- Other medication: see ’Titration schedule.’
Comparison arm 1
- Drug: morphine.
- Dose and dosing: ”The initial dose of opioid was based on the recommendations of the
European Association for Palliative care.“ The suggested initial daily dose was 60 mg/24
hours for participants who had previously received WHO step-II opioids and 30 mg/
24 hours for opioid-naive participants. Mean (± SD) initial dose 45.7 (± 16.2) mg/day.
Mean (± SD) final dose 58.9 (± 38.6) mg/day
- Formulation: Controlled-release
- Route of administration: oral.
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- Length of treatment: 28 days.
- Titration schedule: ”During the follow-up [active treatment phase], any adjustments
necessary for better control of pain was allowed for clinical and ethical reasons. Physicians
could change the dose, add another opioid or adjuvant drug or change the opioid (switch)
. In case of constantly unsatisfactory analgesia or severe toxicity, the opioid could be
discontinued.“
- Rescue medication: not reported.
- Other medication: see ’Titration schedule.’
Comparison arm 2
- Drug: buprenorphine.
- Dose and dosing: ”The initial dose of opioid was based on the recommendations of the
European Association for Palliative care“ ”The suggested initial daily dose was 60 mg of
oral M[orphine] for participants with previous WHO step II treatment or half of this
(30 mg/day) for opioid-naïve participants. The doses of the other opioids were regulated
on the basis of the oral M equivalent dose ratio.“ Protocol listed 35 µg/hour. Mean (SD)
initial dose (as oral morphine equivalent daily dose) 53.7 (12.5) mg/day. Mean (± SD)
final dose (as oral morphine equivalent daily dose) 80.1 (± 40.4) mg/day
- Formulation: patch.
- Route of administration: Transdermal
- Length of treatment: 28 days.
- Titration schedule: ”During the follow-up [active treatment phase], any adjustments
necessary for better control of pain was allowed for clinical and ethical reasons. Physicians
could change the dose, add another opioid or adjuvant drug or change the opioid (switch)
. In case of constantly unsatisfactory analgesia or severe toxicity, the opioid could be
discontinued.“
- Rescue medication: not reported.
- Other medication: see ’Titration schedule.’
Comparison arm 3
- Drug: fentanyl.
- Dose and dosing: ”The initial dose of opioid was based on the recommendations of
the European Association for Palliative care“ The suggested initial daily dose was 60 mg
of oral M[orphine] for participants with previous WHO step II treatment or half of this
(30 mg/day) for opioid-naïve participants. The doses of the other opioids were regulated
on the basis of the oral M equivalent dose ratio.” Protocol lists 25 µg/hour. Mean (± SD)
initial dose (as oral morphine equivalent daily dose) 53.4 (± 14.2) mg/day. Mean (± SD)
final dose (as oral morphine equivalent daily dose) 111.4 (± 74.9) mg/day
- Formulation: patch.
- Route of administration: Transdermal
- Length of treatment: 28 days.
- Titration schedule: “During the follow-up [active treatment phase], any adjustments
necessary for better control of pain was allowed for clinical and ethical reasons. Physicians
could change the dose, add another opioid or adjuvant drug or change the opioid (switch)
. In case of constantly unsatisfactory analgesia or severe toxicity, the opioid could be
discontinued.”
- Rescue medication: not reported.
- Other medication: see ’Titration schedule.’
Outcomes - Pain intensity (average and worst) measured on a 0 to 10 NRS
- Adverse events
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Notes - Study free of commercial funding? Study particularly funded by Grünenthal-Italia, but
funder “had no role in study design, data collection and analysis, decision to publish or
preparation of the manuscript.”
- Groups comparable at baseline? No inferential statistics reported. Treatment groups
appear to be reasonably comparable at baseline
- ITT analyses undertaken? Yes for efficacy; no for safety (which considered the partici-
pants for the treatment received)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation.
Allocation concealment (selection bias) Low risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
High risk Open-label.
Blinding of participants and personnel
(performance bias)
Adverse events
High risk Open-label.
Blinding of outcome assessment (detection
bias)
Pain
High risk Open-label.
Blinding of outcome assessment (detection
bias)
Adverse events
High risk Open-label.
Incomplete outcome data (attrition bias)
Pain
Low risk 498/520 randomised participants were in-
cluded in the analyses
Incomplete outcome data (attrition bias)
Adverse events
Low risk 515/520 randomised participants were in-
cluded in the safety analyses
Selective reporting (reporting bias) Low risk All the obvious outcomes appear to be re-
ported
Other bias Low risk The study does not appear to be subject to
other bias
Were the participants adequately titrated? Low risk The participants appear to be adequately
titrated
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For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
Gabrail 2004
Methods Design: randomised, double-blind, cross-over trial.
Year: not reported.
Country: USA.
Participants Participants: 58 participants screened, 47 participants titrated, 45 participants ran-
domised, and 44 participants received ≥ 1 dose of study medication and had ≥ 1 pain
intensity evaluation after treatment and were therefore analysed for safety (1/45 never
received any double-blind study medication and was excluded from all analyses). 37/
45 randomised participants completed the first double-blind phase and ≥ 5 days of the
second phase and were analysed for efficacy (2/45 participants had insufficient visits or
assessments to be included in the efficacy population); 5/45 randomised participants
discontinued the drug during the double-blind treatment periods: 2 participants with-
drew due to adverse events unrelated to the study drug, 2 participants withdrew consent
and 1 participant due to protocol violation. 0 participants discontinued the study due
to insufficient analgesia or loss to follow-up
21 safety and 18 efficacy participants received extended-release oxymorphone followed
by controlled-release oxycodone and 23 safety and 19 efficacy participants received con-
trolled-release oxycodone followed by extended-release oxymorphone
21 men, 23 women, mean age (range) 59.3 (26-81) years; 80% had severe untreated pain
and 20% had moderate untreated pain. Previous anticancer therapy included surgery
(68%), chemotherapy (82%), radiotherapy (50%), and/or immunotherapy (2.3%)
Inclusion criteria: men and women aged ≥ 18 years with moderate to severe pain sec-
ondary to cancer who required long-term outpatient treatment with an opioid analgesic.
People hospitalised for reasons unrelated to cancer were also eligible
Exclusion criteria: allergy or sensitivity to morphine, extended-release oxymorphone,
controlled-release oxycodone or their components; requirement for a concurrent opioid
analgesic other than the study medication; contraindication to opioid therapy; preg-
nancy; lactation; plan for pregnancy; uncontrolled emesis; inability to take adequate oral
food and hydration; levels of hepatic enzymes (gamma-glutamyl transpeptidase, alanine
aminotransferase, and aspartate aminotransferase) ≥ 3 times the upper limit of the nor-
mal range; receipt of radiotherapy or therapeutic radionuclides within the previous 2
weeks preceding study enrolment
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose and dosing: mean daily dose 91.9 mg (any dose adjustments were made during
the first 3 days of the double-blind phase; dosage remained fixed thereafter)
- Formulation: Controlled-release (CR)
- Route of administration: oral.
- Length of treatment: 7-10 days, take medication at 8 a.m. and 8 p.m
- Titration schedule: “During the open-label titration/stabilization phase, patients re-
ceived either oxymorphone immediate-release (IR) or oxycodone CR to determine a
stable dosage, defined as a fixed dosage that provided adequate analgesia for at least 2
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consecutive days, required no more than 2 doses of rescue medication/day, and produced
tolerable AEs [adverse events].”
- Rescue medication: tablets of 15 mg oral morphine sulphate (IR) every 4-6 hours
as needed. Participants requiring > 2 doses/day after the first 3 days of double-blind
treatment were discontinued. Mean daily dose (range) = 12.6 (0-75) mg
- Other medication: not reported.
Comparison arm
- Drug: oxymorphone.
- Dose and dosing: mean daily dose 45.9 mg (any dose adjustments were made during
the first 3 days of the double-blind phase; dosage remained fixed thereafter)
- Formulation: Extended-release, take medication at 8 am and 8 pm
- Route of administration: oral.
- Length of treatment: 7-10 days.
- Titration schedule: “During the open-label titration/stabilization phase, patients re-
ceived either oxymorphone immediate-release (IR) or oxycodone CR to determine a
stable dosage, defined as a fixed dosage that provided adequate analgesia for at least 2
consecutive days, required no more than 2 doses of rescue medication/day, and produced
tolerable AEs [adverse events].”
- Rescue medication: tablets of 15 mg oral morphine sulphate (IR) every 4-6 hours
as needed. Participants requiring > 2 doses/day after the first 3 days of double-blind
treatment were discontinued. Mean daily dose (range) 16.6 (0-90) mg
- Other medication: not reported.
- For cross-over trials, cross-over schedule: “Following the first double-blind treatment
period, patients crossed over to the alternative double-blind treatment (oxymorphone
ER or oxycodone CR) for an additional 7-10 days.”
Outcomes - Pain intensity: Assessed by daily diary recording by the participants of all study drugs
taken (including supplemental pain medication) and their 24-hour pain intensity, using
an 11-point numerical scale (0 = no pain to 10 = worst possible pain) and the Brief Pain
Inventory
- Quality of life: assessed by the Brief Pain Inventory to assess the interference of pain
with 7 domains of quality of life (general activity, mood, walking ability, normal work,
relations with other people, sleep, and enjoyment of life). Appeared to be rated by the
participants during the study visits that marked the end of each double-blind treatment
phase
- Global assessment of current pain medication, rated by participants and physicians
independently following each double-blind phase. Physicians were asked “Please rate the
subject’s current pain medication used for treating their cancer pain”
- Karnofsky performance status: assessed by physicians at each visit
- Safety analysis: assessed by physical examination, vital signs, clinical laboratory tests
(serum chemistry profile, complete blood count, urinalysis), electrocardiograms, and the
monitoring of adverse events (which were rated by the investigators as mild, moderate,
severe intensity, and as unlikely, possibly, probably related to study medication)
Notes - Study free of commercial funding? No, the study was funded by Endo Pharmaceuticals
Inc., Chadds Ford, PA and Penwest Pharmaceuticals Co., Danbury, CT
- Groups comparable at baseline? The authors report that there were no significant
differences in the demographic or baseline characteristics of the treatment groups, but
did not report these characteristics split by treatment group
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- ITT analyses undertaken? No for efficacy and safety where the analyses were restricted
to 37 and 41 to 43 of 45 randomised participants, respectively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised. No further
information provided
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk The study is described as “double-blind”.
No further information reported, so it is
unclear who was blinded and whether it
was adequately executed
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk 37/45 randomised participants were anal-
ysed for efficacy.
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk 41 to 43 of 45 randomised participants
were analysed for efficacy
Selective reporting (reporting bias) Low risk The main expected outcomes are reported
Other bias Low risk The authors report that “There were no se-
quence effects observed during the study;
comparable pain scores and other effi-
cacy measures were obtained irrespective of
the order in which patients received the
study medication.” No other potential bi-
ases were identified
Were the participants adequately titrated? Low risk The participants were probably adequately
titrated
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For cross-over trials: are data available for
both time periods?
Low risk Yes, data are available for both study periods
for 40/45 participants
Hagen 1997
Methods Design: randomised, double-blind, cross-over trial.
Year: not reported.
Country: Canada.
Participants Participants: 44 participants enrolled, 31 participants completed the study. Reasons for
withdrawal included adverse events (8), inadequate pain control (3), intercurrent illness
(1), and voluntary withdrawal (1). “Failure to complete both phases of the study did
not appear to be related to toxicity of one of the study drugs over another.” The analysis
of all efficacy outcome variables, including VAS and categorical pain intensity, sedation
VAS and nausea VAS were restricted to participants completing both study phases.
Spontaneously reported safety variables were analysed for all enrolled participants
13 men/18 women, mean age (± SE) = 56 (± 3) years. Primary tumour: breast (7),
colorectal (5), lung (1), urological/prostate (5), CNS (4), unknown primary (2), other
(7). Type of pain: bone (61%), soft tissue (29%), visceral (23%), neuropathic (45%).
Pain described as “lancinating” (16%): steady pain (61%), incident pain with or without
steady pain (52%)
Inclusion criteria: Patients with chronic cancer pain and stable analgesic requirements
Exclusion criteria: Knownhypersensitivity to opioid analgesics, intolerance of oxycodone
or hydromorphone, presence of a medical or surgical condition likely to interfere with
drug absorption in the gastrointestinal tract, concurrent use of other opioid analgesics
during the study period, presence of intractable nausea and vomiting, and patients who
had undergone or were expected to undergo therapeutic procedures likely to influence
their pain during the study period
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose and dosing: mean daily initial dose = 120 ± 22 mg, mean final dose = 124 ± 22
mg (blind-label dose changes were permitted, and in case of a dose change, the rescue
analgesic dose was modified accordingly)
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 7 days, 12-hourly.
- Titration schedule: “Patients with 3 days of stable analgesic requirements on a prestudy
opioid were randomized to controlled-release oxycodone or controlled-release hydro-
morphone. Stable analgesia was defined as 2 or fewer rescue doses of opioid analgesic
per 24-hour period, calculated over 3 or more days.”
- Rescue medication: incident and non-incident breakthrough pain was treated with
immediate-release oxycodone at a dosage of approximately 10% of the daily scheduled
dose. Mean daily frequency of rescue use (SD) = 1.4 ± 0.3 mg
-Othermedication: no other opioids were permitted.Non-opioid analgesics, such as cor-
ticosteroids, antidepressants, anticonvulsants, bisphosphonates, and psychostimulants,
that had been part of the participant’s therapy were continued at the same dose level
throughout the study
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Comparison arm
- Drug: hydromorphone.
- Dose/dosing: mean daily initial dose 24 (± 4) mg, mean (± SD) final dose 30 (± 6)
mg (blind-label dose changes were permitted, and in case of a dose change, the rescue
analgesic dose was modified accordingly)
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 7 days, 12-hourly.
- Titration schedule: “Patients with 3 days of stable analgesic requirements on a prestudy
opioid were randomized to controlled-release oxycodone or controlled-release hydro-
morphone. Stable analgesia was defined as 2 or fewer rescue doses of opioid analgesic
per 24-hour period, calculated over 3 or more days.”
- Rescue medication: Incident and nonincident breakthrough pain was treated with im-
mediate-release hydromorphone at a dosage of approximately 10% of the daily scheduled
dose. Mean daily frequency of rescue use (SD) = 1.6 ± 0.3 mg
-Othermedication: no other opioids were permitted.Non-opioid analgesics, such as cor-
ticosteroids, antidepressants, anticonvulsants, bisphosphonates, and psychostimulants,
that had been part of the participant’s therapy were continued at the same dose level
throughout the study
- For cross-over trials, cross-over schedule: “At the end of Phase I, patients were crossed
over to the alternative treatment in Phase II without an intervening washout period.”
Outcomes - Pain intensity: Assessed by participants 4 times daily (8.00, 12.000, 16.00, and 20.00)
on a 100 mm visual analogue scale (going from no pain to excruciating pain) and on a
5-point categorical scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = excruciating)
- Nausea and sedation: Assessed by participants 4 times daily (8.00, 12.000, 16.00, and
20.00) on a 100 mm visual analogue scale (going from no nausea or sedation to severe
nausea or extreme sedation)
- Spontaneously reported, investigator-observed and elicited adverse events were recorded
at the end of each phase
- Participant and investigator treatment preferences were recorded at the end of both
phases
Notes - Study free of commercial funding? No information reported, but the second author
(Najib Babul) is an employee of Purdue Frederick, which is the manufacturer of the
controlled-release oxycodone study drug used in the study
- Groups comparable at baseline? No information provided about initial group allocation
- ITT analyses undertaken? No for efficacy where the analyses were restricted to 31/44
participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
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Blinding of participants and personnel
(performance bias)
Pain
Low risk “Blinding was maintained by the dou-
ble-dummy technique, which involved
matching placebos. In the active treat-
ment phases, patients received either active
controlled-release oxycodone and place-
bosmatching controlled-release hydromor-
phone or active controlled-release hydro-
morphone and placebos matching con-
trolled-release oxycodone.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk The analyses were restricted to 31/44 par-
ticipants
Incomplete outcome data (attrition bias)
Adverse events
High risk The analyses were restricted to 31/44 par-
ticipants, or not reported in a manner that
allowed them to be included in any meta-
analysis
Selective reporting (reporting bias) Unclear risk The adverse event reporting is restricted to
4 adverse events in a manner that does not
allow them to be included in themeta-anal-
ysis
Other bias Low risk The authors reported that analysis of
treatment sequence revealed no significant
carry-over effects
Were the participants adequately titrated? Low risk The participants were probably adequately
titrated
For cross-over trials: are data available for
both time periods?
Low risk Yes, data are available for both study periods
for 31/44 participants
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Methods Design: randomised, double-blind, cross-over trial.
Year: not reported.
Country: Finland.
Participants Participants: 45 participants enrolled, and 27/45 participants were evaluated for efficacy
and safety. Reasons for withdrawal included adverse events (all were nausea/vomiting; 7)
, unstable pain control at the end of titration (5), non-compliance (3), sudden deterio-
ration unrelated to the study (1), and a technical error (1); 1 participant was withdrawn
due to suspected incomplete absorption of controlled-release oxycodone
16 men/11 women, mean age (range) 60 (39-76) years. Primary tumour: breast (2),
rectum (5), lung (4), prostate (6), kidney (1), pancreas (4), unknown primary (2), and
other (3). Former analgesics: morphine alone or in combination with other analgesic
(20), oxycodone alone or in combination with other analgesic (5). 12 participants were
randomised to titration with CR oxycodone and 15 participants with CR morphine
Inclusion criteria: Patients with chronic cancer pain requiring opioid analgesics, who
were co-operative, and able to take oral medication and keep a simple diary
Exclusion criteria: Patients receiving radiation therapy or other cancer treatment that
could affect their pain
Interventions Oxycodone arm
- Drug: oxycodone + morphine-matched placebo.
- Dose and dosing: mean daily initial dose 123 mg at the end of titration
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 3-6 days, unclear how many doses per day
- Titration schedule: in opioid-naive participants, the open-label titration phase (of 21-
day maximum duration) was started with a total daily dose of 40 mg oxycodone. Dose
titration was continued until effective pain relief with acceptable adverse effects was
achieved for ≥ 48 hours. The controlled-release dose was titrated upwards if pain con-
tinued at the moderate to severe level or if > 2 dose of escape analgesic were used in a 24-
hour period. The controlled-release dose was titrated downwards in case of unacceptable
opioid adverse effects which were not manageable with appropriate treatment
- Rescuemedication: oxycodone hydrochloride solution in a dose of approximately 1/6 to
1/8 of the daily dose of controlled-release oxycodone; mean total amount per participant
during the last 3 days of the titration phase = 79 mg. Mean daily number of doses (SE)
during double-blind phase 1.26 (± 0.22) mg
- Other medication: Non-steroidal anti-inflammatory analgesics, if used by the partici-
pant before the study, were continued at the same dose
Comparison arm
- Drug: morphine + oxycodone-matched placebo.
- Dose and dosing: mean daily initial dose 180 mg at the end of titration
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 3-6 days, unclear how many doses per day
- Titration schedule: in opioid-naive participants the open-label titration phase (of 21-
day maximum duration) was started with a total daily dose of 40 mg oxycodone. Dose
titration was continued until effective pain relief with acceptable adverse effects was
achieved for ≥ 48 hours. The controlled-release dose was titrated upwards if pain con-
tinued at the moderate to severe level or if > 2 dose of escape analgesic were used in a 24-
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hour period. The controlled-release dose was titrated downwards in case of unacceptable
opioid adverse effects which were not manageable with appropriate treatment
- Rescue medication: morphine hydrochloride solution in a dose of approximately 1/6 to
1/8 of the daily dose of controlled-release morphine; mean total amount per participant
during the last 3 days of the titration phase = 74 mg. Mean daily number of doses (SE)
during double-blind phase = 0.79 ± 0.18 mg
- Other medication: Non-steroidal anti-inflammatory analgesics, if used by the partici-
pant before the study, were continued at the same dose
- For cross-over trials, cross-over schedule: after 3-6 days of dosing, the participant visited
the Pain Relief Unit for an end of phase visit. A similar 3- to 6-day period was then
completed in a cross-over fashion using the other opioid
Outcomes - Pain intensity: assessed by participants 4 times daily (morning, noon, evening, and
bedtime) on a 4-point verbal rating scale (none, slight, moderate, severe)
- Acceptability of therapy: assessed by participants twice daily, considering pain intensity
and adverse effects during the previous 12-hour period on a 5-point verbal rating scale
(very poor, poor, fair, good, excellent)
- Adverse experiences: recorded by participant in diary along with each dose of scheduled
and escape study medication, concomitant medications, and intercurrent illnesses
- At each double-blind phase ends, a Modified Specific Drug Effect Questionnaire was
completed by the participants and a trained research nurse or investigator
Notes - Study free of commercial funding? No, the study was funded by Purdue Frederick,
which is the manufacturer of the controlled-release oxycodone study drug used in the
study, and the Academy of Finland
- Groups comparable at baseline? No information provided about initial group allocation
- ITT analyses undertaken? No, the analyses were restricted to 27/45 participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer generated randomisation for
the open-label titration phase and again for
the double-blind phase was performed by
the Purdue FrederickCompany and a list of
randomisation codes was kept by the hos-
pital pharmacist.”
Allocation concealment (selection bias) Low risk See cell above. No further details reported.
Probably adequate
Blinding of participants and personnel
(performance bias)
Pain
Low risk A double-blind placebo controlled design
was used. It is unclear whowas blinded, but
it appears that at least the participants were
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above
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Blinding of outcome assessment (detection
bias)
Pain
Low risk Participant-reported. See also cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk The analyses were restricted to 27/45 par-
ticipants
Incomplete outcome data (attrition bias)
Adverse events
High risk The analyses were restricted to 27/45 par-
ticipants
Selective reporting (reporting bias) Low risk All expected main outcomes appear to be
reported
Other bias Low risk It is unclear whether there were any carry-
over effects, but there probably were none
Were the participants adequately titrated? Low risk The participants were probably adequately
titrated
For cross-over trials: are data available for
both time periods?
Low risk Yes, data are available for both study periods
for 27/45 participants
Imanaka 2013
Methods Design: randomised, double-blind, parallel-group multicentre, non-inferiority trial
Year: 25 August 2010 to 16 August 2012.
Country: Japan, Korea.
Participants Participants: 343 participants enrolled, and 340/343 participants received ≥ 1 dose of
study drug (172 oxycodone, 168 tapentadol); 236/343 participants completed treatment
(123 oxycodone, 113 tapentadol), and 231/343 participants completed the study (121
oxycodone, 110 tapentadol). Reasons for withdrawal included adverse events (14 oxy-
codone, 12 tapentadol), progressive disease (15 oxycodone, 11 tapentadol), withdrawal
of consent (8 oxycodone, 8 tapentadol), physician decision (1 oxycodone, 8 tapentadol)
, protocol violation (5 oxycodone, 5 tapentadol), lack of efficacy (1 oxycodone, 4 tapen-
tadol), non-compliance (4 oxycodone, 1 tapentadol), death (1 oxycodone, 0 tapentadol)
, other (0 oxycodone, 6 tapentadol)
Oxycodone: 172, 100 men, 72 women, mean age (± SD) 64.9 (± 11.41) years, 110
Japanese and 62 Korean. Primary tumour: gastrointestinal (65); respiratory or mediasti-
nal (46); > 92% participants had metastatic cancer. Former analgesics: not reported
Tapentadol: 168, 90 men, 78 women, mean age (± SD) 65.5 (11.21) years, 111 Japanese
and 57 Korean. Primary tumour: gastrointestinal (70); respiratory or mediastinal (53);
> 92% participants had metastatic cancer. Former analgesics: not reported
Inclusion criteria: Patients aged ≥ 20 years with a diagnosis of any type of cancer,
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experiencing chronicmalignant tumour-related pain, with an average pain intensity score
over the past 24 hours ≥ 4 on an 11-point numerical rating scale (NRS) (0 = ‘no pain’
to 10 = ‘pain as bad as you can imagine’) on the day of randomisation, who “had not
taken opioid analgesics (except for codeine phosphate (≤ 60mg/day), or dihydrocodeine
phosphate (≤ 30 mg/day) as antitussives) within 28 days before screening. Patients must
have been dissatisfied with the pain relief achieved on their current analgesic treatment
for cancer pain and must have had pain requiring treatment with an opioid analgesic
(based on the investigator’s assessment).”
Exclusion criteria: “an uncontrolled or clinically significant arrhythmia; a history of or
current disease that could result in increased intracranial pressure, disturbance of con-
sciousness, lethargy, or respiratory problems; any disease for which opioids are con-
traindicated; a history of surgery intended for the cure of the primary disease or for the
treatment of cancer pain within 28 days before screening or during the study; radiation
therapy within 7 days before screening; or a psychiatric disorder or concurrent symptoms
with accompanying pain that could interfere with efficacy and safety evaluations. Patients
were also excluded if they had any of the following laboratory values at screening: white
blood cell count ≤ 3000/mL, platelet count ≤ 10 x 104/uL, haemoglobin ≤ 9.5 g/dL,
corrected total serum calcium level > 12.5 mg/dL, alanine aminotransferase or aspartate
aminotransferase ≥ 3 times the upper limit of normal, total bilirubin ≥ 1.5 times the
upper limit of normal, or creatinine ≥ 2 mg/dL. The following medications were pro-
hibited: opioid analgesics (including codeine phosphate and dihydrocodeine phosphate
as antitussives), except morphine IR 5 mg as rescue medication); opioid antagonists
(e.g., naloxone, levallorphan), except for the treatment of respiratory depression; anti-
parkinsonian drugs; neuroleptics (including antipsychotics, except for prochlorperazine)
; monoamine oxidase inhibitors; serotonin norepinephrine reuptake inhibitors; nora-
drenergic and specific serotonergic antidepressants; radiotherapy; nerve block; stimula-
tion analgesia; other investigational drugs. The following drugs were prohibited on an as-
needed basis as newly started treatment (but could be continued at the same and regimen
if started before study entry): Selective serotonin reuptake inhibitors; tricyclic or tetra-
cyclic antidepressants; anti-anxiety agents (e.g., benzodiazepines); hypnotics (e.g., benzo-
diazepines, non-benzodiazepine hypnotics, barbiturates); anticonvulsants; central mus-
cle relaxants; bisphosphonates; corticosteroids; anti-arrhythmics; non-opioid analgesics
(nonsteroidal anti-inflammatory drugs (e.g., cyclo-oxygenase II inhibitors)); pyrazolone
antipyretic agents (e.g., sulpyrine) and analine antipyretic agents (e.g., acetaminophen)
; neurotropin; pregabalin. The following were permitted as needed during the study:
topical corticosteroids; lidocaine (as a local anesthetic); acetaminophen (≤ 1.5 g/day
(Japan) or≤ 4 g/day (Korea) for fever reduction); supportive therapy for chemotherapy;
stable doses of very short-acting, non-benzodiazepine hypnotic drugs (for insomnia);
medications for nausea, vomiting, and constipation; and rescue medication (as described
below). Chemotherapy could be continued at the same dose or chemotherapy doses
could be reduced, discontinued, or restarted (if deemed necessary by the investigator);
however, if a patient’s chemotherapy was considered by the investigator to be interfering
with efficacy or safety evaluations of the study drug, that patient was excluded from the
study.”
Interventions Oxycodone arm
- Drug: Oxycodone HCI
- Dose/dosing: 5 to 40 mg bid. The median of the mean total daily dose = 13.8 mg. The
median modal (or most frequently used) total daily dose = 10 mg
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- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: “4 week double-blind treatment period (including titration and
maintenance periods), and a 1 week post-treatment period.” Median duration of treat-
ment 28 days
- Titration schedule: “Study treatment was initiated with twice daily doses of oxycodone
HCl [hydrochlorine] CR 5 mg. During the titration period, doses of study treatment
could be increased if necessary to achieve adequate pain control to a maximum of oxy-
codone HCl CR 40 mg bid [twice daily] after a patient had received the same dose
at least four consecutive times. Dose escalations could begin on Day 3 of the titration
period. Although not required for dose escalation, the following criteria were evaluated
in patients who needed a dose escalation (based on the investigators assessment): 24
hour pain intensity score (11-point NRS) of at least 4 on the previous evaluation and
rescue medication used for breakthrough pain at least three times per day. Doses could
be decreased during the study as needed for safety reasons to the minimum doses of
oxycodone HCl CR (5 mg bid). Study drug doses were titrated to each patient’s optimal
dose, balancing efficacy and tolerability, until sufficient analgesia was attained. Patients
with a pain intensity score of no more than 3 who did not take rescue medication more
than twice a day while taking stable doses of study drug (six consecutive identical doses)
over a consecutive 3 day period were considered eligible to formally enter the mainte-
nance period; patients who did not meet these criteria were permitted to continue in the
double-blind treatment period while continuing to titrate their dose. During the main-
tenance period, patients continued taking the optimal dose of study drug determined
during the titration period. Dose adjustments were permitted during the maintenance
period except during the last 3 days. Dose levels during the last 3 days of themaintenance
period were to be kept stable.”
- Rescue medication: “Oral morphine IR 5 mg was permitted throughout the study
(except during the screening period) as rescue medication for breakthrough pain, with
no limit on the number and timing of doses per day.” The mean (SD) of the average
number of morphine IR doses taken per day = 1.4 (0.43); mean (SD) of the average total
daily dose = 6.7 (2.15) mg morphine IR
- Other medication: See the inclusion and exclusion criteria in cell above
Comparison arm
- Drug: tapentadol.
- Dose and dosing: 25 to 200 mg bid. The median of the mean total daily dose = 64.5
mg. The median modal (or most frequently used) total daily dose = 50 mg
- Formulation: Extended-release
- Route of administration: oral.
- Length of treatment: “4 week double-blind treatment period (including titration and
maintenance periods), and a 1 week post-treatment period.” Median duration of treat-
ment 28 days
- Titration schedule: “Study treatment was initiated with twice daily doses of tapentadol
ER 25 mg. During the titration period, doses of study treatment could be increased if
necessary to achieve adequate pain control to a maximum of tapentadol ER 200 mg
bid [twice daily] after a patient had received the same dose at least four consecutive
times. Dose escalations could begin on Day 3 of the titration period. Although not
required for dose escalation, the following criteria were evaluated in patients who needed
a dose escalation (based on the investigators assessment): 24 hour pain intensity score
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(11 point NRS) of at least 4 on the previous evaluation and rescue medication used
for breakthrough pain at least three times per day. Doses could be decreased during the
study as needed for safety reasons to the minimum doses of tapentadol ER (25 mg bid)
. Study drug doses were titrated to each patient’s optimal dose, balancing efficacy and
tolerability, until sufficient analgesia was attained. Patients with a pain intensity score
of no more than 3 who did not take rescue medication more than twice a day while
taking stable doses of study drug (six consecutive identical doses) over a consecutive 3 day
period were considered eligible to formally enter the maintenance period; patients who
did not meet these criteria were permitted to continue in the double-blind treatment
period while continuing to titrate their dose. During the maintenance period, patients
continued taking the optimal dose of study drug determined during the titration period.
Dose adjustments were permitted during the maintenance period except during the last
3 days. Dose levels during the last 3 days of the maintenance period were to be kept
stable.”
- Rescue medication: “Oral morphine IR 5 mg was permitted throughout the study
(except during the screening period) as rescue medication for breakthrough pain, with
no limit on the number and timing of doses per day.” The mean (SD) of the average
number of morphine IR doses taken per day = 1.4 (0.46); mean (SD) of the average total
daily dose = 7 (2.3) mg morphine IR
- Other medication: See the inclusion and exclusion criteria in cell above
Outcomes - Pain intensity: Assessed by participants once daily (evening on an 11-point numerical
rating scale from 0 (no pain) to 10 (= pain as bad as you can imagine). Primary efficacy
endpoint was the mean change in average pain intensity from baseline to the last 3 days
of study
- Patient global impression of change: questionnaire completed at weeks 1, 2, 3 of double-
blind treatment and at the end of study or early withdrawal. Participants rated their
overall condition on a scale from 1 (very much improved) to 7 (very much worse) by
completing the following statement, “Since the start of this treatment, my cancer-related
pain overall is...”
- Adverse events: monitored and coded using the Medical Dictionary for Regulatory
Activities. Each instance of disease progression was considered an adverse event and
included in the analysis of treatment-emergent adverse events
Notes - Study free of commercial funding? No, the study was funded by Janssen Research and
Development
- Groups comparable at baseline? The groups appear to be comparable at baseline
- ITT analyses undertaken? No, the analyses were per protocol (“a subset of the full
analysis population that excluded any patient with a major protocol deviation from a
predefined list of deviations”)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patient assignments to study treatment
were based on a computer-generated ran-
domization schedule prepared by the spon-
sor prior to the study; randomization was
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balanced using randomly permuted blocks
and stratified by study site. An Interac-
tive Voice Response System (IVRS) as-
signed each patient a unique treatment
code,which determined that patient’s treat-
ment assignment.”
Allocation concealment (selection bias) Low risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “The blindwas not broken until all patients
completed the study and the database was
finalized, except in case of emergency.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk Per protocol analyses including 139/
172 oxycodone participants and 126/168
tapentadol participants
Incomplete outcome data (attrition bias)
Adverse events
Low risk The safety population included all ran-
domised participants who received at least
one dose of study drug, that is 340/343 ran-
domised participants (172 oxycodone par-
ticipants and 168 tapentadol participants)
Selective reporting (reporting bias) Low risk All main expected outcomes are reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the participants adequately titrated? Low risk The participants were probably adequately
titrated
For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
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Methods Design: randomised, double-blind, cross-over trial.
Year: not reported.
Country: Finland.
Participants Participants: 20 participants entered, 19 participants analysed (1 participant excluded as
her morphine dose had to be considerably reduced due to adverse effects); 11 women,
9 men; median age (range): 56 (20-75) years; cancer type: pancreatic (3), breast (5),
prostate (1), gastric (1), rectal (2), other (8): cancer stage: metastatic; type of pain: vis-
ceral (6), nerve (7), bone (5), bone-fracture (1), bone-nerve (1), soft tissue (1); setting:
not reported, tertiary ?; previous analgesic medication: buprenorphine (7), oxycodone
(1), dextropropoxyphene (1), aspirin + codeine (1), ibuprofen + buprenorphine (2), in-
domethacin + buprenorphine (1), dextropropoxyphene + buprenorphine (1), diclofenac
+ buprenorphine (1), indomethacin + codeine (2), naproxen + dextropropoxyphene (1)
, noramidopyrin + pitofenone (1), ketoprofen + dextropropoxyphene (1)
Inclusion criteria: “Twenty patients, 11 women and nine men, who had metastasised
cancer and severe pain and who required a change from weaker narcotic analgesic agents
(codeine, dextropropoxyphene, buprenorphine) to morphine, participated in the study.
”
Exclusion criteria: none reported.
Interventions Oxycodone arm
- Drug: oxycodone hydrochloride.
- Dose and dosing: previous opioid treatment was discontinued 12-24 hours before com-
mencing the study, and during this time 1 mg/kg meperidine was given intramuscularly
when requested. The participants titrated themselves free from pain in 48 hours using
a patient-controlled analgesia (PCA) device. The concentration of both morphine hy-
drochloride and oxycodone hydrocloride was 10 mg/ml.This treatment was continued
for another 48 hours with the use of the same drug, which was now taken orally. The
oral dose was calculated from the IV consumption during the previous 24 hours. The
daily oral dose was calculated in ml by assuming that the bioavailability of morphine was
either 44% (first 10 participants, group 1) or 33% (last 10 participants, group 2) and
that the bioavailability of oxycodone hydrocloride was 66% (group 1) and 50% (group
2). To overcome the differences in bioavailabilities of the two drugs, the concentrations
of the oral solutions were 2.7 mg/ml for oxycodone hydrocloride and 4 mg/ml for mor-
phine. The dosing interval was 4 hours and the dose was increased by 1 ml at a time if
the participant was not pain free during the 4-hour period. If the participant was pain-
free, but too sedated, the dose was decreased by 1 ml. PCA device: The bolus dose was
3 mg, which was given over a period of 60 seconds, followed by a tail dose of 2 mg over
1 hour. The lockout time, during which the participant was unable to initiate another
dose, was 15 minutes. If the participant was not free from pain with this regimen, the
tail dose was increased by 2 mg at a time
- Formulation: Immediate-release (oral)
- Route of administration: IV (2 days) then oral (2 days).
- Length of treatment: 4 days.
- Titration schedule: see ’Dose and dosing.’
- Rescue medication: see ’Dose and dosing.’ No further information was reported
- Other medication: any pre-existing treatment with non-steroidal anti-inflammatory
drugs was continued
Comparison arm:
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Same as oxycodone arm, just replacing oxycodone with morphine
- For cross-over trials, cross-over schedule: “The same protocol was then repeated with
the other drug for another 96 hours.”
Outcomes - Pain severity: Assessed by participant at study start and every 4 hours from 8 am to 8
pm; VAS from 0 to 10
- Adverse effects: determined by questioning (have you had nausea, constipation, drowsi-
ness, sedation symptoms, hallucinations, or any other symptoms you would connect
with the analgesic?) scored according to grade (moderate = 1, severe = 2); registered on
the second day of each study period
- Sleep quality, registered on the second day of each study period
- Participant preference or acceptability with reason
The last 24 hours of each of the four study stages were considered as the steady state and
the drug consumptions, and the ratings from the VAS during this period were used for
the statistical calculations
Notes - Study free of commercial funding? Yes. Supported by the Paolo (non-profit) Foundation,
Helsinki, Finland
- Groups comparable at baseline? No participant details reported by initial treatment
allocation
- ITT analyses undertaken? No, data from 1 participant in regard to morphine consump-
tion was excluded as her morphine dose had to be considerably reduced due to adverse
effects. Her data was included in the participant preference analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised. No further
information provided
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk The study is described as “double-blind”.
No further information reported, so it is
unclear who was blinded and whether it
was adequately executed
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above:
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above
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Incomplete outcome data (attrition bias)
Pain
Low risk The data from 1/20 participants were ex-
cluded
Incomplete outcome data (attrition bias)
Adverse events
Low risk Think the data from1/20 participants were
excluded
Selective reporting (reporting bias) Low risk The main expected outcomes are reported
Other bias Low risk The authors report that “The order in
which the drugs were given (either as the
first or the second study drug) had no ef-
fect on the drug consumption.” No other
potential biases were identified
Were the participants adequately titrated? Low risk The participants were probably adequately
titrated
For cross-over trials: are data available for
both time periods?
Low risk Yes, data are available for both study periods
for 19/20 participants
Kaplan 1998
Methods Design: randomised, double-blind, parallel-group trial.
Year: not reported.
Country: USA.
Participants Participants: 180 participants enrolled (108 before protocol amendment allowing dose
titration before randomisation and 72 after the amendment; 16/72 participants dis-
continued before randomisation due to lack of acceptable pain control (6), intercur-
rent illness (4), adverse event (2), death (1), withdrawal of consent (1), other (2). 164
participants were randomised (controlled-release oxycodone: N = 81; immediate-release
oxycodone 83); 156 were included in efficacy analyses (4 participants did not receive
the study medication, 3 participants did not complete the efficacy ratings, and 1 par-
ticipant may have received unblinded treatment). All 160 participants who received at
least 1 dose of study medication were included in the safety analyses (of adverse events)
. 74% of participants were white; mean (SE) age = 59 (1) years; 58% were male; most
participants were receiving oral morphine at study entry; cancer type: gastrointestinal
(22%), lung (21%), prostate (17%), breast (10%), gynaecological (10%): predominant
pain sites were bone and viscera, with an additional 15 participants (9 in controlled-
release oxycodone group and 6 in the immediate-release oxycodone group) reporting
neuropathic pain
Inclusion criteria: “Male and female patients with cancer-related pain were enrolled at
17 centers. The study received institutional review board approval at each center and all
patients gave written informed consent. At the time of enrollment, patients were being
treated with a strong single-entity opioid or 10 or more tablets per day of a fixed-dose
opioid/nonopioid analgesic; were receiving a stable opioid dose; and had stable coexistent
disease. Under the original protocol, patients were excluded if they were receiving any
other analgesics (opioid or nonopioid) or if theywere to receive radiotherapy immediately
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before enrollment or during the study period. After the study had begun, these exclusion
criteria were eliminated by an amendment to facilitate enrollment into the study, which
had been slow.”
Exclusion criteria: See above
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose/dosing: Oxycodone tablets (10 mg) every 12 hours (8 am and 8 pm) and placebo
tablets every 2 pm and bedtime. Mean daily dose (range) = 114 (20 to 400) mg
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 6 days
- Titration schedule: The original study design did not allowdose titration or use of rescue
medication for breakthrough/incident pain. Participants whose pain was not effectively
controlled at the initial oxycodone dose calculated from previous opioid use were discon-
tinued from the study. However, an interim analysis conducted to determine whether
dose adjustments were required showed that dropout rates were too high for relevant
conclusions. This suggested that the initial conversion dose estimate was not adequate
for a subgroup of participants, and the protocol was amended to include open-label
titration with immediate-release oxycodone before the participants were randomised to
double-blind treatment, as well as the use of immediate-release oxycodone 5 mg tablets
as rescue medication throughout the trial. Supplemental doses could be taken no more
frequently than every 4 hours at no more than approximately 1/6 of the daily dose of
study medication. No further information was reported
- Rescue medication: See ’Titration schedule’ above. Mean number of rescue medication
doses per day = 0.6
- Other medication: See ’Inclusion criteria’ above. No further information reported
Comparison arm
- Drug: Oxycodone
- Dose and dosing: Oxycodone tablets (5 mg)every 6 hours (8 pm, bedtime (≥ 3 hours
after 8 pm, but not after 2 am), 8 am and 2 pm). Mean daily dose (range) = 127 (40 to
640) mg
- Formulation: Immediate-release
- Route of administration: oral.
- Length of treatment: 6 days.
- Titration schedule: The original study design did not allowdose titration or use of rescue
medication for breakthrough/incident pain. Participants whose pain was not effectively
controlled at the initial oxycodone dose calculated from previous opioid use were discon-
tinued from the study. However, an interim analysis conducted to determine whether
dose adjustments were required showed that drop-out rates were too high for relevant
conclusions. This suggested that the initial conversion dose estimate was not adequate
for a subgroup of participants, and the protocol was amended to include open-label
titration with immediate-release oxycodone before the participants were randomised to
double-blind treatment, as well as the use of immediate-release oxycodone 5 mg tablets
as rescue medication throughout the trial. Supplemental doses could be taken no more
frequently than every 4 hours at no more than approximately 1/6 of the daily dose of
study medication. No further information was reported
- Rescue medication: see ’Titration schedule.’ Mean number of rescue medication doses
per day 1
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- Other medication: see ’Inclusion criteria.’ No further information reported
Outcomes - Pain intensity: Assessed by participant at study start and 4 times daily at 8 am, 2 pm,
8 pm and bedtime; categorical verbal scale from 0 (= none, 1 = slight, 2 = moderate) to
3 (= severe)
- Acceptability of treatment: Assessed by participant at study start and twice daily at 8am
and 8 pm; categorical verbal scale from 1 (= very poor; 2 = poor, 3 = fair, 4 = good) to 5
(= excellent)
- Adverse events: Those spontaneously reported by participants or observed by investi-
gators were recorded, and their severity and relationship to study drug (none, possible,
probable, definite) were assessed by each investigator
Notes - Study free of commercial funding? No, some or 1 of the authors (including the corre-
sponding author) were or was employee(s) of Purdue Pharma Ltd, the manufacturer of
the study drugs
- Groups comparable at baseline? The authors reported, “There were no significant
differences in the primary pain site, prestudy opioid, or cancer diagnosis between the
two treatment groups.” No other information reported
- ITT analyses undertaken? No, 156 and 160/164 participants, respectively, were in-
cluded in the safety and efficacy analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The authors state that the participants were
randomised, but give no further details
Allocation concealment (selection bias) Unclear risk The authors state that the participants were
randomised, but give no further details
Blinding of participants and personnel
(performance bias)
Pain
Low risk Double-blind placebo-controlled study. To
maintain the blind, all doses of the study
medication were encapsulated in green size
#00 lactose-filled capsules
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
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Incomplete outcome data (attrition bias)
Pain
Low risk A total of 156/164 participants were in-
cluded in the efficacy analyses
Incomplete outcome data (attrition bias)
Adverse events
Low risk A total of 160/164 participants were in-
cluded in the safety analyses
Selective reporting (reporting bias) Low risk All obvious outcomes are reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the participants adequately titrated? High risk No before amendment, unclear after
amendment
For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
Lauretti 2003
Methods Design: randomised, double-blind, cross-over trial.
Year: not reported.
Country: Brazil.
Participants Participants: 22/26 enrolled participants evaluated (withdrawals due to death (unrelated
to the study 1), uncontrollable nausea/vomiting (1), and unstable pain control requiring
spinal drugs (2)); mean/median (?) (SD/interquartile range?) age 59 (19) years; 15 men,
7 women; cancer type: oropharynx (9), lung (3), prostate gland (2), colon (4), gastric
(2), ovary (2); pain types were somatic and visceral; adjuvant therapy: radiation (1),
chemotherapy (6), radiation/chemotherapy (4), none (11)
Inclusion criteria: “26 patients with chronic cancer pain of the visceral and somatic type.
.... Before enrolling in this actual study, patients received 3-4mg/kg−1 tramadol, plus
nonsteroidal anti-inflammatory drugs: however they still complained of pain VAS ≥ 4
cm.”
Exclusion criteria: none listed.
Interventions Oxycodone arm
- Drug: oxycodone
-Dose/dosing:The optimumdosagewas calculated on a daily basis, and the consumption
ratio of oxycodone to morphine was set at 1:1.8
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 14 days.
- Titration schedule: The study started with an open-label, randomised titration phase to
achieve stable pain control for 7 days. Participants only used immediate-releasemorphine
and had free access to it to keep pain VAS < 4
- Rescue medication: At any point, participants were allowed to use immediate-release
morphine (10 mg tablets) as needed to keep pain VAS ≤ 4
- Other medication: as part of the protocol, all participants were taking oral 25 mg
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amitriptyline at bedtime
Comparison arm
- Drug: morphine
-Dose/dosing:The optimumdosagewas calculated on a daily basis, and the consumption
ratio of oxycodone to morphine was set at 1:1.8
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 14 days.
- Titration schedule: The study started with an open-label, randomised titration phase to
achieve stable pain control for 7 days. Participants only used immediate-releasemorphine
and had free access to it to keep pain VAS < 4
- Rescue medication: at any point, participants were allowed to use immediate-release
morphine (10 mg tablets) as needed to keep pain VAS ≤ 4
- Other medication: as part of the protocol, all participants were taking oral 25 mg
amitriptyline at bedtime
- For cross-over trials, cross-over schedule: “After stable pain relief was achieved [during
titration phase], this was followed by a double-blind, cross-over phase in two periods,
14 days each...... and no period of washout was was allowed for ethical reasons”
Outcomes - Pain intensity: assessed by participants; 10 cm VAS from 0 (= no pain at all) to 10 (=
worst possible pain)
- Participant satisfaction: assessed by participant
- Adverse events: assessed by participant (possibly using a 10 cm VAS similar to pain
intensity, but data not reported that way)
- Number of rescue morphine tablets: Assessed by participant
It also appears that an investigator recorded these data on a weekly basis
Notes - Study free of commercial funding? No information reported.
- Groups comparable at baseline? Unclear, no information reported
- ITT analyses undertaken? No, 22/26 participants were included in the analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Pain
Low risk The participants were blinded, but it is un-
clear whether the investigator administer-
ing the drugs was
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk The participants were blinded, but it is un-
clear whether the investigator administer-
ing the drugs was
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Blinding of outcome assessment (detection
bias)
Pain
Low risk The participants andoutcome assessorwere
blinded
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk The participants andoutcome assessorwere
blinded
Incomplete outcome data (attrition bias)
Pain
Unclear risk Data from 22/26 participants included.
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Data from 22/26 participants included.
Selective reporting (reporting bias) High risk All obvious outcomes are reported, al-
though not in the most useful manner (e.
g., no collapsing across study phase weeks,
that is, mean final weekly dose of CR oxy-
codone and morphine are reported for 4
weeks, not 2 weeks)
Other bias Low risk It is unclear whether there were any carry-
over effects, but there probably were none
Were the participants adequately titrated? Low risk The participants were probably adequately
titrated
For cross-over trials: are data available for
both time periods?
Low risk Yes, data are available from both time peri-
ods, although not reported by arm (see two
cells above)
Leow 1995
Methods Design: randomised, open-label, single-dose, cross-over trial.
Year: not reported.
Country: Australia.
Participants Participants: 12 participants entered; 5 women, 7 men; mean age (± SD): 68.8 (± 12.6)
years; cancer type: cervical (2), breast (1), prostate (1), bowel (1), anal (1), endometrial (1)
, renal (1), lung/bronchial (2), skeletal or thoracic-vertebral metastases (2); all inpatients;
all receiving oral nutrition; none hypovolaemic; all opioid-naive apart from 1 participant
who was receiving paracetamol + dextropropoxyphene. 2 participants had compromised
renal function, and 5 participants had impaired liver function to varying degree
Inclusion criteria: inpatients with moderate to severe cancer pain.
Exclusion criteria: known hypersensitivity to oxycodone or other opioid analgesics or a
history of drug dependence, or both
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Interventions Oxycodone arm
- Drug: oxycodone hydrochloride.
- Dose and dosing: single dose of IV oxycodone hydrochloride in a concentration of 5
mg/ml, equivalent to 4.5 mg/ml oxycodone base. The mean (SD) IV oxycodone dose
administered was 0.11 (0.02) mg/kg (range 5.4 to 9 mg), which a previous study by the
authors had shown to produce satisfactory analgesia in participants with moderate to
severe cancer. Participants with impaired liver function received the lower doses of IV
oxycodone. The IV oxycodone dose was administered into a forearm vein. The rate of
injection (0.5 to 5 min) was titrated by the anaesthetist
- Formulation: IV
- Route of administration: IV
- Length of treatment: 24 hours, 1 dose
- Titration schedule: See ’Dose and dosing’ section.
- Rescue medication: oral paracetamol (up to 1 g every 4 hours) or Di-Gesic (up to
2 tablets every 4 hours) were available as rescue medication on participant request. 9
participants asked for supplementary analgesics after 4 hours postdosing
- Other medication: “Medications that had been taken routinely by patients before the
study, were permitted.”
Comparison arm
- Drug: oxycodone.
- Dose and dosing: single dose of 30 mg oxycodone base in a rectal suppository
- Formulation: suppository.
- Route of administration: rectal.
- Length of treatment: 24 hours, 1 dose.
- Titration schedule: see ’Dose and dosing’ section.
- Rescue medication: oral paracetamol (up to 1 g every 4 hours) or digesic (up to 2 tablets
every 4 hours) were available as rescue medication on participant request. 9 participants
asked for supplementary analgesics after 6-8 hours postdosing
- Other medication: “Medications that had been taken routinely by patients before the
study, were permitted.”
- For cross-over trials, cross-over schedule: “Patients were randomly assigned to begin
treatment with either a single dose of... The second treatment was administered 24 h
[hours] after the first dose.”
Outcomes - Pain intensity: Assessed by participant at study start at 0.5, 1, 2, 4, 8, 12 and 24 hours
post-dosing; 10 cm VAS with delimiters ’no pain’ and ’worst pain imaginable.’
- Adverse effects: assessed by questioning the participant at study start at 0.5, 1, 2, 4, 8, 12,
and 24 hours postdosing; participants were asked to report any adverse effects, but were
specifically asked whether they experienced nausea, vomiting, pruritus, lightheadedness,
or drowsiness, using a 4-point verbal rating scale going from 0 to 3 (none = 0, mild = 1,
moderate = 3, severe = 3)
Notes - Study free of commercial funding? No. Supported by the Boots Company (Australia;
manufacturer of the rectal suppository study drug), Pty Ltd, theUniversity ofQueensland
Cancer Research Fund, and the Queensland Cancer Fund
- Groups comparable at baseline? No participant details reported by initial treatment
allocation
- ITT analyses undertaken? Appears so. It was not possible to confirm it based on the
presented date, but no information to the contrary was reported
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned to begin
treatment with...” No further information
reported
Allocation concealment (selection bias) Unclear risk “Patients were randomly assigned to begin
treatment with...” No further information
reported
Blinding of participants and personnel
(performance bias)
Pain
High risk The study was open-label
Blinding of participants and personnel
(performance bias)
Adverse events
High risk The study was open-label
Blinding of outcome assessment (detection
bias)
Pain
High risk The study was open-label
Blinding of outcome assessment (detection
bias)
Adverse events
High risk The study was open-label
Incomplete outcome data (attrition bias)
Pain
Low risk All data appear to be included. It is not pos-
sible to confirm it based on the presented
data, but no information to the contrary is
reported
Incomplete outcome data (attrition bias)
Adverse events
Low risk All data appear to be included. It is not pos-
sible to confirm it based on the presented
data, but no information to the contrary is
reported
Selective reporting (reporting bias) Low risk All expected outcomes seem to be reported
Other bias Low risk “An absence of carryover effects (P > 0.05)
betweenTreatments 1 and 2was confirmed
using the Grizzle analysis for cross-over de-
signs”
Were the participants adequately titrated? Unclear risk Not enough information reported
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For cross-over trials: are data available for
both time periods?
Low risk Yes, data are available from both time peri-
ods
Lux 2014
Methods Design: randomised, double-blind, non-inferiority cross-over trial
Year: 2010-2012. (www.clinicaltrialsregister.eu/ctr-search/trial/2010-020402-15/
results).
Country: Germany, Poland, Switzerland.
Participants Participants: 85 participants entered into titration/stabilisation phase, 71 participants
randomised and 68 took at least 1 dose of the study drug and comprised the safety data
set. The full analysis set comprised the 60 participants with at least 1 measurement of the
primary efficacy parameter. 56 participants completed the trial of whom 46 qualified for
the per protocol data set (23 in each sequence), of the 60 participants in the full analysis
set, 40 had malignant pain of the following type: lung (7), breast (6), cervix (5), prostate
(5), colon/rectum/anus (4), oropharynx (3), skin (2), lymphoma (2), and other (6). 32
women, 36 men. Mean age (SD) of the 68 participants in the safety data set were 60.8
(10) years
Inclusion criteria: white men and women, ≥ 18 years of age with chronic cancer pain
(in the protocol) or non-cancer pain (not in the protocol) and predominantly non-
neuropathic pain, requiring at least 40 mg oxycodone per day (or equivalent), ECOG
(Eastern Cooperative Oncology Group) performance status < 3, life expectancy of at
least 3 months, adequate analgesia (mean ’current’ pain intensity per day ≤ 40 mm
on VAS) prior to randomisation for at least 3 consecutive days and stable analgesic
requirements prior to randomisation for at least 3 days (stable maintenance dose of
oxycodone; requirement of≥ 40 mg oxycodone per day;≤ 2 doses of rescue medication
per day)
Exclusion criteria: hypersensitivity to oxycodone or any of the excipients of the study
drugs, requirement of> 120 mg oxycodone per day (or equivalent), surgery within 1
month prior to study start and/or anticipated or scheduled surgical intervention during
the study, intravenous chemotherapy and/or radiotherapy for pain alleviation and/or
neural blockade within 2 weeks prior to study start, significant hepatic impairment or
severe renal impairment (creatinine clearance <30 ml/min), and pregnancy or lactation
However, only outcome data pertaining to the participants with malignant pain alone were
included in this review.
Interventions Oxycodone arm
- Drug: oxycodone (Oxygesic/OxyContin).
- Dose and dosing: twice-daily administration of oxycodone at 8.00 and 20.00 hours.
No dose adjustment of oxycodone was allowed during the double-blind treatment phase
after the titration/stabilisation phase. The total daily dose was determined during the
titration/stabilization phase and fixed throughout the study. The mean daily dose was
not reported
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 10 days per cross-over phase (data only analysed for days 6-10)
- Titration schedule: after a screening phase (maximum 14 days), a titration/ stabilisation
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period followed (maximum 14 days) where the participants were switched to oxycodone
and the dose was adjusted for sufficient pain relief, i.e. daily mean current pain ≤ 40
mm on VAS
- Rescue medication: 10 mg immediate-release morphine sulfate (≤ 2 doses of rescue
medication per day)
- Other medication: not reported
Comparison arm
- Drug: oxycodone + placebo.
- Dose and dosing: once-daily administration of oxycodone at 8.00 hours and placebo
at 20.00 hours. No dose adjustment of oxycodone was allowed during the double-blind
treatment phase after the titration/stabilisation phase. Total daily dose was determined
during the titration/stabilisation phase and fixed throughout the study. Mean daily dose
was not reported
- Formulation: Extended-release
- Route of administration: oral.
- Length of treatment: 10 days per cross-over phase (data only analysed for days 6-10)
- Titration schedule: after a screening phase (maximum 14 days), a titration/ stabilisation
period followed (maximum 14 days) where the participants were switched to oxycodone
and the dose was adjusted for sufficient pain relief, i.e. daily mean current pain ≤ 40
mm on VAS
- Rescue medication: 10 mg immediate-release morphine sulfate (≤ 2 doses of rescue
medication per day)
- Other medication: not reported
- For cross-over trials, cross-over schedule: “After 10 days of treatment with the first study
medication of the respective sequence, patients were directly switched to the second
medication without wash-out.” “During the double-blind phase of the study, for each
study medication the current pain and recalled pain scores obtained from days 6 to 10
were employed for statistical evaluations. Days 1 to 5 of each period were regarded as an
active 5 day run-in phase in order to avoid any potential carry-over effects between the
different study periods.”
Outcomes Primary outcome measures:
- Overall ’current’ pain intensity (PI) on 0 to 100 mm VAS (mean ’current’ PI of the last
5 days of each treatment period). Pain intensity (PI) was assessed five times daily, i.e., at
08:00 h (before study drug intake), 11:00 h, 14:00 h, 17:00 h, and 20:00 h (before study
drug intake; allowed deviation ± 20 min for all assessments) on a 0 to 100 mm VAS
(’current’ pain). PI assessment at 08:00 h and 20:00 h also comprised ratings of PI over
the past 12 hours (’recalled’ pain during day- and night-time). From the PI scores the
mean ’current’ PI over all time points of the last 5 treatment days of period 1 and period
2 (= overall mean ’current’ PI) will be calculated for each participant as the primary
efficacy endpoint
Secondary outcome measures:
- mean ’current’ pain intensity (PI) per day
- mean ’current’ PI per time point
- mean ’recalled’ PI over the past 12 hours at 08:00 h
- mean ’recalled’ PI over the past 12 hours at 20:00 h
- overall effectiveness on 4-point categorical scale (CAT; 0 = not effective, 3 = highly
effective) by participant and investigator (assessed at the end of each treatment period)
- daily dose of rescue medication for each of the last 5 days of period 1 and 2
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- mean daily dose of rescue medication over the last 5 treatment days of period 1 and 2
- total amount of rescue medication over the last 5 treatment days of period 1 and 2
- Adverse events and serious adverse events recorded using the Medical Dictionary for
Regulatory Activities (MedDRA).
- Nausea and sedation assessed on 0 to 100 mm VAS at 08:00 h and 20:00 h by partici-
pants
However, only the primary outcome data was reported on a per protocol basis for participants
with malignant pain alone. These are therefore the only study results included in this review.
Notes - Study free of commercial funding? No. Study was funded by study sponsor Develco
Pharma Schweiz AG
- Groups comparable at baseline? Unclear. The groups comprising the safety data set
were comparable at baseline in terms of age, sex, weight, height, and body mass index,
but this was not the analysis set used for the present review (i.e. included both benign
and malignant pain)
- ITT analyses undertaken? The only data available for the participants with malignant
pain only is per protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The treatment sequence (test-reference;
reference- test) was assigned by randomiza-
tion code and central randomization pro-
cedure.”
Allocation concealment (selection bias) Low risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “OTD, OOD and a dummy were blinded
using the same type of over-encapsulation.
The patients received the same number of
encapsulated tablets in both periods of the
double-blind treatment phase in themorn-
ing (OTD or OOD) and in the evening
(OTD or dummy).”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above:
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
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Incomplete outcome data (attrition bias)
Pain
High risk Outcome data only available for 31/40 par-
ticipants.
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Adverse events only reported for the 68 par-
ticipants in the safety data set of whom 40
had malignant pain. These data are there-
fore not included in this review
Selective reporting (reporting bias) High risk Adverse events were not reported separately
for the participants with malignant pain
and could therefore not be extracted for the
purposes of this review
Other bias Low risk The study appears to be free of other bias.
Were the participants adequately titrated? Low risk Adequate titration was an inclusion crite-
rion.
For cross-over trials: are data available for
both time periods?
Low risk Yes, data were available for both time peri-
ods collapsed across the time periods
Mercadante 2010
Methods Design: randomised, parallel group trial.
Year: not reported.
Country: Italy.
Participants Participants: 60 participants randomised; 46/60 participants completed baseline evalu-
ation (21 participants in group oxycodone and 25 participants in group morphine, 14/
60 participants did not complete baseline evaluation as they were lost to follow up); 27
females, 19 males; mean age (SD): 63.2 (9.48) years. 19 oxycodone and 20 morphine
participants completed 4 weeks of study participation and 7 and 10 participants, respec-
tively, completed 8 weeks of study participation
Inclusion criteria: Patients with pancreatic cancer with local disease, presenting abdom-
inal pain with an intensity ≥ 4/10 numerical rating scale from 0 to 10, and no longer
responsive no nonopioid analgesics
Exclusion criteria: Distant and bone metastases, or prevalent somatic pain due to evident
peritoneal involvement, changes in chemotherapy regimen, hepatic or renal failure, cog-
nitive failure, lack of cooperation, aged < 18 or > 80 years, and a Karnofsky performance
status < 50
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose and dosing: starting dose of 20 mg/day, according to an approximate morphine to
oxycodone ratio of 1.5:1. For participants requiring an increase in the dose for increasing
pain (> 4/10 or > 3 breakthrough pain medications per day) during the study period,
opioid doses were increased according to clinical needs. Mean dose (SD) at week 1: 23.8
(8) mg/day; mean dose (SD) at week 2: 25.5 (8) mg/day; mean dose (SD) at week 3: 27.
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9 (9) mg/day; Mean dose (SD) at week 4: 33.1 (14) mg/day; mean dose (SD) at week
8: 45.7 (24) mg/day
- Formulation: Sustained-release
- Route of administration: oral.
- Length of treatment: 4 weeks (with a study extension up to 8 weeks)
- Titration schedule: “Patients were recruited and followed during admission to the
palliative care unit, as outpatients and at home. Physicians provided frequent call contacts
to adjust the opioid dose at any time.” See also ’Dose and dosing’ section. No further
information provided
- Rescue medication: oral morphine in doses of 1/6 of the daily dose was provided
(starting at 5 mg)
- Other medication: “Adjuvants and symptomatic drugs were prescribed as indicated by
the clinical situation.”
Comparison arm
- Drug: morphine.
- Dose and dosing: starting dose of 30 mg/day, according to an approximate morphine:
oxycodone ratio of 1.5:1. For participants requiring an increase in the dose for increasing
pain (> 4/10 or > 3 breakthrough pain medications per day) during the study period,
opioid doses were increased according to the clinical needs. Mean dose (SD) at week 1:
35 (9) mg/day; mean dose (SD) at week 2: 36.2 (14) mg/day; mean dose (SD) at week
3: 41 (19) mg/day; mean dose (SD) at week 4: 42.6 (21) mg/day; mean dose (SD) at
week 8: 60 (46) mg/day
- Formulation: Sustained-release
- Route of administration: oral.
- Length of treatment: 4 weeks (with study extension up to 8 weeks)
- Titration schedule: “Patients were recruited and followed during admission to the
palliative care unit, as outpatients and at home. Physicians provided frequent call contacts
to adjust the opioid dose at any time.” See also ’Dose and dosing’ section. No further
information provided
- Rescue medication: oral morphine in doses of 1/6 of the daily dose was provided
(starting at 5 mg)
- Other medication: “Adjuvants and symptomatic drugs were prescribed as indicated by
the clinical situation.”
Outcomes - Pain intensity (average in the last 24 hours): Assessed by participant, using a numerical
rating scale from 0 to 10
- Opioid-related symptoms (including nausea and vomiting, drowsiness and confusion)
: Assessed by participant, using a categorical scale from 0 (= absent, 1 = slight, 2 =
moderate) to 3 (= severe)
- Constipation: Assessed by participant, using a categorical scale from 0 (= 1 passage, 1
to 2 days; 1 = 1 passage, 3 to 4 days; 2 = 1 passage, 4 days) to 3 (= only by enema)
Notes - Study free of commercial funding? Unclear. No details reported
- Groups comparable at baseline? No participant details reported by initial treatment
allocation
- ITT analyses undertaken? No, did not appear so. From baseline to study end at 4 weeks,
11/30 oxycodone participants and 10/30 morphine participants dropped out of study
and only data from participants who completed study phases were reported/analysed by
week (0, 1, 2, 3, 4, and 8)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized by a computer
system in 2 groups.” No further informa-
tion reported
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
High risk Unblinded study
Blinding of participants and personnel
(performance bias)
Adverse events
High risk Unblinded study
Blinding of outcome assessment (detection
bias)
Pain
High risk Unblinded study
Blinding of outcome assessment (detection
bias)
Adverse events
High risk Unblinded study
Incomplete outcome data (attrition bias)
Pain
High risk From baseline to study end at 4 weeks 11/
30 oxycodone participants and 10/30 mor-
phine participants dropped out of the study
and only the data from participants who
completed the study phases are reported/
analysed by week (0, 1, 2, 3, 4, and 8)
Incomplete outcome data (attrition bias)
Adverse events
High risk From baseline to study end at 4 weeks 11/
30 oxycodone participants and 10/30 mor-
phine participants dropped out of the study
and only the data from participants who
completed the study phases are reported/
analysed by week (0, 1, 2, 3, 4, and 8)
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the participants adequately titrated? Unclear risk Not enough information reported
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For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
Mucci-LoRusso 1998
Methods Design: randomised, parallel group trial.
Year: not reported.
Country: USA.
Participants Participants: 101 participants randomised; 100/101 participants received ≥ one dose
of study medication; N = 48 in oxycodone group and 52 in the morphine group, 55%
participants were male, mean (range) age = 59 (30 to 83) years; bone and viscera were
most common pain sites; nerve pain was the primary pain type in 10/48 oxycodone
and 9/52 morphine participants; most common pre-study pain medication was fixed-
dose oxycodone-acetaminophen combination (22 participants in each group), followed
by single-entity morphine (13 oxycodone and 17 morphine participants). Most partic-
ipants were receiving > 1 pain medication pre-study and all but 3 participants (all in
the oxycodone group) were receiving opioids prior to enrolment, the mean (range) oral
oxycodone equivalent of the pre-study dose = 64 (14 to 280) mg in the oxycodone group
and 70 (14-235) mg in the morphine group. 7 oxycodone and 9 morphine participants
discontinued the study before achieving stable pain control due to adverse experiences
(2 oxycodone and 6 morphine participants), intercurrent illness (3 oxycodone partic-
ipants), ineffective treatment (1 oxycodone and 1 morphine participants), participant
request (1 oxycodone and 1 morphine participants), and protocol violation (1 morphine
participant). An additional 4 participants dropped out of the study after achieving stable
pain control due to adverse experience (1 oxycodone participant), protocol violation (1
oxycodone participant), intercurrent illness (1 morphine participant) and worsening of
pre-existing condition (1 morphine participant)
Inclusion criteria: Patients who required around-the-clock treatment with opioid anal-
gesics for chronic cancer-related pain with the equivalent of 30 to 340 mg of oral oxy-
codone daily. Patients whose pain was not controlled by maximum recommended doses
of nonopioid analgesics were also eligible if they would require ≥ 30 mg
Exclusion criteria: “a history of sensitivity to oxycodone or morphine, any contra-indi-
cation for opioid therapy (such as paralytic ileus or severe pulmonary disease) or severely
compromised organ function that could obscure efficacy or or adversely affect safety. Pa-
tients whose pain control was so fragile they could not switch opioids were also excluded.
”
Interventions Oxycodone arm
- Drug: oxycodone hydrochloride.
-Dose and dosing:multiples of 20mg tablets, every 12 hours (8 a.m. and 8 p.m.). Starting
dose calculated fromparticipants’ prestudy daily opioid dose and could be adjusted based
on the investigator’s judgement. Dose was titrated until stable pain control was achieved.
Pain control was considered stable when, over a 48-hour period, the ’every 12 hours’
dose was unchanged, ≤ 2 supplemental analgesic doses were taken per day, the dosing
regimen for any non-opioids or adjuvants was unchanged, and the participant reported
that pain control was acceptable and any adverse effects were tolerable. Participants who
could not be stabilised within 10 days were discontinued. Mean final daily doses of every
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12 hour (range): 101 (40-360) mg
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: up to 12 days.
- Titration schedule: see ’Dose and dosing’ section.
- Rescue medication: Immediate-release oxycodone in multiples of 2 × 5 mg tablets.
Each supplemental medication dose was 1/4 to 1/3 of every 12 hours scheduled dose.
Participants were instructed to take a supplemental dose as needed for breakthrough pain,
but not more frequently than once every 2-4 hours or 1 hour before activity associated
with incident pain. Median dose use on the next to last study day (during stable pain
control) 1 (range 0-4) and median dose use on last study day (during stable pain control)
1 (range 0-3)
- Other medication: “Non-opioid analgesics and adjuvant medications were allowed
during the study provided they had been given on a regular basis (not as needed) before
the study.”
Comparison arm
- Drug: morphine sulfate
- Dose and dosing: multiples of 30 mg tablets, every 12 hours (8 a.m. and 8 p.m.).
Starting dose was calculated from the participants’ prestudy daily opioid dose and could
be adjusted based on the investigator’s judgement. Dose was titrated until stable pain
control was achieved. Pain control was considered stable when, over a 48-hour period,
the q12h dose ( = dose every 12 hours) was unchanged,≤ 2 supplemental analgesic doses
were taken per day, the dosing regimen for any non-opioids or adjuvants was unchanged,
and the participant reported that pain control was acceptable and any adverse effects were
tolerable. Participants who could not be stabilised within 10 days were discontinued.
Mean final daily doses every 12 hours (range) 140 (60-300) mg
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: ≤ 12 days.
- Titration schedule: see ’Dose and dosing’ section.
- Rescue medication: Immediate-release morphine in multiples of 15 mg tablets. Each
supplemental medication dose was 1/4 to 1/3 of every 12 h scheduled dose. Participants
were instructed to take a supplemental dose as needed for breakthrough pain, but not
more frequently than once every 2 to 4 hours or 1 hour before activity associated with
incident pain. Median dose use on the next to last study day (during stable pain control)
= 1 (range 0 to 3) and median dose use on last study day (during stable pain control) =
1 (range 0 to 3)
- Other medication: “Non-opioid analgesics and adjuvant medications were allowed
during the study provided they had been given on a regular basis (not as needed) before
the study.”
Outcomes - Pain intensity (average since previous evaluation): Assessed by participant at baseline
and before every q12h dose, using a categorical scale from 0 (= none) (1 = slight, 2 =
moderate) to 3 (= severe). Also assessed after ≥ 48 hours of stable pain control using
the categorical scale and a 100 mm VAS scale from 0 (= no pain) to 100 (worst possible
pain)
- Adverse experiences and drug effects: Assessed by participant in a daily diary, and after
≥ 48 hours of stable pain control by using the Specific Drug Effect Questionnaire 100
mm VAS scale (?) from 0 (= not at all) to 100 (an awful lot); also assessed by observers
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after ≥ 48 hours of stable pain control by using the Specific Drug Effect Questionnaire
100 mm VAS scale (?) from 0 (= not at all) to 100 (extremely)
- Drowsiness and nausea: Assessed by participant after ≥ 48 hours of stable pain control
(?), using a categorical scale from 0 (= none, 1 = slight, 2 = moderate) to 3 (= severe) and
a 100-mm VAS scale from 0 (= none) to 100 (worst possible)
- Acceptability of therapy: Assessed by participant at baseline and study end, using a
categorical scale from 1 (= very poor, 2 = poor, 3 = fair, 4 = good) to 5 (= excellent)
- Quality of life: Assessed by participant at baseline and study end, using the Functional
Assessment of Cancer Therapy-General (FACT-G), a 28-item questionnaire consisting
of 5 subscales measuring different aspects of quality of life: Physical, social/family, rela-
tionship with physician, emotional and functional
Notes - Study free of commercial funding? No. The authors were either “financially compen-
sated for their efforts” or employees of the study drug manufacturer
- Groups comparable at baseline? Unclear. No participant details reported by initial
treatment allocation
- ITT analyses undertaken? No, 100/101 participants were analysed for safety; 79/101
participants who achieved stable pain control and had simultaneous pharmacokinetic-
pharmacodynamic assessments were analysed for efficacy (39 oxycodone, 40 morphine)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Block randomization was used to ensure
that all centers had a comparable number
of patients in each treatment group.” No
further information reported
Allocation concealment (selection bias) Unclear risk No further information reported than that
in the cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “The double-dummy technique was used
to blind the study medications.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk “The double-dummy technique was used
to blind the study medications.”
Blinding of outcome assessment (detection
bias)
Pain
Low risk Participant recorded. See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
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Incomplete outcome data (attrition bias)
Pain
High risk A total of 79/101 participants who
achieved stable pain control and had
simultaneous pharmacokinetic-pharmaco-
dynamic assessments were analysed for ef-
ficacy
Incomplete outcome data (attrition bias)
Adverse events
Low risk A total of 100/101 participants were anal-
ysed for safety
Selective reporting (reporting bias) Low risk All obvious outcomes are reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the participants adequately titrated? Low risk The participants were adequately titrated
For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
Parris 1998
Methods Design: randomised, double-blind, parallel group trial.
Year: not reported.
Country: USA.
Participants Participants: 111 participants randomised; 103/111 participants received ≥ one dose
of study medication; N = 52 in controlled-release group and 51 in the immediate-re-
lease group, 50% participants were female, average (mean?) (range) age = 57 (31 to
80) years; bone (45%) and viscera (28%) were most common pain sites; most com-
mon cancer diagnoses were breast, gastrointestinal, lung, and gynaecological. 66/111
participants completed the 5-day study period (33 in each group). Pre-study analgesics:
Oxycodone and acetaminophen (71%), most lower-dose participants received a total
daily pre-study oxycodone dosage of 30 to 45 mg with 2.0 to 2.9 g of acetaminophen;
higher-dose participants received a daily oxycodone dosage of 50 to 60 mg with 3.2 to 3.
9 g of acetaminophen; other prior opioids included codeine and acetaminophen (17%),
hydrocodone and acetaminophen (10%), propoxyphene napsylate and acetaminophen
(2%), and transdermal fentanyl (1%) (protocol violation). A total of 19 controlled-
release and 18 immediate-release participants discontinued the study due to adverse
events (4 controlled-release and 7 immediate-release participants), unrelated illness (1 in
each group), ineffective treatment (10 controlled-release and 4 immediate-release par-
ticipants), protocol violation (4 controlled-release and 5 immediate-release participants)
, and other (1 immediate-release participant)
Inclusion criteria: “The study included adult patients recruited from 15 centers in the
United States who were receiving 6 to 12 tablets or capsules per day of fixed-combination
analgesics for cancer-related pain. Patients were of either gender and had stable coexistent
disease.”
Exclusion criteria: “Patients were excluded if their pain was not already acceptably con-
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trolled; if they had surgery or radiotherapy within 10 days of prior to study or anticipated
these procedures during study; of they had compromised function of a major organ sys-
tem; or of they were receiving nonopioid analgesics (before the protocol was amended)
. Of course, concomitant nonanalgesic therapies were allowed during the study. To en-
courage participation and to lower the discontinuation rate, the protocol was modified
during the study to include patients undergoing or recently given radiotherapy and those
receiving stable doses of nonopioid analgesics or analgesic adjuvants. In addition, patients
receiving ten to more tablets or capsules of fixed-combination analgesics were no longer
permitted to enter the study, but could be enrolled in a companion study intended for
patients with greater opioid requirements.”
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose and dosing: 30 mg, every 12 hours, total daily dosage 60 mg. Mean daily dosage
60 mg (see ’Titration schedule’)
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 5 days.
- Titration schedule: participants needing titration of analgesic or supplemental medi-
cation were required to discontinue from the study
- Rescue medication: see ’Titration schedule.’
- Other medication: see ’Titration schedule.’ “Of course, concomitant nonanalgesic
therapies were allowed during the study.”
Comparison arm
- Drug: oxycodone.
- Dose and dosing: 15 mg, 4 times daily, total daily dose 60 mg, mean daily dose 60 mg.
See ’Titration schedule.’
- Formulation: Immediate-release
- Route of administration: oral.
- Length of treatment: 5 days.
- Titration schedule: participants needing titration of analgesic or supplemental medi-
cation were required to discontinue from the study
- Rescue medication: see ’Titration schedule.’
- Other medication: see ’Titration schedule.’ “Of course, concomitant nonanalgesic
therapies were allowed during the study.”
Outcomes - Pain intensity: Assessed by participant at baseline and 4 times daily, that is, morning
(overnight pain rating), midday (morning pain rating), evening (afternoon pain rating),
and bedtime (evening pain rating), using a categorical scale from 0 (= none) (1 = slight,
2 = moderate) to 3 (= severe)
- Acceptability of current therapy: Assessed by participant at baseline and 2 times daily,
that is, for both day and night, using a categorical scale from 1 (= very poor) (2 = poor,
3 = fair, 4 = moderate) to 5 (= excellent)
- Adverse experiences: “Observers contacted patients by telephone daily throughout the
5-day study period and recorded information about adverse events and changes in the
patients’ condition.”
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Notes - Study free of commercial funding? No. The study was sponsored by the drug manu-
facturers (The Purdue Frederick Company and Purdue Pharma L.P.) and some of the
authors were employees of the study drug manufacturer
- Groups comparable at baseline? No participant details reported by initial treatment
allocation
- ITT analyses undertaken? Yes, it seems so. 103/111 participants who took ≥ 1 study
drug dose constituted the ITT population (52 controlled-release, 51 immediate-release)
, 8/111 participants were excluded for administrative reasons, which are not further
specified; 109/111 participants were analysed for safety
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported beyond that
“Thiswas a randomized, double-blind, par-
allel-group study”
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “This was a randomized, double-blind,
parallel-group study”.... “using a double-
dummy technique”. No further informa-
tion reported
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above. We here assume that the
participants were blinded, but it is unclear
whether the personnel administering the
study medication or the personnel assess-
ing some of the outcomes, or both, were
also blinded
Blinding of outcome assessment (detection
bias)
Pain
Low risk This outcome was participant-assessed. See
cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above. We here assume that the
participants were blinded, but it is unclear
whether the personnel administering the
study medication and/or the personnel as-
sessing some of the outcomes were also
blinded
Incomplete outcome data (attrition bias)
Pain
Low risk A total of 103/111 participants who took
≥ 1 study drug dose constituted the ITT
population (52 controlled-release, 51 im-
mediate-release), 8/111 participants were
excluded for administrative reasons, which
are not further specified. The pain data ap-
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pear to include these 103 participants
Incomplete outcome data (attrition bias)
Adverse events
Low risk A total of 109/111 participants were anal-
ysed for safety
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the participants adequately titrated? Low risk The participants were probably adequately
titrated because otherwise they were dis-
continued
For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
Riley 2015
Methods Design: randomised, double-blind, parallel group trial (with cross-over to other arm for
non-responders to first line opioid)
Year: 2006-2011.
Country: UK.
Participants Participants: 200 participants randomised; 198/200 participants received ≥ 1 dose of
study medication; N = 100 in the oxycodone group and 98 in the morphine group; 198
were included in the intention-to-treat analyses:
- Oxycodone: N = 100; 38 males and 62 females, mean (SD) age = 58.9 (13.2) years;
cancer diagnosis: breast (18), lower gastrointestinal (16), upper gastrointestinal (2), pan-
creas and hepatobiliary (4), sarcoma (8), lung (13), gynaecological (9), urinary tract (3)
, prostate (8), haematological (7), malignant melanoma (6), head and neck (3), other
(3); concomitant opioid medications before randomisation: As required morphine (40)
, as required oxycodone (3), codeine (45), tramadol (45), dihydrocodeine (5), dextro-
propoxyphene (1), buprenorphine (3). A total of 20/100 participants who received first
line oxycodone withdrew from the trial for drug (16) or trial (4) reasons
- Morphine: N = 100; 50 males and 50 females, mean (SD) age = 59.2 (11.6) years;
cancer diagnosis: breast (14), lower gastrointestinal (11), upper gastrointestinal (10),
pancreas and hepatobiliary (10), sarcoma (11), lung (5), gynaecological (7), urinary tract
(12), prostate (2), haematological (6), malignant melanoma (4), head and neck (2), other
(6); concomitant opioid medications before randomisation: as required morphine (51)
, as required oxycodone (1), codeine (47), tramadol (47), dihydrocodeine (3), dextro-
propoxyphene (0), buprenorphine (0). 13/98 participants who received first-line oxy-
codone withdrew from the trial for drug (10) or trial (3) reasons
Inclusion criteria: “Inpatients and outpatients were identified and recruited at a tertiary
referral cancer center by the specialist palliative care team. Patients were eligible if they
needed to begin a regular oral strong opioid for cancer-related pain and were strong
opioid naive, that is, had not taken a regular strong opioid within the previous month.
The use of an ”as required“ strong opioid was permitted (less than six doses in 24 hours)
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. Patients were recruited before, or within 24 hours, of starting a regular strong opioid.”
Exclusion criteria: renal impairment (serum creatinine ≥ 1.5 times the upper limit of
normal), requirement of parenteral opioids, previous poor response to either morphine
or oxycodone, and pregnancy
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose and dosing: see ’Titration schedule.’ No further information reported
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 1 year.
- Titration schedule: “Patients were initially titrated on immediate-release preparations,
administered at four-hourly intervals with additional as required doses available for
breakthrough pain .... the starting dose was determined by the treating physician on
an individual patient basis and titrated accordingly.... until adequate pain control was
achieved or intolerable side effects were reported by the patient. At this stage, patients
were converted to the comparable modified-release preparations.
Nonresponders to the first opioid were switched to the alternative opioid. As this was
not a stable analgesic setting, the ratio of oral morphine:oxycodone (2:1).... Doses were
retitrated according to response.”
- Rescue medication: see ’Titration schedule.’
- Other medication: “adjuvant medications (laxatives, antiemetics, coanalgesics) were
either started or continued where indicated.”
Comparison arm
- Drug: morphine.
- Dose and dosing: see ’Titration schedule.’ No further information reported
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 1 year.
- Titration schedule: “Patients were initially titrated on immediate-release preparations,
administered at four-hourly intervals with additional as required doses available for
breakthrough pain .... the starting dose was determined by the treating physician on
an individual patient basis and titrated accordingly.... until adequate pain control was
achieved or intolerable side effects were reported by the patient. At this stage, patients
were converted to the comparable modified-release preparations.
Nonresponders to the first opioid were switched to the alternative opioid. As this was
not a stable analgesic setting, the ratio of oral morphine:oxycodone (2:1).... Doses were
retitrated according to response.”
- Rescue medication: see ’Titration schedule.’
- Other medication: “Adjuvant medications (laxatives, antiemetics, coanalgesics) were
either started or continued where indicated.”
Outcomes - Pain intensity: Assessed by participant at baseline and daily during titration in addition
to the following times: (1) when the participant is clinically stabilised on first line opioid,
(2) if the participant does not respond to first-line opioid and requires switching to
alternative opioid, (3) when participant is clinically stabilised on second line opioid, (4)
if the participant’s analgesic requirement have increase by 200% of their initial stable
opioid dose, and (5) if the participant does not respond to second line opioid or fits
the criteria to exit the study, using an 11-point numerical rating scale (the Brief Pain
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Inventory) with five pain modalities from 0 (= no pain) to 10 (= worst pain imaginable)
- Adverse experiences: Assessed by participant at baseline and daily during titration in
addition to the following times: (1) when the participant is clinically stabilised on first
line opioid, (2) if the participant does not respond to first-line opioid and requires
switching to alternative opioid, (3) when participant is clinically stabilised on second
line opioid, (4) if the participant’s analgesic requirement have increase by 200% of their
initial stable opioid dose, and (5) if the participant does not respond to second line
opioid or fits the criteria to exit the study, using an 11-point numerical rating scale from
0 (= no symptom) to 10 (= worst symptom severity imaginable) for nausea, vomiting,
constipation, diarrhoea, drowsiness, confusion or disorientation or hallucinations, bad
dreams and other notable symptoms. During assessments participants were also asked
to report any new adverse events
- Responding participants (primary outcome): Defined as participants who responded
clinically to morphine and oxycodone when used as the first line strong opioid in cancer-
related pain, that is, opioid non-response was classified as inadequate analgesia despite
dose escalation or intolerable adverse effects, or both, and adequacy of pain control
and tolerability of adverse effects were defined by participants’ subjective assessment,
regardless of score
Notes - Study free of commercial funding? “This study was funded by the Palliative Care
Research Fund from the Royal Marsden Hospital, St. Joseph’s Hospice, the Asmarley
Trust, and an unrestricted educational grant from Napp Pharmaceuticals. None of the
funding bodies had any role in the design and conduct of the study, the collection,
management, analysis, or interpretation of the data, and the preparation, review, and
approval of the manuscript, or in the decision to submit for publication. The authors
report no conflicts of interest. The study also was supported by the National Institute for
Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton
and Harefield National Health Service Foundation Trust and Imperial College London.
”
- Groups comparable at baseline? Yes, the groups seem to be comparable at baseline
- ITT analyses undertaken? Yes for efficacy, but data only included for 153/198 partici-
pants for safety
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized to either mor-
phine or oxycodone in a 1:1 ratio via com-
puter-generated random permuted blocks.
”
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Pain
High risk “This independent study was an open-label
one because of safety, logistical, and finan-
cial considerations.”
87Oxycodone for cancer-related pain (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Riley 2015 (Continued)
Blinding of participants and personnel
(performance bias)
Adverse events
High risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
High risk Participant-assessed. See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
High risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk Data only available for 80/100 participants
in the oxycodone group and 85/100 in the
morphine group for the meta-analyses
Incomplete outcome data (attrition bias)
Adverse events
High risk Adverse events reported for 153/198 par-
ticipants.
Selective reporting (reporting bias) Low risk All obvious outcomes are reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the participants adequately titrated? Low risk Yes, the participants appear to be ade-
quately titrated
For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
Salzman 1999
Methods Design: randomised, double-blind, parallel group trial.
Year: not reported.
Country: USA.
Participants Participants: 50 participants randomised; 48/50 participants received≥ 1 dose of study
medication; N = 24 in each group. 35/50 participants completed the titration period, 3
participants discontinued the study due to adverse events, 8 due to ineffective treatment
or intercurrent illnesses, and 2 due to other reasons
Controlled-release group: 8 males and 16 females, mean (range) age = 60 (25 to 77)
years; participants taking pre-study opioids: Yes: N = 23, No: N = 1
Immediate-release group:13 males and 11 females, mean (range) age = 61 (39 to 91)
years; participants taking pre-study opioids: Yes: N = 22, No: N = 2
Inclusion criteria: Patients aged ≥ 18 years with stable cancer pain not adequately con-
trolled by prior analgesic therapy with or without opioids. Among patients who were
receiving nonopioid analgesic therapy, the dosing regimen was stabilised≥ 1 week before
the initiation of study medication and remained stable for the duration of the studies
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Exclusion criteria: ”Patients excluded from the studies included individuals with an
allergy or contraindication to opioid therapy; patients with a history of substance abuse;
patients receiving an opioid analgesic that could not be discontinued; cancer patients
prescribed oral oxycodone at a total dose of more than 400 mg/day.“
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose and dosing: starting dose for opioid-naive participants 20 mg/day, and for non-
opioid-naive participants starting dose was based on prior 3 days of analgesic therapy;
every 12 hours at 8 a.m. and 8 p.m. (± 1 hour each time). Mean final daily dose (SE) =
104 (20) mg
- Formulation: Controlled-release
- Route of administration: oral
- Length of treatment: Up to 21 days
- Titration schedule: ”The starting dose was titrated upward in each study to a limit of
400 mg/day..... Among those who required titration, the dose was increased until the
patients rated their level of pain at an intensity of no greater than “slight” (1.5) on the
CAT scale. The dose could be adjusted every 24 to 48 hours if necessary. Criteria for
stable pain control were said to be met if pain was stabilized at 1.5 or below for 48 hours
while patients were taking no more than two doses per day of supplemental analgesic.“
- Rescue medication: ”Supplemental analgesic was permitted as needed for control of
breakthrough or incident pain and was provided in doses of 5mg IR oxycodone (1 tablet)
for patients titrated to 20 to 40 mg/day and 10 mg IR oxycodone (2 X 5 mg tablets) for
patients titrated to 60 to 80 mg/day. For patients receiving doses greater than 80 mg/
day, the supplemental analgesic dose was approximately 1/6 of the patient’s total daily
oxycodone dose rounded to the nearest 5 mg. Rescue medication was taken no more
than once every 4 hours.“
- Other medication: ”All other opioid analgesics were prohibited. Besides nonopioid
analgesic medications (discussed above), othermedications necessary for patients’ welfare
were administered under the supervision of the investigator/physician.“
Comparison arm
- Drug: oxycodone.
- Dose and dosing: starting dose for opioid-naive participants 20 mg/day, and for non-
opioid-naive participants starting dose was based on prior 3 days of analgesic therapy; 4
times daily at 8 a.m., 2 p.m., 8 p.m., and bedtime (± 1 hour each time). Bedtime dose
was to be taken ≥ 3 hours after the 8 p.m. dose. Mean final daily dose (SE) = 113 (24)
mg
- Formulation: Immediate-release
- Route of administration: oral.
- Length of treatment: Up to 21 days
- Titration schedule: ”The starting dose was titrated upward in each study to a limit of
400 mg/day..... Among those who required titration, the dose was increased until the
patients rated their level of pain at an intensity of no greater than “slight” (1.5) on the
CAT scale. The dose could be adjusted every 24 to 48 hours if necessary. Criteria for
stable pain control were said to be met if pain was stabilized at 1.5 or below for 48 hours
while patients were taking no more than two doses per day of supplemental analgesic.“
- Rescue medication: ”Supplemental analgesic was permitted as needed for control of
breakthrough or incident pain and was provided in doses of 5mg IR oxycodone (1 tablet)
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for patients titrated to 20 to 40 mg/day and 10 mg IR oxycodone (2 × 5 mg tablets) for
patients titrated to 60 to 80 mg/day. For patients receiving doses greater than 80 mg/
day, the supplemental analgesic dose was approximately 1/6 of the patient’s total daily
oxycodone dose rounded to the nearest 5 mg. Rescue medication was taken no more
than once every 4 hours.“
- Other medication: ”All other opioid analgesics were prohibited. Besides nonopioid
analgesic medications... other medications necessary for patients’ welfare were adminis-
tered under the supervision of the investigator/physician.“
Outcomes - Pain intensity: Assessed by participant in daily diary, using a categorical scale from 0
(= none) (1 = slight, 2 = moderate) to 3 (= severe). Also assessed at the clinic visit at the
end of the titration period
- Adverse events: Assessed by participant in daily diary, using a categorical scale from 0
(= none) (1 = slight, 2 = moderate) to 3 (= severe). Also assessed at the clinic visit at the
end of the titration period
- Time to stable pain control was recorded as zero for participants meeting the criteria
for success in the first 48 hours (i.e., no titration was needed).”
Notes - Study free of commercial funding? No. The study was sponsored by the drug manufac-
turer (Purdue Pharma L.P.) and some of the authors were employees of the study drug
manufacturer
- Groups comparable at baseline? The groups appear to be comparable at baseline
- ITT analyses undertaken? Yes, it seems so for adverse events where the data from 48/50
participants are analysed, but only the data from 35/50 are analysed for pain intensity
as only 35/50 participants completed the titration phase
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Pain
High risk The study was open-label
Blinding of participants and personnel
(performance bias)
Adverse events
High risk The study was open-label
Blinding of outcome assessment (detection
bias)
Pain
High risk The study was open-label
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Blinding of outcome assessment (detection
bias)
Adverse events
High risk The study was open-label
Incomplete outcome data (attrition bias)
Pain
High risk Data reported for 35/50 participants.
Incomplete outcome data (attrition bias)
Adverse events
Low risk Data reported for 48/50 participants
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the participants adequately titrated? Unclear risk Not applicable. This study was a titration
study
For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
Stambaugh 2001
Methods Design: randomised, double-blind, cross-over trial.
Year: not reported.
Country: USA.
Participants Participants: 40 participants entered; 30/40 participants completed both of the double-
blind periods with 100% compliance; 9 participants discontinued the study during the
titration phase due to adverse events (2), lack of efficacy (4), intercurrent illness (1), and
’other’ reasons (2), and 1 participant discontinued the study during the double-blind
phase due to weakness secondary to progressive disease
10 males and 20 females, mean (range) age = 60 (34 to 83) years; primary pain site
was bone (27), viscera (1), and other (2). All participants were receiving therapy that
included opioids pre-study
Inclusion criteria: Patients aged > 18 years with moderate or severe cancer-related pain
who did not require > 240 mg/day oral oxycodone equivalent for pain relief who were
able to take oral medication and and practiced a medically acceptable method of birth
control if female with childbearing potential
Exclusion criteria: Primary tumour or metastatic disease in the brain, received chemo-
therapy within 3 days of study entry, drug abuse, severe cognitive impairment, com-
promised hepatic or renal function, radiotherapy to the pain site, or hypersensitivity to
oxycodone
Interventions Oxycodone arm
- Drug: oxycodone + placebo.
- Dose and dosing: The total 24-hour oxycodone dose was equal to the stable daily dose
obtained at the end of the titration phase. Drug administration 4 times daily consisting
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of oxycodone interspersed with placebo, resulting in q12h dosing of oxycodone. Mean
final daily dose is not reported
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: Up to 35 days, consisting of a titration period of 2-21 days,
followed by 2 double-blind cross-over periods each lasting 3-7 days
- Titration schedule: open-label with immediate-release oxycodone, starting dose was
comparable to that calculated, based on the past 3 days of analgesia therapy. “The sub-
jects completed the titration phase at home while monitored on a daily basis by tele-
phone by the research monitor. Recommendations regarding changes in in medication
were used to minimize oxycodone use while providing adequate analgesia. More than 2
rescue medication doses per 24-hour period or a moderate or severe global pain score
indicated inadequate pain control. Participants whose pain was inadequately controlled
after 21 days or who required more than 240 mg or less than 20 of oxycodone daily were
discontinued from the study”
- Rescue medication: Immediate-release oxycodone in 5 mg tablets
- Othermedication: “Concurrent, stable therapy with acetaminophen, NSAIDs, or anal-
gesic adjuvants and coanalgesics were allowed. Opioids other than the study medication
were prohibited. All medically necessary but noninvestigational medications were per-
mitted.”
Comparison arm
- Drug: oxycodone.
- Dose and dosing: The total 24-hour oxycodone dose was equal to the stable daily dose
obtained at the end of the titration phase. Drug administration 4 times daily, qid dosing
of oxycodone. Mean final daily dose is not reported
- Formulation: Immediate-release
- Route of administration: oral.
- Length of treatment: Up to 35 days, consisting of a titration period of 2-21 days,
followed by 2 double-blind cross-over periods each lasting 3-7 days
- Titration schedule: open-label with immediate-release oxycodone, starting dose was
comparable to that calculated, based on the past 3 days of analgesia therapy. “The sub-
jects completed the titration phase at home while monitored on a daily basis by tele-
phone by the research monitor. Recommendations regarding changes in in medication
were used to minimize oxycodone use while providing adequate analgesia. More than 2
rescue medication doses per 24-hour period or a moderate or severe global pain score
indicated inadequate pain control. Participants whose pain was inadequately controlled
after 21 days or who required more than 240 mg or less than 20 of oxycodone daily were
discontinued from the study”. Stable pain control for 48 hours to 10 days was required
before entry into the double-blind phase
- Rescue medication: Immediate-release oxycodone in 5 mg tablets
- Othermedication: “Concurrent, stable therapy with acetaminophen, NSAIDs, or anal-
gesic adjuvants and coanalgesics were allowed. Opioids other than the study medication
were prohibited. All medically necessary but noninvestigational medications were per-
mitted.”
- For cross-over trials, cross-over schedule: “After successful completion of period 1,
patients were crossed over into the double-blind period 2 without a washout.” The
procedures for this period were identical to those in period 1
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Outcomes - Pain intensity or pain relief: Assessed by participant in daily diary, using an 11-point
scale from 0 (= no pain or no relief ) to 10 (= severe pain or complete relief )
- Acceptability of treatment: Assessed by participant in daily diary, using a 5-point scale
from 1 (= very poor) (2 = poor, 3 = fair, 4 = good) to 5 (= excellent)
- Adverse events: Spontaneously reported by participant in daily telephone contact
Notes - Study free of commercial funding? No. The study was sponsored by the drug manufac-
turer (Purdue Frederick Company) and one of the authors was employed by the study
drug manufacturer
- Groups comparable at baseline? No details reported about initial group allocation
- ITT analyses undertaken? Yes, although only data from 30/40 participants are analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Pain
Low risk “The double-blind periods were blinded by
using three tablets identical in appearance:
5mg IR oxycodone, 10mgCR oxycodone,
and placebo.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk Participant reported outcome. See also cell
above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk Data from 30/40 participants analysed.
Incomplete outcome data (attrition bias)
Adverse events
High risk See cell above
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
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Were the participants adequately titrated? Low risk The participants were probably adequately
titrated. Pain intensity dropped from6 (SD
= 2.2) at the beginning of titration to 2.7
at the completion of the titration phase
For cross-over trials: are data available for
both time periods?
Low risk Yes, data are available for both study periods
for 30/40 participants
Su 2015
Methods Design: randomised, parallel-group trial.
Year: 2011-2014.
Country: China.
Participants Participants: 80 participants selected; cancer types were lung (N = 22), breast (N = 20)
, gastric (N = 18), colon (N = 9), prostate (N = 6) and oesophageal (N = 5). Pain was
assessed on a numerical rating scale (NRS) going from 0 (no pain), 1-3 (mild pain), 4-
6 (moderate pain), 7-9 (severe pain), to 10 (very severe pain). All participants enrolled
were NRS ≥ 4 points
The participants were randomly allocated to 2 treatment groups:
-Oxycodone: N = 42; 25 males / 17 females; mean age = 55.48 (SD = 11.54; range = 29-
76) years; mean Karnofsky score (KPS) = 55.14 (SD = 5.25); mean NRS = 6.93 (SD =
1.73), N = 16 with NRS of 4-6 points, and N = 26 with NRS of 7-9 points. Pain types
were chest pain (N = 18), abdominal pain (N = 7), ostealgia (N = 11), and shoulder and
back pain (N = 6)
-Fentanyl: N = 38; 22 males / 16 females; mean age = 54.89 (SD = 11.07; range 32-83)
years, mean KPS score = 56.05 (SD = 5.77); mean NRS = 7.16 (SD = 1.64), N = 14
with NRS of 4-6 points, and N = 24 with NRS of 7-9 points. Pain types were chest pain
(N = 16), abdominal pain (N = 8), ostealgia (N = 10), and shoulder and back pain (N
= 4)
Inclusion criteria: Patients with a diagnosis of malignant tumours with moderate-severe
pain, and no radiotherapy for the pain; no respiratory, cardiovascular and cerebrovascular
dysfunction, and no obstruction and serious liver and kidney dysfunction; and no history
of psychosis and opioids drug abuse history
Exclusion criteria: not reported.
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose and dosing: 10 mg every 12 hours as initial dose for morphine-naive partici-
pants, while participants who had previously received morphine were given Oxycontin
according to used dosage (total daily dose of morphine × 0.5 and then divided into 2
equal doses for 12 hourly treatment). The drug should be taken as whole tablets, but
not grinded pieces. Mean final daily dose was not reported
- Formulation: Controlled-release (Oxycontin)
- Route of administration: oral.
- Length of treatment: 2 weeks.
- Titration schedule: effectiveness and adverse events were evaluated 15 minutes after
the drugs were administered. If NRS increased or did not change, dose increased by
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50-100%. If NRS decreased to 4-6, administered the same dose after 15 min. If NRS
decreased to 0-3, the basic treatment for alleviating painwas continued, and administered
the same dose if needed. On the second day, the needed dose was calculated according
to the total amount of analgesics used during the first day, in an attempt to maintain the
NRS at 0-3
- Rescue medication: IV short-acting morphine was used as rescue medication for break-
through pain. The initial dose for those who had not used morphine before was 2-5
mg. For those who had used morphine before, the total amount of analgesics needed in
the first 24 hours was calculated and converted to the equivalent dose of morphine for
injection, of which 10-20% was the initial dose
- Other medication: not reported.
Comparison arm
- Drug: fentanyl.
- Dose and dosing: 25 µg/hour replaced after 72 hours as initial dose for morphine-
naive participants, while participants who had previously received morphine, received a
dose 0.5 × morphine dose. Mean final daily dose was not reported
- Formulation: patch (Durogesic).
- Route of administration: Transdermal
- Length of treatment: 2 weeks.
- Titration schedule: effectiveness and adverse events were evaluated 15 minutes after
the drugs were administered. If NRS increased or did not change, the dose increased by
50-100%. If NRS decreased to 4-6, administered same dose after 15 minutes. If NRS
decreased to 0-3, the basic treatment for alleviating painwas continued, and administered
the same dose if needed. On the second day, the needed dose was calculated according
to the total amount of analgesics used during the first day, in an attempt to maintain the
NRS at 0-3
- Rescue medication: IV short-acting morphine was used as rescue medication for break-
through pain. The initial dose for those who had not used morphine before was 2-5
mg. For those who had used morphine before, the total amount of analgesics needed in
the first 24 hours was calculated and converted to the equivalent dose of morphine for
injection, of which 10-20% was the initial dose
- Other medication: not reported.
Outcomes - Pain relief: Categorised as complete remission (CR; pain disappeared), partial remission
(PR; medication significantly reduced pain), mild remission (MR, pain after treatment
reduced, but sleep still affected?), and invalid (NR; no pain relief after medication). Pain
relief rate (%) = (CR + PR + MR) / total number of cases × 100%
-Quality of life: Assessed using Karnofsky (KPS) score, with participants’ daily life, men-
tal status, and appetite evaluated before and after treatment. “Interpersonal communi-
cation and other aspects of the situation” were also assessed before and after treatment
- Adverse events: “Sleep, dizziness, nausea and vomiting, constipation, dysuria and other
adverse reactions” observed using WHO standards
Notes - Study free of commercial funding? Unclear, no information appeared to be reported
- Groups comparable at baseline? The treatment groups did not differ statistically sig-
nificantly in terms of sex, age, KPS, type of pain, and degree of pain (P > 0.05)
- ITT analyses undertaken? Unclear.
Risk of bias
95Oxycodone for cancer-related pain (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Su 2015 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk No information reported.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk No information reported.
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk No information reported.
Incomplete outcome data (attrition bias)
Pain
Low risk The data from all the participants are re-
ported
Incomplete outcome data (attrition bias)
Adverse events
Low risk The data from all the participants are re-
ported
Selective reporting (reporting bias) Low risk All obvious outcomes appear to have been
reported
Other bias Unclear risk No information reported
Were the participants adequately titrated? Low risk The participants appear to be adequately
titrated
For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
Yu 2014
Methods Design: randomised, double-blind, non-inferiority parallel-group trial
Year: 2009-2011 (from ClinicalTrials.gov).
Country: China.
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Participants Participants: Of 260 randomised participants, 137 completed the maintenance (active
treatment) phase of the study (70 in the hydromorphone group and 67 in the oxy-
codone group), and these 137 participants presumably comprised the per protocol data
set, although the criteria for the per-protocol set were also that they needed to have
completed all efficacy evaluations with good compliance. The full analysis set comprised
all randomised participants with at least one dose of medication administered during
the titration phase and one measurement of efficacy. The safety data set comprised all
randomised participants with at least one dose of medication administered during the
titration phase and one measurement of safety
- Hydromorphone: N = 125, 82 males / 43 females; mean/median (SD, range) age = 53.
5 / 54 (10.86; 22-70) years; cancer type: Breast (N = 8), lung (N = 38), bone (N = 0)
, oral cavity (N = 1), gastrointestinal (N = 46), genitourinary (N = 13), lymphoma (N
= 0), leukaemia (N = 0), other (N = 17), not known (N = 2); tumour metastatic: Yes
(N = 118), no (N = 7); concomitant cancer therapy (N = 75); administration of strong
opioids (N = 104), weak opioids (N = 21)
- Oxycodone: N = 123, 80 males / 43 females; mean/median (SD, range) age = 52.7 /
55 (10.75; 18-68) years; cancer type: Breast (N = 7), lung (N = 34), bone (N = 0), oral
cavity (N = 0), gastrointestinal (N = 46), genitourinary (N = 17), lymphoma (N = 0)
, leukaemia (N = 0), other (N = 16), not known (N = 3); tumour metastatic: Yes (N
= 112), no (N = 11); concomitant cancer therapy (N = 72); administration of strong
opioids (N = 105), weak opioids (N = 18)
Inclusion criteria: Patients aged 18 to 70 years; currently receiving strong oral or transder-
mal (through the skin) opioid analgesics with inadequate control of moderate to severe
cancer pain or currently receiving weak opioids for cancer pain and are eligible according
to the study protocol to receive treatment with a strong opioid analgesic; who require
or are expected to require between 40 mg and 184 mg of oral morphine or morphine
equivalents every 24 hours and who are reasonably expected to achieve a stable dose of
opioid study medication during the study; with a life expectancy of 12 weeks or longer
Exclusion criteria: Patients with pure neuropathic pain, pain of unknown origin, acute
pain, or only pain on movement; requiring other opioid analgesics (apart from immedi-
ate-release morphine hydrochloride as rescue medication for breakthrough pain), with
any significant central nervous system (CNS) disorder or any disorder that predisposes
the patient to respiratory depression or any condition wherein the risks of treatment with
study drug may outweigh the potential benefits; and women of childbearing potential
who were pregnant or lactating
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose and dosing: twice daily administration of oxycodone morning and evening at
12-hourly intervals. The mean (SD) (daily?) dose of study medication in the overall
maintenance phase 38.5 (20.94) mg oxycodone CR
- Formulation: Controlled-release provided in 10, 20 and 40 mg over-encapsulated
tablets,
- Route of administration: oral.
- Length of treatment: 28 days
- Titration schedule: Up to 8 days during which participants were converted from their
prior opioids to their morphine equivalents (morphine to oxycodone CR, 2:1) and
titrated to adequate effect (as determined by pain assessments and supplementary anal-
gesic requirements). Dosage adjustments were made no more frequently than every 2
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days, both upwards and downwards. Maximum total daily dose allowed was 80 mg oxy-
codone. For breakthrough pain episodes observed within a 2-day period, rescue med-
ication (IR morphine hydrochloride tablets, 5 mg or 10 mg) was administered once
every 4 hours as needed. The participants had to achieve a stable dose providing pain
control (maximum use of rescue medication allowed was 3 times per day on average)
at least in the last 2 days the titration phase (2-8 days) and this does was continued for
28 consecutive days. In the 28-day active treatment phase “upward and downward dose
titrations were not to exceed a total daily dose of ” 80 mg oxycodone CR
- Rescue medication: see “’Titration schedule.’ ”A single dose of rescue medication was
approximately 15% of the corresponding total daily dose of study medication.“
- Othermedication: other opioids (than study drugs and rescue medication) not allowed
during the study. The following therapies were not allowed during the study or within 2
weeks before study entry: monoamine oxidase inhibitors, neuroablative procedures, ther-
apy with isotopes, anaesthetic procedures including acupuncture, or surgical procedures
relevant to cancer pain. Fentanyl patches were not allowed during the study or within 5
days of study entry. Adjuvant medications (e.g. paracetamol, NSAIDs, anxiolytics, an-
tidepressants, antiarrhythmic drugs, hormone therapy, anticonvulsants, corticosteroids,
and neuroleptics were allowed if the participant, at study start, was on a stable dose,
which was to be maintained
Comparison arm
- Drug: hydromorphone + placebo.
- Dose and dosing: twice-daily administration of hydromorphone and placebo morning
and evening at 12-hourly intervals. The mean (SD) (daily?) dose of study medication in
the overall maintenance phase 16 (8.51) mg hydromorphone ER
- Formulation: Extended-release provided in 8 and 16 mg over-encapsulated tablets
- Route of administration: oral
- Length of treatment: 28 days
- Titration schedule: Up to 8 days during which participants were converted from their
prior opioids to their morphine equivalents (morphine to hydromorphone ER, 5:1)
and titrated to adequate effect (as determined by pain assessments and supplementary
analgesic requirements). Dosage adjustments were made no more frequently than every
2 days, both upwards and downwards. Maximum total daily dose allowed was 32 mg
hydromorphone. For breakthrough pain episodes observed within a 2-day period, rescue
medication (IR morphine hydrochloride tablets, 5 mg or 10 mg) was administered once
every 4 hours as needed. The participants had to achieve a stable dose providing pain
control (maximum use of rescue medication allowed was 3 times per day on average)
at least in the last 2 days the titration phase (2-8 days) and this does was continued for
28 consecutive days. In the 28-day active treatment phase ”upward and downward dose
titrations were not to exceed a total daily dose of “ 32 mg oxycodone CR
- Rescue medication: see ’Titration schedule.’ ”A single dose of rescue medication was
approximately 15% of the corresponding total daily dose of study medication.“
- Othermedication: other opioids (than study drugs and rescue medication) not allowed
during the study. The following therapies were not allowed during the study or within
2 weeks before study entry: monoamine oxidase inhibitors, neuroablative procedures,
therapy with isotopes, anaesthetic procedures including acupuncture, or surgical proce-
dures relevant to cancer pain. Fentanyl patches were not allowed during the study or
within 5 days of study entry. Adjuvant medications (e.g. paracetamol, nonsteroidal anti-
inflammatory drugs, anxiolytics, antidepressants, antiarrhythmic drugs, hormone ther-
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apy, anticonvulsants, corticosteroids, and neuroleptics were allowed if the participant, at
study start, was on a stable dose, which was to be maintained
Outcomes - Participant assessment of ”pain at its worst in the last 24 hours,“ included as an item
in the Brief Pain Inventory (BPI) Short Form (0 = no pain and 10 = pain as bad as you
can imagine). ”Endpoint was defined as the last recorded BPI score of worst pain, just
before taking the morning dose of study drug
- “Pain at its least in the past 24 hours”, “average pain,” “pain right now;” all assessed in
the same way as “pain at its worst in the past 24 hours.”
- Number of breakthrough pain medication doses taken, recorded by participants in
dairies
- Number of participants with treatment emergent adverse events, serious adverse events,
and adverse events leading to discontinuation from the study
Notes - Study free of commercial funding? No. Some of the authors are from Janssen Pharma-
ceutical Company
- Groups comparable at baseline? “The baseline characteristics were comparable between
the 2 treatment groups, except in the hydromorphone ER group, in which a higher per-
centage of participants with bone metastasis (hydromorphone ER: 52.0%; oxycodone
CR: 37.4%) and Eastern Cooperative Oncology Group performance status of 3 (hydro-
morphone ER: 25.6%; oxycodone CR: 18.7%).”
- ITT analyses undertaken? No, the analyses are per protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation by an online dy-
namic minimisation allocation programme
with stratification for centre, concomitant
cancer therapy, and administration of opi-
oids during the last 14 days before study
entry
Allocation concealment (selection bias) Low risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Low risk “The interactive web based response sys-
tem designated a unique patient number
and treatment code, which dictated the
treatment assignment for each patient. The
blindwas broken only if specific emergency
treatment dictated knowing the treatment
status.”
All study drugs, including placebo, pro-
vided in over-encapsulated tablets
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above.
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Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above.
Incomplete outcome data (attrition bias)
Pain
High risk Only data from 81/260 randomised partic-
ipants are analysed
Incomplete outcome data (attrition bias)
Adverse events
Low risk The data from 254/260 randomised par-
ticipants are analysed
Selective reporting (reporting bias) Low risk All obvious outcomes appear to have been
reported
Other bias Low risk The results do not appear to be subject to
other bias
Were the participants adequately titrated? Low risk The participants appear to be adequately
titrated.
For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable.
Zecca 2016
Methods Design: randomised, open-label, superiority parallel-group trial.
Year: 2006-2007.
Country: Italy.
Participants Participants: 187 participants randomised to oxycodone or morphine:
- Oxycodone: N = 92, 60 males and 32 females, mean (SD) age = 62.1 (12.5) years;
cancer types were GI tract (digestive tract, liver, pancreas; N = 23), urogenital system (N
= 16), breast (N = 10), lung (N = 20), sarcoma (N = 9), head and neck (N = 3), other (N
= 10) and unknown (N = 1); anatomical pain site(s) were lower back (N = 25), abdomen
(N = 21), lower limb (N = 3), thorax (N = 11); 81 participants had metastatic disease
and 11 had localised disease; and 36 participants were receiving ongoing chemotherapy
while 56 participants were not
-Morphine: N = 95, 56 males and 39 females, mean (SD) age = 61.8 (11.5) years; cancer
types were GI tract (digestive tract, liver, pancreas; N = 23), urogenital system (N = 15)
, breast (N = 16), lung (N = 16), sarcoma (N = 1), head and neck (N = 5), other (N =
17) and unknown (N = 2); anatomical pain site(s) were lower back (N = 11), abdomen
(N = 20), lower limb (N = 7), thorax (N = 25); 80 participants had metastatic disease
and 15 had localised disease; and 39 participants were receiving ongoing chemotherapy
while 56 participants were not
Inclusion criteria:Patients aged 18 years or above; previous 24 hours average pain intensity
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score of at least 5 on a 0-10 numerical rating scale; Karnofsky performance status score
of at least 40; > 1 month expected survival; and minimum expectedfollow-up of two
weeks at the study center
Exclusion criteria: treatment with WHO step-III opioids within 30 days of study entry;
severe renal impairment; severe hepatic failure; dyspnoea or severe chronic obstructive
pulmonary disease; inability to take oral medications; history of psychiatric illness; cere-
bral metastasis; cognitive impairment; medical history of intolerance to morphine or
oxycodone; pregnancy; or breastfeeding
Interventions Oxycodone arm
- Drug: oxycodone.
- Dose and dosing: every 12 hours. “The initial daily dose of the study medication was
decided by the treating physician, based on patient characteristics, pain intensity, and
previous analgesic dosage, according to usual clinical practice.” “and the dose was titrated
to effect. Dose adjustments during follow-up were encouraged if patients required more
than two rescue analgesic doses over 24 hours.” Mean(?; 95% CI) oral morphine equiv-
alent daily dose at baseline = 36.6 (33.6 to 39.6) mg; mean(?; 95% CI) oral morphine
equivalent daily dose at study end = 69.8 (58.3 to 81.4) mg
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 14 days.
- Titration schedule: see “Dose and dosing.”
- Rescuemedication: “Oral immediate release or parenteral morphine could be prescribed
as supplemental analgesics for breakthrough pain.”
- Othermedication: “Administration of hormonotherapy, chemotherapy, analgesic adju-
vants (steroids, anticonvulsants, and antidepressants) was permitted only if started before
study entry and had to be kept unchanged during the study period.” “Use of antiemetics
and laxatives was permitted for treatment of adverse effects as required.”
Comparison arm
- Drug: morphine.
- Dose and dosing: every 12 hours. “The initial daily dose of the study medication was
decided by the treating physician, based on patient characteristics, pain intensity, and
previous analgesic dosage, according to usual clinical practice.” “and the dose was titrated
to effect. Dose adjustments during follow-up were encouraged if patients required more
than two rescue analgesic doses over 24 hours.” Mean(?; 95% CI) oral morphine equiv-
alent daily dose at baseline = 30.9 (27.7 to 34.1) mg; mean(?; 95% CI) oral morphine
equivalent daily dose at study end = 53.9 (44.4 to 63.4) mg
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: 14 days.
- Titration schedule: see ’Dose and dosing.’
- Rescuemedication: “Oral immediate release or parenteral morphine could be prescribed
as supplemental analgesics for breakthrough pain.”
- Othermedication: “Administration of hormonotherapy, chemotherapy, analgesic adju-
vants (steroids, anticonvulsants, and antidepressants) was permitted only if started before
study entry and had to be kept unchanged during the study period.” “Use of antiemetics
and laxatives was permitted for treatment of adverse effects as required.”
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Outcomes - Participant assessment of “average pain intensity in the previous 24 hours” on 0 (no
pain) to 10 (worst possible pain) numerical rating scale at baseline, 7 days and 14 days
- Participant assessment of “average intensity of adverse events in the previous week” on 0
(no symptom) to 10 (worst possible symptom) numerical rating scale at baseline, 7 days
and 14 days of the following adverse events: Nausea, vomiting, confusion, constipation,
somnolence, drymouth, itching, andhallucinations (rated as present/absent).Other than
hallucinations, an adverse event was considered to occur when there was a worsening,
relative to baseline of ≥ 2 points
Notes - Study free of commercial funding? No. Study supported by Mundipharma Pharma-
ceuticals; Floriani Foundation, Milan (del.CDA 22/11/12) and by Associazione Italiana
per la Ricerca sul Cancro (IG15314). The authors stated that the funders had no part
in study design, data analysis and interpretation, nor in writing the report
- Groups comparable at baseline? Yes apart from Kanofsky Performance Status: Higher
number of participants in the oxycodone group (N = 46/52%) with a performance status
of 70 or below compared to morphine (N = 36/39%)
- ITT analyses undertaken? No, the analyses were based on available data
Study terminated early due to slow accrual
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation to treatment group in a 1:1
ratio via a computer-generated block ran-
domisation with a block size of 4 and strat-
ification by age (<70 v 70 years or above)
and ongoing (administered from 15 days
before to 15 days after randomisation) v
not ongoing chemotherapy
Allocation concealment (selection bias) Low risk Centralised randomisation by a trial office.
Randomisation sequence concealed until
interventions assignment
Blinding of participants and personnel
(performance bias)
Pain
High risk Open-label study.
Blinding of participants and personnel
(performance bias)
Adverse events
High risk Open-label study.
Blinding of outcome assessment (detection
bias)
Pain
High risk Open-label study.
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Blinding of outcome assessment (detection
bias)
Adverse events
High risk Open-label study.
Incomplete outcome data (attrition bias)
Pain
Low risk Data included from 85/92 participants in
the oxycodone arm and 88/95 participants
in the morphine arm
Incomplete outcome data (attrition bias)
Adverse events
Low risk Data from 185 of 187 randomised partici-
pants analysed
Selective reporting (reporting bias) Low risk The obvious outcomes are reported
Other bias Low risk The study does not appear to be subject to
other bias
Were the participants adequately titrated? Low risk The participants appear to be adequately
titrated
For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
Zhang 2014
Methods Design: randomised, double-blind, parallel-group trial.
Year: 2013-2014.
Country: China.
Participants Participants: 171 participants selected; 94 males and 77 females, median (range) age =
62 (39 to 74) years; cancer types were lung (N = 48), pancreatic (N = 13), liver (N = 30)
, gastric (N = 15), nasopharynx (N = 21), colorectal (N = 25) and bone metastases (N =
19); 49 participants had moderate pain and 122 had severe pain. The participants were
randomly allocated to 3 treatment groups with N = 57 in each
Inclusion criteria: Not explicitly given, but “All patients had moderate or severe stable
pain, theKPS score >50, Expected survival > 3months, no obvious respiratory depression
or airway obstruction, normal liver function and blood routine examination, no drug
allergy history, no use of other analgesics at 5 h before treatment.”
Exclusion criteria: Not reported
Interventions Oxycodone arm
- Drug: oxycodone (supplied by Mundipharma (China) Pharmaceutical Co. Ltd.)
- Dose and dosing: 10 mg every 12 hours as initial dose. Mean final daily dose was not
reported
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: not reported.
- Titration schedule: “The above-mentioned drugs must be swallowed wholly, not par-
tially or trituration. If the patients cannot take the drugs, the same dose of rectal ad-
103Oxycodone for cancer-related pain (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zhang 2014 (Continued)
ministration was considered. The dose was evaluated once every 48 h and regulated
according to the degrees of pain relief. The dose was added and each dose was increased
by 50%~100% due to poor control of disease but the administration frequency was not
changed until the cancer pain was relived satisfactorily.”
- Rescue medication: “During the treatment, if the unsound short-term effect or sudden
aggravated pain, a short-acting morphine injection was given.”
- Other medication: not reported.
Comparison arm 1
- Drug: morphine (supplied by Taiji Group, Southwest Pharmaceutical Co Ltd)
- Dose and dosing: 30 mg every 12 hours as initial dose. Mean final daily dose is not
reported
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: not reported.
- Titration schedule: “The above-mentioned drugs must be swallowed wholly, not par-
tially or trituration. If the patients cannot take the drugs, the same dose of rectal ad-
ministration was considered. The dose was evaluated once every 48 h and regulated
according to the degrees of pain relief. The dose was added and each dose was increased
by 50%~100% due to poor control of disease but the administration frequency was not
changed until the cancer pain was relived satisfactorily.”
- Rescue medication: “During the treatment, if the unsound short-term effect or sudden
aggravated pain, a short-acting morphine injection was given.”
- Other medication: not reported.
Comparison arm 2
- Drug: MS Contin (supplied by Mundipharma (China) Pharmaceutical Co Ltd)
- Dose and dosing: 30 mg every 12 hours as initial dose. Mean final daily dose is not
reported
- Formulation: Controlled-release
- Route of administration: oral.
- Length of treatment: not reported.
- Titration schedule: “The above-mentioned drugs must be swallowed wholly, not par-
tially or trituration. If the patients cannot take the drugs, the same dose of rectal ad-
ministration was considered. The dose was evaluated once every 48 h and regulated
according to the degrees of pain relief. The dose was added and each dose was increased
by 50%~100% due to poor control of disease but the administration frequency was not
changed until the cancer pain was relived satisfactorily.”
- Rescue medication: “During the treatment, if the unsound short-term effect or sudden
aggravated pain, a short-acting morphine injection was given.”
- Other medication: not reported.
Outcomes - Pain: Classified according toWorldHealthOrganisation (WHO) from level 0 (painless)
, through level 1 (mild pain, no need to use drugs), level 2 moderate pain, influences
sleep, analgesics needed) to level 3 (severe pain, strong impact on sleep, analgesics needed)
- Pain relief: Measured on degree scale from 0 (non-remission pain), through degree
(mild pain relief, pain which is reduced by 1/4), degree (moderate pain relief, pain
reduced by 1/2), degree (obvious pain relief, pain reduced by 3/4), and degree
(complete pain relief, pain disappears). “The pain relief rate refers to the rate of moderate
or above pain, that is, The pain relief rate =patients of The degree and the above/the
total selected patients.” (p. 8798)
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- Adverse events: Nausea, vomiting, constipation, dizziness, dysuria and somnolence. No
further details reported
Notes - Study free of commercial funding? Unclear, the study drugs were provided by Taili
Group Southwest Pharmaceuticals Co. Ltd. (morphine) and Mundipharma (China)
Pharmaceuticals Co. Ltd
- Groups comparable at baseline? No differences were found between the 3 groups in
mean age, gender, disease categories, KPS score, pain types, and degrees (p > 0.05)
- ITT analyses undertaken? Yes, data from 57 participants in each group are analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk No information reported
Incomplete outcome data (attrition bias)
Pain
Unclear risk Unclear how many were entered into the
trial
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Unclear how many were entered into the
trial
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be reported
Other bias Unclear risk It cannot be evaluated whether this study
is at risk of other bias due to the sparse
reporting of study details
Were the participants adequately titrated? Low risk The participants were probably adequately
titrated. About 90% of patients in each of
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the three groups achieved at least moderate
pain relief
For cross-over trials: are data available for
both time periods?
Unclear risk Not applicable
cm: centimeters; CNS: central nervous system; CR: controlled release; ER: extended-release; g: grams; g/dL: grams per decilitre; h or hr:
hour(s); IM: intramuscular; IR: Immediate-release; ITT: intention to treat; IV: intravenous; kg: kilograms;KPS: Karnofsky Perfor-
mance Status; max: maximum; mg: milligrams; mg/dL: milligrams per decilitre; min: minute(s); ml: millilitres; mm: millimetres; N:
number of participants; NRS: numerical rating scale; NSAID: non-steroidal anti-inflammatory drug; OOD: oxycodone once daily;
OTD: oxycodone twice daily; PCA: patient-controlled analgesia; PI: pain intensity; SD: standard deviation; SE: standard error; SR:
sustained-release; TD: transdermal; uL: microlitres; v: versus; VAS: visual analogue scale; WHO: World Health Organization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahmedzai 2012 Comparison not in PICO: Oxycodone-naloxone versus oxycodone
Awerbuch 2011 Not cancer pain
Bekkering 2011 Systematic review. Checked for relevant, previously unidentified studies for current review
Bell 2006 Systematic review. Checked for relevant, previously unidentified studies for current review
Borchgrevink 2004 Narrative review
Caraceni 2011 Systematic review. Checked for relevant, previously unidentified studies for current review
Carroll 2011 Comparison not in PICO: Patients received a variety of sustained-release opioids + immediate-release morphine
or oxycodone versus placebo
Chary 1994 Intervention not in PICO
Chen 2009 Comparison not in PICO: Oxycodone-acetominophen versus morphine
De Conno 1991 Not RCT
Dunlop 2013 Comparison not in PICO: Oxycodone-naloxone versus oxycodone
Fallon 2011 Systematic review. Checked for relevant, previously unidentified studies for current review
Garassino 2010 Comparison not in PICO: Fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of
oxycodone and fixed-dose pregabalin
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Garassino 2011 Comparison not in PICO: Fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of
oxycodone and fixed-dose pregabalin
Garassino 2013 Comparison not in PICO: Fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of
oxycodone and fixed-dose pregabalin
George 2003 Narrative review
Hanks 2002 Narrative review
Hongmei 2013 Not RCT
Igarashi 2015 Letter to the editor
Katz 2008 Letter to the editor
Kim 2015 Comparion not in PICO: Transdermal fentanyl versus transdermal fentanyl + oral oxycodone
King 2011 Systematic review. Checked for relevant, previously unidentified studies for current review
Koyyalagunta 2012 Systematic review.Checked for relevant, previously unidentified studies for current review
Kummer 2011 Particpants were healthy individuals, not people with cancer
LeBon 2009 Systematic review.Checked for relevant, previously unidentified studies for current review
Leppert 2011 Comparison not in PICO: Oxycodone-naxolone versus oxycodone
Li 2008 Comparison not in PICO: Oxycodone-acetominophen versus oxycodone
Li 2010 Comparison not in PICO: Oxycodone + gabapentin versus oxycodone
Ma 2016 Systematic review. Checked for relevant, previously unidentified studies for current review
Marineo 2012 Not randomised enrolment
Meng 2008 Published completely in Chinese. Translator confirmed that the study is not an RCT, but rather a retrospective
review of cancer patient charts
Moertel 1974 Comparison not in PICO: Aspirin versus aspirin+codeine versus aspirin+oxycodone versus aspirin+pentazocine
hydrochloride
Moksnes 2012 Comparison not in PICO: Study compared two switching strategies frommorphine/oxycodone to methadone
Nadstawek 2008 Comparison not in PICO: Comparing different doses of naloxone in patients on oxycodone
Nalamachu 2013 Not RCT
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NCT01859715 Population not in PICO: “Patients with pain and/or nausea are enrolled in the Emergency Department
(ED). They are given either oxycodone, hydrocodone, or ondansetron at the discretion of the Emergency
Department (ED) provider or the triage nurse by triage protocol. Detailed prescription, over the counter,
herbal, supplement, and illicit drug ingestion histories are taken from the patient or their health care proxy.
Serial visual analogue scales are captured prior to study drug administration then between 30 and 90 minutes
following drug administration.” “Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/
500 mg by ED provider decision or by triage nurse randomization.” Unclear whether it is a RCT
NCT01885182 Comparison not in PICO: Oxycodone-naxolone versus oxycodone
Nunez Olarte 2008 Narrative review
Oosten 2015 Systematic review. Checked for relevant, previously unidentified studies for current review
Pang 2009 Comparison not in PICO: fixed doses of oxycodone-acetominophen versus background doses of oxycodone-
acetominophen plus additional dose for breakout pain versus controlled-release oxycodone plus oxycodone-
acetominophen for breakout pain
Passik 2014 Comparison/population not in PICO (N = 2 with cancer)
Reid 2006 Systematic review. Checked for relevant, previously unidentified studies for current review
Rentz 2009 Not RCT-based analyses
Shi 2008 Comparison not in PICO: Oxycodone-acetominophen versus morphine
Sima 2010a Comparison not in PICO: Oxycodone + aceteminophen versus placebo
Sima 2010b Comparison not in PICO: Oxycodone + aceteminophen versus placebo
Sima 2012 Comparison not in PICO: Oxycodone + paracetamol versus placebo
Stambaugh 1980a Comparison not in PICO: Oxycodone + aspirin + caffiene + phenaticin (Percodan) versus zomepirac versus
placebo
Stambaugh 1980b Comparison not in PICO: Oxycodone-acetominophen (tylox) versus oxycodone-aspirin (Percodan)
Stambaugh 1981 Comparison not in PICO: Oxycodone + aspirin + caffiene + phenaticin (Percodan) versus zomepirac versus
placebo
Stambaugh 1985 Comparison not in PICO: Ibuprofen vs. placebo
Stambaugh 1987 Comparison not in PICO: Xorphanol versus oxycodone-acetominophen versus placebo
Stambaugh 1990 Comparison not in PICO: Flurbiprofen versus oxycodone-acetominophen versus placebo
Stambaugh 1991 Narrative review
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Taeron 2002 Narrative review
Wallace 2013 Case report
Wang 2012 Systematic review. Checked for relevant, previously unidentified studies for current review
Watanabe 2008 N = 1 received oxycodone
Wu 2009 Comparison not in PICO: Oxycodone-acetominophen versus tramadol
Wu 2015 Comparison not in PICO: Morphine versus oxycodone + morphine
Xiong 2008 Comparison not in PICO: Oxycodone-acetominophen versus morphine
Xu 2008 Not RCT
Zou 2009 Comparison not in PICO: Oxycodone + acetaminophen versus increased dose of existing opioid treatment
PICO: P = participant, problem, or population; I = intervention; C = comparison, control, or comparator; O = outcome; RCT:
randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
2012-001578-26
Methods Randomised, parallel-group, open-label controlled trial:
An International, Multicentre, Open Randomised Parallel Group Trial Comparing a Two Step Approach for Cancer
Pain Relief With the Standard Three Step Approach of the WHO Analgesic Ladder in Patients With Cancer Pain
Requiring Step 2 Analgesia
Participants Inclusion Criteria:
- A18 years of age and over.
- Patient has a cancer diagnosis (based on radiological, histological, cytological, or operative evidence). Those with
haematological malignancies are eligible
- Cancer related pain - which in the opinion of the clinician is caused by the presence of tumour or metastases
- Average pain score > 4, on a numerical rating scale from 0 to 10, requiring step 2 analgesia (weak opioid)
- Patient is able to comply with trial procedures
Exclusion criteria:
- Patients who have received radiotherapy in the previous 6 weeks or are planned to receive radiotherapy during the
trial period where in either case, it is expected to affect pain during the trial period
- Pain due to surgery in the preceding 4 weeks
- Life expectancy less than two months (based on clinical impression)
- Patients with psychotic disorders or cognitive impairment
- Patients who have received regular doses (scheduled doses - not as required dosing) of weak or strong opioids in the
preceding two weeks
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- Patients using immediate-release opioids > 2 doses/24 hours, in the previous 24 hours
Interventions Standard 3 Step approach (participants will be managed according to the standard 3 Step approach of the WHO
analgesic ladder (Step 1 - Step 2 - Step 3))
versus
2 Step approach (participants managed according to the WHO analgesic ladder bypassing Step 2, i.e. participants
will move from Step 1 of the WHO analgesic ladder to Step 3)
Drugs to be used: oral morphine, oral oxycodone, oral tramadol, codeine
Outcomes Primary outcome measures:
- Time to achieving stable pain control, where stable pain control is defined as the first day of three consecutive days
with average pain score less than or equal to 3 using scores from the Patient Diary and participant assessments. (Time
frame: Up to 20 days)
Secondary outcome measures:
- Mean of daily average pain scores from the Patient Diary
- Mean of daily worst pain scores from the Patient Diary
- Percentage of days with average pain score ≥ 6 from the Patient Diary
- Percentage of days with worst pain score ≥ 6 from the Patient Diary
- Pain intensity, pain relief, and pain interference scores at day 10 and 20 from the Brief Pain Inventory
- Patient distress score at day 10 and 20 from the NCCN Distress Thermometer
Notes Location: UK, Norway, Australia, Italy, Germany, Uganda, Spain
Sponsors and collaborators: University of Edinburgh, NHS Lothian, Mundipharma (UK), St Olavs Hospital (Nor-
way)
Principal investigators: Marie Fallon, University of Edinburgh
Target enrolment: N = 450
Study dates: March 2012 to December 2014
Other study ID numbers: NCT01493635, 11/SS/0079
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Methods Poster Presentations
Session title: Chronic pain
Presentation date: Sunday, 15 March 2009
Evaluation of efficacy and safety of prolonged-release oxycodone at different dosages for the treatment of severe
chronic pain
Aurilio C, Sansone P, Pace MC, Passavanti MB, Romano SV, Pota V
Second University of Naples, Department of Anaesthesiological, Surgical and Emergency Sciences, Napoli, Italy
Background and aims: It’s important to arrange a correct and flexible therapy for the treatment of chronic malignant
and non-malignant pain especially in fragile patients. The aim of this study is to evaluate the efficacy and safety of
prolonged-release (PR) oxycodone 10 mg/morning and 20 mg/evening versus PR oxycodone 20 mg twice a day
Methods: After local ethical committee approval and written informed consent 40 patients (13 men and 27 women)
, affected by severe chronic pain (mean NRS 8) were randomised in two groups: OD group: 20 patients receiving
PR oxycodone 10 /morning and 20 /evening; OS Group: 20 patients who receiving PR oxycodone 20 mg every 12
hours. The observation period was 28 days with 5 visits, once a week (T0 to T5). NRS was the parameter of efficacy
while the incidence and intensity of nausea, vomiting, somnolence, stipsis and itching were the parameters of safety.
Any assumption of rescue medication (immediate-release oral morphine 10 mg) was registered
Results: Both the groups presented a 50% reduction of pain T1, and kept a very good analgesia for all the observation
period. In OD group there was a lower incidence of adverse events than in OS Group. In OS group there was a lower
assumption of rescue medication than in OD Group
Conclusion: Therapy using PR oxycodone at different dosages allows a pain reduction similar to therapy with PR
oxycodone at same dosage. Moreover with this therapeutic scheme it’s possible to reduce the incidence of adverse
events
Participants E-mailed authors to ask for clarification re population on 23 May 2013
Interventions
Outcomes
Notes
JapicCTI-090789/090/091
Methods JapicCTI-090789: An open-label study of intravenous (i.v.) S-811717 (oxycodone hydrochloride solution for injec-
tion) in patients with cancer pain
JapicCTI-090790: An extension study of S-811717 (oxycodone hydrochloride solution for injection) in patients
with cancer pain
JapicCTI-090791: An open-label study of subcutaneous injection (s.c.) S-811717 (oxycodone hydrochloride solution
for injection) in patients with cancer pain
Participants Inpatients with pain associated with various cancers aged ≥ 20 years
Interventions S-811717
Outcomes - To evaluate the efficacy and safety of S-811717 in patients with pain caused by various cancers
- To determine the pharmacokinetics of S-811717 and its metabolites. No other information available
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Notes Location: Japan
Sponsors, collaborators, investigators: Shionogi & Co, Ltd., Research and Development
No other information available
NCT00378937
Methods An Open, Randomized, Parallel Group Study in Patients With Cancer Pain, To Compare a Two-Step Analgesic
Ladder (Non-Opioid to Oxycodone) With Conventional Management Using A Three-Step Approach
Participants Disease characteristics:
- Diagnosis of cancer
- Requires regular Istep-2 analgesia for the management of cancer-related pain
Patient characteristics:
- Aged ≥ 18 years
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Must be able to take oral medication
Must be willing and able to complete a daily patient assessment booklet (PAB)
- No history of the following conditions: Depression, personality disorders that may lead to self-harm, admission to
the hospital for psychiatric reasons, any other psychological disorder that, in the opinion of the investigator, would
preclude study treatment
- Not at risk of additional CNS depressant effects due to study drugs
- No known history of alcohol or drug abuse or, in the opinion of the investigator, tendency towards drug abuse or
addiction
- No current abuse of alcohol or drugs
- No known sensitivity to oxycodone hydrochloride or other opioids
- No history of a specific or allergic reaction to study drugs
- No contraindications as a result of adverse drug reaction or drug interactions of oxycodone or other opioid drugs
- No other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation
Prior concurrent therapy:
- More than 30 days since prior and no concurrent chemotherapy or radiotherapy
- At least 2 weeks since prior regular (i.e., 4 times per day) step-2 analgesics
- More than 3 months since prior regular use of opioids, defined as having a regular prescription of an opioid
medication
- Not planning to undergo cancer-related surgery
- No other concurrent opioid-based medication other than oxycodone hydrochloride capsules as escape medication
(arm II)
- No concurrent participation in another clinical trial involving a new chemical entity
Interventions Arm 1:
Participants receive an analgesic regimen, according to their level of pain, for up to 18 weeks
- Step 1: Participants in mild pain receive oral acetaminophen 4 times daily
- Step 2: Participants in mild-to-moderate pain receive oral codeine or oral dextropropoxyphene hydrochloride 4
times daily and oral acetaminophen 4 times daily
- Step 3: Participants in moderate-to-severe pain receive oral morphine or oral oxycodone hydrochloride 6 times daily
(every 4 hours) with or without a non-opioid analgesic
Participants may also receive an adjuvant drug (i.e., for side effects or for primary indication other than pain
management that is analgesic in selected circumstances)
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versus
Arm 2:
Participants receive oral oxycodone hydrochloride twice daily for up to 18 weeks. Participants may receive a different
opioid analgesic or analgesia or adjuvant medication as in arm I, if needed
Participants in both arms may also receive additional medication for breakthrough pain. Participants complete a
participant-assessment booklet (PAB) daily which includes a Box-Scale (BS)-11 rating for average pain; questions
regarding contact (e.g., telephone or visit) with healthcare professionals on that day; and information regarding the
number of times escape medication is used. Quality of life and levels of cancer pain are assessed using the short form
of the Brief Pain Inventory (BPI). After completion of study treatment, participants are followed at 4 weeks
Outcomes Primary Outcome Measures:
- Percentage of time in assessment periods 1 and 2 (i.e., first 4 weeks) with a BS-11 pain score of ≤ 4 (i.e., mild pain)
Secondary Outcome Measures:
- Percentage of time in assessment periods 3 and 4 with a BS-11 pain score of ≤ 4
- Mean BS-11 pain scores
- Time to reach stable pain control
- Mean escape medication use
- Quality of sleep
- Global assessment of pain relief with study drugs
- Mean pain intensity, pain interference, and pain relief scores as measured by the BPI
- Overall number of phone calls, home visits by a nurse, home visits by a doctor, and unscheduled visits to a healthcare
provider, related to pain control or analgesic medication during study treatment
Notes Location: US
Sponsors and collaborators: University Hospitals Bristol NHS Trust
Study chair: Geoff Hanks, University Hospitals Bristol NHS Trust
Target enrolment: N = 30
Study dates: ?
Other study ID numbers: CDR0000507650, CRUK-ON/2003/1772, EU-20640, EUDRACT-2004-004235-66,
NAPP-CRUK-ON/2003/1772
NCT00726830
Methods Randomised, parallel-group, open-label controlled trial:
A Randomized Comparison of Oral Methadone as a “First-Switch” Opioid Versus Opioid Switching Between Sus-
tained-ReleaseMorphine andOxycodone forOncology-Hematology OutpatientsWith PainManagement Problems:
The “Simply Rotate” Study
Participants Disease characteristics:
- Receiving ongoing care in the outpatient medical oncology setting
- Self-reported pain (of any cause) for which long-acting strong opioids (morphine or oxycodone) have been prescribed
or administered oral morphine-equivalent daily dose (MEDD) of existing opioid regimen (long-acting or immediate-
release) 40 to 300 mg/day
-Worst pain score on a scale of 0 (no pain) to 10 (worst pain) of≥ 5 for≥ 1 week duration based on verbal self-report
or ≥ 1 persistently bothersome symptom attributed to an opioid side effect (e.g., fatigue, confusion, depressed level
of consciousness, memory loss, personality change, anorexia, constipation, dehydration, nausea, vomiting, weight
loss, pruritus, urticaria, impotence, reduced libido, and urinary retention or hesitancy), or both
Patient characteristics:
- Aged ≥ 18 years
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- None of the following conditions that could predispose the patient to prolongedQT interval-associated tachycardia:
serum potassium < 3.0 mg/dL; cocaine abuse within the past 3 months; family history of sudden death; advanced
heart failure (ejection fraction < 40% or New York Heart Association (NYHA) class III or IV heart disease, or both
- No known or suspected cognitive impairment that could interfere with adherence to the medication plan or self-
report of symptoms and side effects
- Not pregnant or nursing
- Fertile patients must use effective contraception
Prior concurrent therapy:
- See ’Disease characteristics’
- More than 4 weeks since prior radiotherapy or surgery for local control of cancer or pain palliation
- More than 60 days since prior use of the same long-acting opioid (i.e., the new long-acting opioid) that patient is
switching to on the study
- More than 12 weeks since prior methadone therapy
- More than 3 days since prior and no concurrent transdermal fentanyl, oxymorphone, or buprenorphine
- Concurrent systemic anticancer therapy or bisphosphonates allowed provided therapy was initiated ≥ 4 weeks ago
- Concurrent tricyclic antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, or other
adjuvant analgesics or psychostimulants allowed provided therapy was initiated ≥ 2 weeks ago; dose expected to
remain stable until after the first week of opioid rotation on study
- No concurrent methadone maintenance therapy for opioid addiction
- No concurrent intrathecal infusion of analgesics
- No concurrent antiarrhythmic medications (e.g., amiodarone or quinidine)
Interventions Opioid rotation to oral methadone (participants are switched from their current opioid medication (oxycodone or
morphine) to methadone. Participants receive oral methadone 2 to 3 times daily for 4 weeks) versus
Opioid rotation to another long-acting strong opioid (participants currently receiving oxycodone are switched to sus-
tained-release (SR) morphine. Participants currently receiving morphine are switched to SR oxycodone. Participants
receive either oral SR morphine or oxycodone 2 to 3 times daily for 4 weeks)
Outcomes Primary outcome measures:
- Number of participants with at least a 3-point reduction in pain score on the M.D. Anderson Symptom Inventory
(MDASI) (time frame: 28 days)
- MDASI questionnaire completed on days 8, 15, and 22 after enrollment. The ’primary success’ is defined as a 3-
point reduction in pain score on the MDASI. Scores from baseline and from four weeks later compared using the
MDASI average pain intensity on a scale of 0 (no pain) to 10 (worst pain)
Secondary outcome measures:
- Number of participants with 30% reduction in total summary score for the Individual Composite Drug Toxicity
Score (CDTS) Items (time frame: 28 days) (Designated as safety issue)
Notes Location: US
Sponsors and collaborators: M.D. Anderson Cancer Institute, National Cancer Institute
Principal investigators: Michael J Fisch, MD, Anderson Cancer Center; James D Bearden, CCOP - Upstate Carolina
Target enrolment: N = ?
Study dates: March 2009 to October 2010
Other study ID numbers: 2007-0791, MDA-2007-0791, CDR0000598283
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Methods It is unclear whether this is a retrospective study or a randomised controlled trial. Authors e-mailed on 14 January
2014 for clarification
Design: ’Randomized’, parallel-group
Year: 2006 to 2008
Country: China
Participants Participants:
- Oxycodone (commercial name Tai Lening): N = 42, 42 analysed, M/F = unclear, median (range) age = 55 (28 to
83) years. Primary tumours were: lung cancer (12) , breast cancer (5), liver cancer (6), gastric cancer (4), nasopha-
ryngeal carcinoma (3), colorectal cancer (3), oesophageal cancer (3), lymphoma (2), osteosarcoma (2), chordoma (1)
, pancreatic cancer (1)
-Morphine sulfate controlled-release (MSContin): N = 45, 45 analysed, 27 males and 18 females; median (range) age
= 53 (30 to 76) years. Primary tumours were: Lung cancer (14), breast cancer (6), liver cancer (6); gastric cancer (6),
oesophageal cancer (3), pancreatic cancer (2), nasopharyngeal (2), colorectal cancer (2), non-Hodgkin’s lymphoma
(2), ovarian cancer (2)
Inclusion criteria: “87 patients who were diagnosed with malignant tumour based on histopathology and cytology,
with moderate to severe cancer pain and who did not respond to non-steroidal anti-inflammatory drugs and weak
opioid analgesics”
Exclusion criteria: Not reported
Interventions Oxycodone arm
- Drug: Oxycodone + 1 tablet (each containing oxycodone 5 mg, acetaminophen 325 mg),
- Dose and dosing: every 6 h (2 oxycodone tables has equal titration dose with oral morphine 30 to 40 mg)
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 5 days
- Titration schedule: Not clear but seems they have same dose increased as the contin group
- Rescue medication: During the treatment, if participants have short term unsatisfactory treatment efficacy or have
sudden intensified pain, then short-acting morphine injection was administrated. The participants were considered
treatment failure if the pain relief was not relieved until the observation period had ended or the limit dose was
reached
- Other medication: Unclear
Comparison arm
- Drug: Morphine sulfate (MS Contin)
- Dose and dosing: 20 mg/day as the first dose
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 5 days
- Titration schedule: MS Contin group with 20 mg/day as the first dose, if the pain could be relieved, then continued
using the same dose as maintenance treatment. If the pain was not relieved after 24 hr, then increased the dose until
a satisfactory pain relief, or till reach the maximum dose (the maximumdose = 270 mg/day)
- Rescue medication: During the treatment, if participants have short-term unsatisfactory treatment efficacy or have
sudden intensified pain, then short-acting morphine injection was administrated. The participants were considered
treatment failure if the pain relief was not relieved until the observation period had ended or the limit dose was
reached
- Other medication: Unclear
For both groups, if the participants had intolerable adverse reactions when increasing the dose, the drugs could be
discontinued at any time, then the participants were observed 30 days and then evaluated the treatment efficacy
The participant was also considered as treatment failure if the treatment has to be stopped due to intolerable adverse
events
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Outcomes - Pain Intensity (PI) and pain relief: the WHO linear Visual Analog Scale VAS was used, the degree of pain was
graded using by dividing a line into 10 segments: 0 = no pain, 1 to 3 as mild, 4 to 7 as moderate, severe pain as 8 to
9, 10 = extreme pain
Complete remission (CR): completely no pain after treatment, with a pain score of 0 on a 0 to 10 VAS. Partial
remission (PR): pain reduced significantly, there was no sleep disturbance, have normal daily life, the pain reduced
4 or more grades in the segments.(YY’s note: they did not say scores lower than 4, they said reduced 4 or more, CR
can be translated as complete relief ). Mild remission (NC): certain degree of pain relief, but require enhanced pain
control, participants had sleep disturbances, VAS score reduced 1 to 3 grades in the 0 to 10 VAS line. (YY note, NC
normally means no changes). Treatment failure (PD): no pain relief compared to baseline. (YY note - PD normally
means progression of disease). The authors considered participants who were CR or PR as “treatment was effective”
- Adverse reactions. Participants were observed for all kinds of adverse reactions: constipation, nausea, vomiting,
dizziness, drowsiness, skin rash or itching, abdominal discomfort etc
Notes Study free of commercial funding? Unclear
Were the participants adequately titrated? Unclear, possibly?
Groups comparable at baseline? Unclear, probably if properly randomised
ITT analyses undertaken? Yes
BPI: Brief Pain Inventory; MDASI: M.D. Anderson Symptom Inventory; NCCN: National Comprehensive Cancer Network; NHS:
National Health Service; NRS: numerical rating scale; PR: prolonged-release; SR: sustained-release; VAS: visual analogue scale;
WHO: World Health Organization.
Characteristics of ongoing studies [ordered by study ID]
2008-002273-12
Trial name or title Long term opioid administration in oncologic chronic pain: open label, prospective study on efficacy, safety
and pharmacogenetic factors
Methods Randomised, parallel-group, open controlled trial
Participants Inclusion criteria:
- age > 18 years
- oncologic, chronic, neurophatic or nociceptive peripheral pain
Exclusion criteria:
- abuse history
- opioid analgesic use history
- opioid allergies
Interventions Morphine (oral solution)
versus
morphine (oral tablet)
versus
oxycodone (oral tablet)
versus
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fentanyl (transdermal patch)
versus
buprenorphine (transdermal patch)
versus
hydromorphone (prolonged-release oral tablet)
Outcomes Pain reduction at least 40% in VAS scale
Starting date Not reported
Contact information Location: Italy
Sponsors: Ospedale Policlinico S. Matteo
Principal investigators: Not reported
Notes Target enrolment: N = 320
Study completion date: ? but of 3-year duration
Other study ID numbers: None reported, but is it the same as NCT00916890NCT00916890 below?
2009-013118-28
Trial name or title Bukkaalinen fentanyyli syöpäpotilaiden toimenpidekivun hoidossa (“The buccal fentanyl in cancer pain
management measure”)
Methods Randomised, cross-over (open or blind?) controlled trial
Participants Inclusion criteria:
- Cancer metastatic to the bone
- beginning radiotherapy to bone metastases (?)
Exclusion criteria:
- Severe hepatic, renal or cardiac dysfunction
- uncontrolled or rapidly increasing pain
- dry mouth
- oral mucositis or stomatitis
- pregnancy or breastfeeding
- impaired cognitive performance
- increased intracranial pressure
- drug abuse or history of drug use within the previous 5 years, or of use of CYP3A4 inhibition drug(s?)
(translated from Finnish)
Interventions Fentanyl (buccal) versus
oxycodone (oral) (Oxynorm)
Outcomes Pain relief and speed of effect for fentanyl compared to oxycodone, radiation therapy-related acute, short-
term pain relief (translated from Finnish), side effects
Starting date Not reported
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Contact information Location: Finland
Sponsors: Tarja Heiskanen
Principal investigators: Not reported
Notes Target enrolment: N = ?
Study completion date: ?
Other study ID numbers: None reported
Elsayem 2010
Trial name or title Abstract (this is all the information in the record)
TPS324
Background:Methadone is an opioidwithmany unique pharmacologic properties and it ismuch less expensive
than other opioids commonly used in cancer painmanagement. It is a particularly attractive analgesic to use for
opioid switching,with the goal of improving analgesia and/or decreasing opioid-related side effects. Prospective
trials involving methadone for opioid switching are uncommon in publicly-funded, clinical cooperative
groups. This trial in progress will help determine the feasibility, safety, and efficacy of two approaches to
opioid switching. It will also provide useful information regarding the feasibility of opioid-related research
conducted by oncologists in the outpatient community setting
Methods: This NCI-funded, randomized, prospective, open-label trial intends to enroll 300 cancer patients in
the outpatient community setting. Eligible patients have inadequate pain control and/or intolerable opioid-
related side effects and are prescribed either sustained-release morphine or oxycodone, with an oral morphine
equivalent daily dose between 40mg and 300mg. Patients are randomly assigned to be rotated to either
oral methadone or oral sustained-release morphine or oxycodone, and the new opioid dose is determined
using study-specific equianalgesic tables. Patients receive immediate-release opioids for breakthrough pain
and supportive measures for side effects, and patients have their opioids titrated according to study protocol
Evaluation occurs at enrollment and thenweekly for a total of 4 weeks using validated tools that include:M.D.
Anderson Symptom Inventory (MDASI), Composite Drug Toxicity Score (CDTS), and Revised Edmonton
Staging System (rESS) for Cancer Pain. We hypothesize that 60% of patients rotated to methadone will
achieve a 30% reduction in pain and/or opioid-related side effects; whereas 40% of patients rotated to either
sustained-release morphine or oxycodone will achieve this response. We define primary success as a 3-point
reduction in pain score-measured by MDASI-from baseline to completion of the study
No significant financial relationships to disclose
Methods
Participants
Interventions
Outcomes
Starting date 2010?
Contact information
Notes
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Trial name or title DS-7113b phase III study
A randomized double-blind comparison studywith immediate release (IR) oxycodone in opioid-naive patients
with cancer pain
Methods A multicentre, active controlled, randomised, double-blind, parallel-group study
Participants Inclusion criteria:
- Both genders, aged ≥ 20 years
- Patients receiving non-opioid analgesics for cancer pain, who have not been receiving opioid analgesics
- Patients whose VAS is ≥ 35 mm and judged necessary to be treated with strong opioid analgesics
- Patients with an ECOG Performance Status (PS) ≤ 3, etc
Exclusion criteria:
- Patients with symptom(s) or finding(s) falling under the contraindications or relative contraindications
stated in the package insert for oxycodone hydrochloride powder and morphine hydrochloride preparations,
etc
Interventions DS-7113b:
Each participant will be administered 4 doses a day orally for 5 days, versus
Oxycodone hydrochloride powder:
Each participant will be administered 4 doses a day orally for 5 days
Outcomes Primary outcome measures:
Change of VAS between pre-treatment and end of treatment
Secondary outcome measures:
Response rate at end of treatment (analgesia improvement rate), efficacy and safety
Starting date 1 October 2013.
Contact information Location: Japan
Sponsors, collaborators, investigators: Daiichi Sankyo Company, Limited
Principal investigator: Not reported
Notes Target enrolment: Not reported
Study completion date: 31 March 2015
Other study ID numbers: None reported
NCT00916890
Trial name or title Chronic Administration of Opioids in Cancer Chronic Pain:an Open Prospective Study on Efficacy, Safety
and Pharmacogenetic Factors Influence
Methods Randomised (parallel group), single-blind (outcome assessor) controlled trial
Participants Inclusion criteria:
- Adult oncologic patients (≥ 18 years old)
- Chronic peripheral neuropathic or nociceptive pain, or both
- Written informed consent
Exclusion criteria:
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- Pediatric patients
- Mental impaired patients
- Substance abuse disorder
- Opioid allergy
- History of opioids use or addiction
- Severe immunodeficiency, severe renal impairment, severe liver disease
- Cachectic state
- HIV positive patients
Interventions Morphine (after a titration phase with fast-release oral morphine, once the optimal dosage (no side effects
and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will
be randomly assigned to a participant) versus
oxycodone (after a titration phase with fast-release oral morphine, once the optimal dosage (no side effects
and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will
be randomly assigned to a participant) versus
fentanyl (after a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and
less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly
assigned to a participant) versus
buprenorphine (after a titration phase with fast-release oral morphine, once the optimal dosage (no side effects
and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will
be randomly assigned to a participant)
Outcomes Primary outcome measures:
- To identify the drug with the best clinical-pharmacological safety-efficacy profile among the four opi-
oids: oral extended-release morphine, oral extended-release oxycodone, transdermal fentanyl and transdermal
buprenorphine. (Time frame: 15 days after randomisation (Reduction of at least 40% of median daily pain,
on a NRS))
“We will define a treatment effective if it will produce a mean reduction of NRS values at least of 40% than
basal values. Among all effective treatments, we will identify the best as the one that will have a reduction of
NRS to a value of 4 or less in 90% of participants compared to the 70% of the others treatments. To evaluate
pharmacological safety the plasma concentrations of the drugs and their metabolites will be measured. We
will branch participants population in 3 groups to evaluate the correlation between clinical-pharmacological
response and genetics (responder,partially and not responder).”
Secondary outcome measures:
- Pharmacokinetic of opioids and of their metabolites during long-term administration; correlation between
specific genotypes and clinical response or the clinical/pharmacological susceptibility to side-effects on ad-
ministration of a specific opioid. (Time frame: 6 months (each participant will be followed for 6 month after
enrolment with clinical and pharmacological evaluations once a month and if inefficacy, tolerance or side
effects))
- Comparison of plasma levels of opioids and of their metabolites in ’responder’ participants (clinical effective-
ness without side effects), ’partial responder’ participants (clinical effectiveness without side effects but taking
not more than 2 rescue doses per day), and in ’non-responder’ participants (3 groups: clinical inefficacy, side
effects, tolerance or opioid induced hyperalgesia). Evaluation of the correlation between the polymorphisms
studied and clinical response; the frequency of allelic variants of interest will be compared in ’responder’,
’partial responder’ and ’non-responder’
Starting date February 2009
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Contact information Location: Italy
Sponsors, collaborators, investigators: IRCCS Policlinico S. Matteo, University of Pavia, Italy
Principal investigator: Massimo Allegri, IRCCS Foundation Policlinico “San Matteo”, Pavia, Italy; e-mail:
m.allegri@smatteo.pv.it, Tel: 00390382502627
Notes Target enrolment: N = 320
Study completion date: December 2015
Other study ID numbers: PT-SM-1-Op-Cancer
NCT01165281
Trial name or title A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the
Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate
to Severe Chronic Malignant Tumor Related Cancer Pain
Methods Randomised (parallel-group), double-blind (participant, caregiver, investigator) controlled trial
Participants Inclusion criteria:
- Aged ≥ 20 years
- Documented clinical diagnosis of any type of cancer
- Diagnosis of chronic malignant tumour-related cancer pain with an average score for pain intensity in the
past 24 hours of ≥ 4 on the 11-point numerical rating scale (NRS) on the day of randomisation (Day -1)
- Have not received treatment with opioid analgesics within 28 days before screening (note: codeine phosphate
(≤ 60 mg/d) or dihydrocodeine phosphate (≤ 30 mg/d) for antitussive use are allowed)
- Dissatisfied with pain relief by the current treatment and for whom the investigator or designee judges that
treatment with opioid analgesics is required
Exclusion criteria:
- Have complicated with uncontrolled or clinically significant arrhythmia
- Have previous or concurrent presence of any disease which may develop increased intracranial pressure,
disturbance of consciousness, lethargy, or respiratory problems such as traumatic encephalopathywith cerebral
contusion, intracranial hematoma, disturbance of consciousness, brain tumour, cerebral infarction, transient
ischemic attack, epilepsy or convulsive diseases
- Have history of alcohol or drug abuse
- Have any disease for which opioids are contraindicated such as serious respiratory depression of serious
chronic obstructive pulmonary disease, bronchial asthma attack, cardiac failure secondary to chronic pul-
monary disease, paralytic ileus, status epileptics, tetanus, strychnine poisoning, acute alcohol poisoning, hy-
persensitivity to opium alkaloid, haemorrhagic colitis, or bacterial diarrhoea
Interventions R331333 ((referred to as JNS024 ER or CG5503) one 25 mg to 200 mg capsule twice daily for 4 weeks)
versus
Oxycodone CR (one 5 mg to 40 mg capsule twice daily for 4 weeks)
Outcomes Primary outcome measures:
- The average pain intensity score using an 11-point numerical rating scale (NRS) (time frame: change from
baseline to the last 3 days of study drug administration)
Secondary outcome measures:
- The Patient Global Impression of Change (PGIC) (time frame: at the end of the 4-week double-blind
treatment phase)
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- The duration of rescue medication (time frame: during the 4-week double-blind treatment phase)
- The concentration of JNS024 in blood samples from participants (time frame: protocol-specified time
points during Weeks 1, 2, and 4)
- The proportion of participants responding to treatment, including at least 30% and 50%, based on the per
cent change from baseline using an 11-point numerical rating score (NRS) (time frame: at Week 4 of the
double-blind treatment phase on an 11-point NRS)
- Adverse events and findings from clinical laboratory tests, physical examinations, vital signs measurements,
and ECG measurements reported (time frame: from time of screening (Days -7 to -1) to post-treatment
(Week 5) or time of early termination from study)
Starting date August 2012
Contact information Location: Japan, Republic of Korea
Sponsors, collaborators, investigators, study director: Janssen Research &Development, L.L.C. Clinical Trial
(no other contact information reported)
Notes Target enrolment: N = 343
Study completion date: August 2012
Other study ID numbers: CR017188, JNS024ER-KAJ-C02
NCT01675622
Trial name or title A Comparative Study of Immediate-Release Oxycodone Capsules Versus Immediate-Release Morphine
Tablets for the Treatment of Chinese Patients With Cancer Pain
Methods Randomised, parallel-group, double (triple?)-blind (participant, care-giver, investigator, outcome-assessor)
controlled trial
Participants Inclusion criteria:
- Patients of either sex aged 18 to 80 years inclusive, with cancers of all types
- Patients with moderate to severe cancer pain, whose pain intensity NRS ≥ 4
- Patients who can understand and are able to complete NRS and BPI assessment
- Patients who have given written informed consent to participate in the study
Exclusion criteria:
- Patients who are pregnant, or lactating
- Patients who are unable to manage their pain effectively with opioids
- Patient who need ≥ 120mg morphine or equivalent for treatment of pain at time of study entry
- Patients who are receiving chemotherapy, or still under the responsive period of chemotherapy (patients who
are at the interval period of chemotherapy can be enrolled into study. That is to say, patients who completed
chemotherapy for more than 2 weeks can enrolled, or patients has completed chemotherapy for at least one
week could be enrolled at the discretion of the investigator)
- Patients who have received radiotherapy for bony metastasis, patients receiving radiotherapy within the 4-
week period before study entry (patient receiving radiotherapy for area other than pain area can be enrolled)
, or patients who were scheduled to receive radiotherapy for pain area during study period
- Patients are receiving or should receive anticonvulsive drugs or antidepressant drugs considered by investigator
for the treatment of neuropathy pain
- Patients are receiving or should receive any analgesic other than study medicine, including NSAIDs
- Patients with other unstable disease, or with dysfunction of important organ
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- Patients with an ongoing infection, abscess or fever
- Patient with serious abnormal liver or renal function (ALT, AST, creatinine, urea nitrogen) which is higher
than 3 times upper limit
- Paralytic or mechanical ileus
- Persistent asthma, chronic obstructive diseases, and cor pulmonary
- Intracranial neoplasms, and intracranial hypertension with central respiratory depression risk
- Monoamine oxidase inhibitors (MAOIs) or same type drugs have been administered in last 2 weeks
- Patients who are currently taking active treatment for epilepsy or arrhythmias
- Patients with known sensitivity or record of specific or allergic reaction to oxycodone or morphine
- Patients excludedby the contra-indications, adverse drug reaction (ADRs) anddrug interactions of oxycodone
or morphine as detailed in the data sheet, summary of product characteristics or investigator’s brochure
- Patients with a history of drug or alcohol abuse
- Patients who participated in another clinical research study involving a new chemical entity within one
month prior to study entry
- Patients whose concomitant medication is likely to be changed within the study period, with the exception
of treatment for opioid side effects
- Patients who, in the opinion of the investigator, are unsuitable to participate in the study for any other
reason not mentioned in the inclusion and exclusion criteria
Interventions Oxycodone (5 mg, l0 mg and 20 mg capsules every 6 h, 5 to 8 days) versus
morphine (tablets 10 mg and 20 mg, oral every 4 to 6 hours)
Outcomes Primary outcome measures:
- NRS (Numerical Rating Scale) score (time frame: 5 to 8 days). To compare the average for decrease of NRS
score after double-blind treatment between the two treatment groups
- The average dose of study medicine used during double blind treatment period (time frame: 5 to 8 days).
To compare the average dose of study medicine used during double-blind treatment period between the two
treatment groups
Secondary outcome measures:
- BPI (Brief pain inventory) (time frame: 19 to 22 days). To compare BPI score at baseline, after completion
of double-blind treatment and open-label treatment to baseline between the two treatment groups
- Times and frequency of breakthrough pain and the total dose of rescue medicine for breakthrough pain
(time frame: 19 to 22 days). To compare the times and frequency of breakthrough pain and the total dose of
rescue medicine for breakthrough pain during double-blind phase between the two treatment groups
- Participant assessments of satisfaction for pain management (time frame: 19 to 22 days). To compare
participant assessments of satisfaction for pain management between the two treatment groups at the end of
double-blind treatment and the open-label treatment period
- Average time for titration (time frame: 1 to 3 days). To compare the average time for titration between the
two treatment groups
Starting date December 2010
Contact information Location: China
Sponsors, collaborators: Mundipharma
Principal investigator: Shiying Yu, Wuhan Tong Ji Hospital
Notes Target enrolment: N = 240
Study completion date: July 2012
Other study ID numbers: OXYC10-CN-303
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Trial name or title Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate
to Severe Cancer Pain - Open Label, Randomized, Prospective Study
Methods Open-label, randomised, prospective study
Participants Inclusion criteria:
- age > 18 years
- patients who are being treated with one of strong opioids including oral oxycodone, oral hydromorphone,
or fentanyl patch with range from 60 mg to 200 mg of oral morphine equivalent daily dose (MEDD)
- moderate to severe cancer pain (numeric rating scale more than 3) at screening
- patients without uncontrolled adverse effects associated with currently applied opioid
Exclusion criteria:
- previous opioid rotation
- unable to take oral medication
- life expectancy less than a month
- newly started chemotherapy or radiotherapy within past 2 weeks of screening
- serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase > 2.5 times upper
normal limit
- serum total bilirubin or creatinine > 1.5 times of upper normal limit
Interventions Opioid rotation:
Participants who are randomised to opioid rotation are treated with strong opioid other than currently used
strong opioid (reduce the dose by 25% to 50% to allow for incomplete cross-tolerance between different
opioids):
Oral oxycodone: convert to oral hydromorphone or fentanyl patch
Oral hydromorphone: convert to oral oxycodone or fentanyl patch
Fentanyl patch: convert to oral oxycodone or oral hydromorphone versus
opioid dose escalation:
Participants who are randomised to opioid dose escalation will be treated cancer pain by escalation dose of
same strong opioid:
Oral oxycodone: maintain oral oxycodone and titrate the dose
Oral hydromorphone: maintain oral hydromorphone and titrate the dose
Fentanyl patch: maintain fentanyl patch and titrate the dose
Outcomes Primary outcome measures:
The rate of successful pain control defined as a 30% or 2-point reduction in the numeric rating scale (time
frame: 18 months). (Designated as safety issue: Yes)
Starting date April 2014
Contact information Location: Republic of Korea
Sponsors, collaborators: Gyeongsang National University Hospital
Principal investigator/contact: Se-Il Go, M.D., tel@ +82 55 750 9454 ext 9454, e-mail: gose1@hanmail.net
Notes Target enrolment: N = 136
Study completion date: January 2016
Other study ID numbers: GNUH-2013-07-014
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Trial name or title Randomized study of fentanyl citrate versus Oxycodone Hydrochloride Hydrate in patients with unresectable
advanced pancreatic cancer (FRONTIER)
Methods Randomised, single arm (?), phase III, open trial
Participants Inclusion criteria:
- Aged 20 to < 100 years
- unresectable advanced pancreatic cancer
- ≥ 15 to 25 mg oxycodone hydrochloride hydrate per day required for cancer pain
Exclusion criteria:
- Serious liver, kidney, cardiac disorders
- pulmonary impairment
- nervous system and psychic disorders
Interventions Oxycodone hydrochloride hydrate: 10 mg every 12 hours, versus
Transdermal fentanyl citrate: 1 mg once a day
Outcomes Primary outcome measures:
The rates of gastrointestinal disorders events in four weeks
Secondary outcome measures:
Quality of life, rates of opioid rotation, pain score, time until stable pain control, overall survival time, adverse
events
Starting date 27 March 2014
Contact information Location: Japan
Sponsors, collaborators: National Cancer Center Hospital East; Welfare labor science research cost (MHLW
(Japan))
Principal investigator/contact: Minori Odanaka, Clinical Trial Support Office, National Cancer Center Hos-
pital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan Tel: +81-3-3547-5201, e-mails: minochant23@yahoo.
co.jp; modanaka@ncc.go.jp
Notes Target enrolment: N = 80
Study completion date: Not reported
Other study ID numbers: None reported
ALT: alanine transaminase; AST: aspartate aminotransferase; BPI: Brief Pain Inventory; CR: controlled-release; ECG: electrocardiogram;
ECOG: Eastern Cooperative Oncology Group; NRS: numerical rating scale; VAS: visual analogue scale.
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D A T A A N D A N A L Y S E S
Comparison 1. Pain
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain intensity and pain relief 17 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Controlled-release (CR)
oxycodone vs immediate-
release (IR) oxycodone
3 578 Std. Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.06, 0.26]
1.2 CR oxycodone vs
extended-release (ER)
oxycodone
1 62 Std. Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.42, 0.57]
1.3 CR oxycodone vs CR
morphine
7 882 Std. Mean Difference (IV, Fixed, 95% CI) 0.14 [0.01, 0.27]
1.4 CR oxycodone vs CR
hydromorphone
1 62 Std. Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.63, 0.37]
1.5 CR oxycodone vs ER
hydromorphone
1 81 Std. Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.34, 0.54]
1.6 CR oxycodone vs ER
oxymorphone
1 74 Std. Mean Difference (IV, Fixed, 95% CI) 0.23 [-0.23, 0.69]
1.7 CR oxycodone vs ER
tapentadol
1 265 Std. Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.30, 0.18]
1.8 CR oxycodone vs
transdermal (TD) fentanyl
2 329 Std. Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.19, 0.24]
1.9 CR oxycodone vs TD
buprenorphine
1 252 Std. Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.15, 0.35]
1.10 IR oxycodone vs IR
morphine
1 38 Std. Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.79, 0.49]
Comparison 2. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any adverse events 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Controlled-release (CR)
oxycodone vs CR morphine
3 399 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.87, 1.09]
2 Asthenia 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 CR oxycodone vs
immediate-release (IR)
oxycodone
2 208 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.20, 1.68]
3 Confusion 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 CR oxycodone vs IR
oxycodone
2 157 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.20, 3.02]
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3.2 CR oxycodone vs CR
morphine
3 584 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.78, 1.31]
4 Constipation 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 CR oxycodone vs IR
oxycodone
3 317 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.45, 1.13]
4.2 CR oxycodone vs CR
morphine
5 797 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.82, 1.16]
4.3 CR oxycodone vs
transdermal (TD) fentanyl
2 336 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.88, 1.32]
5 Dizziness/lightheadedness 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 CR oxycodone vs IR
oxycodone
3 317 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.40, 1.37]
5.2 CR oxycodone vs CR
morphine
3 367 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.33, 1.76]
6 Drowsiness/somnolence 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 CR oxycodone vs IR
oxycodone
3 317 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.69, 1.54]
6.2 CR oxycodone vs CR
morphine
5 798 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.75, 1.08]
7 Dry mouth 7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 CR oxycodone vs IR
oxycodone
3 317 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.48, 2.75]
7.2 CR oxycodone vs CR
morphine
4 684 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.80, 1.26]
8 Dysuria 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 CR oxycodone vs CR
morphine
2 372 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.40, 1.26]
8.2 CR oxycodone vs TD
fentanyl
2 336 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.62, 2.16]
9 Hallucinations 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 CR oxycodone vs CR
morphine
4 696 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.28, 0.97]
10 Headache 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 CR oxycodone vs IR
oxycodone
3 317 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.34, 2.02]
11 Insomnia 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 CR oxycodone vs IR
oxycodone
2 269 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.31, 3.53]
12 Nausea 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 CR oxycodone vs IR
oxycodone
3 317 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.56, 1.28]
12.2 CR oxycodone vs CR
morphine
5 798 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.82, 1.26]
13 Nervousness 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 CR oxycodone vs IR
oxycodone
2 208 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.20, 1.64]
14 Pruritus 7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 CR oxycodone vs IR
oxycodone
3 317 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.65, 3.25]
14.2 CR oxycodone vs CR
morphine
4 684 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.51, 1.29]
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15 Sweating 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 CR oxycodone vs IR
oxycodone
2 269 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.22, 1.93]
16 Vomiting 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 CR oxycodone vs IR
oxycodone
3 317 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.38, 1.15]
16.2 CR oxycodone vs CR
morphine
5 798 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.68, 1.29]
17 Discontinuation due to adverse
events
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 CR oxycodone vs IR
oxycodone
3 317 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.29, 1.22]
17.2 CR oxycodone vs CR
morphine
3 399 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.43, 2.60]
Analysis 1.1. Comparison 1 Pain, Outcome 1 Pain intensity and pain relief.
Review: Oxycodone for cancer-related pain
Comparison: 1 Pain
Outcome: 1 Pain intensity and pain relief
Study or subgroup Oxycodone Comparison
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Controlled-release (CR) oxycodone vs immediate-release (IR) oxycodone
Kaplan 1998 (1) 156 1.3 (1.25) 156 1.3 (1.25) 54.2 % 0.0 [ -0.22, 0.22 ]
Parris 1998 (2) 103 1.4 (1.01) 103 1.1 (1.01) 35.4 % 0.30 [ 0.02, 0.57 ]
Stambaugh 2001 (3) 30 2.7 (1.9) 30 2.8 (1.9) 10.4 % -0.05 [ -0.56, 0.45 ]
Subtotal (95% CI) 289 289 100.0 % 0.10 [ -0.06, 0.26 ]
Heterogeneity: Chi2 = 3.08, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.19 (P = 0.23)
2 CR oxycodone vs extended-release (ER) oxycodone
Lux 2014 (4) 31 14.76 (17.4) 31 13.46 (16.47) 100.0 % 0.08 [ -0.42, 0.57 ]
Subtotal (95% CI) 31 31 100.0 % 0.08 [ -0.42, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
3 CR oxycodone vs CR morphine
Bruera 1998 23 24.3 (20) 23 22.9 (21) 5.2 % 0.07 [ -0.51, 0.65 ]
Corli 2016 125 2.9 (2.1) 122 2.6 (2.1) 28.1 % 0.14 [ -0.11, 0.39 ]
Heiskanen 1997 27 0.99 (0.62) 27 0.77 (0.36) 6.0 % 0.43 [ -0.11, 0.97 ]
-2 -1 0 1 2
Favours oxycodone Favours comparison
(Continued . . . )
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(. . . Continued)
Study or subgroup Oxycodone Comparison
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mercadante 2010 (5) 19 3.15 (3) 20 2.35 (2.36) 4.4 % 0.29 [ -0.34, 0.92 ]
Mucci-LoRusso 1998 79 1.3 (0.89) 79 1 (0.89) 17.8 % 0.34 [ 0.02, 0.65 ]
Riley 2015 80 2.05 (1.71) 85 2.36 (2.18) 18.8 % -0.16 [ -0.46, 0.15 ]
Zecca 2016 85 3.51 (1.99) 88 3.27 (1.71) 19.7 % 0.13 [ -0.17, 0.43 ]
Subtotal (95% CI) 438 444 100.0 % 0.14 [ 0.01, 0.27 ]
Heterogeneity: Chi2 = 6.49, df = 6 (P = 0.37); I2 =7%
Test for overall effect: Z = 2.04 (P = 0.042)
4 CR oxycodone vs CR hydromorphone
Hagen 1997 31 28 (22.27) 31 31 (22.27) 100.0 % -0.13 [ -0.63, 0.37 ]
Subtotal (95% CI) 31 31 100.0 % -0.13 [ -0.63, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
5 CR oxycodone vs ER hydromorphone
Yu 2014 (6) 41 5.1 (1.92) 40 4.9 (2.07) 100.0 % 0.10 [ -0.34, 0.54 ]
Subtotal (95% CI) 41 40 100.0 % 0.10 [ -0.34, 0.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
6 CR oxycodone vs ER oxymorphone
Gabrail 2004 37 2.8 (1.3) 37 2.5 (1.3) 100.0 % 0.23 [ -0.23, 0.69 ]
Subtotal (95% CI) 37 37 100.0 % 0.23 [ -0.23, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
7 CR oxycodone vs ER tapentadol
Imanaka 2013 139 2.57 (2.027) 126 2.69 (2.223) 100.0 % -0.06 [ -0.30, 0.18 ]
Subtotal (95% CI) 139 126 100.0 % -0.06 [ -0.30, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
8 CR oxycodone vs transdermal (TD) fentanyl
Corli 2016 125 2.9 (2.1) 124 2.8 (2.2) 75.7 % 0.05 [ -0.20, 0.29 ]
Su 2015 42 3.02 (2.19) 38 3.13 (2.16) 24.3 % -0.05 [ -0.49, 0.39 ]
Subtotal (95% CI) 167 162 100.0 % 0.02 [ -0.19, 0.24 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
9 CR oxycodone vs TD buprenorphine
Corli 2016 125 2.9 (2.1) 127 2.7 (1.9) 100.0 % 0.10 [ -0.15, 0.35 ]
Subtotal (95% CI) 125 127 100.0 % 0.10 [ -0.15, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
-2 -1 0 1 2
Favours oxycodone Favours comparison
(Continued . . . )
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(. . . Continued)
Study or subgroup Oxycodone Comparison
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
10 IR oxycodone vs IR morphine
Kalso 1990 19 1.3 (1.2) 19 1.5 (1.4) 100.0 % -0.15 [ -0.79, 0.49 ]
Subtotal (95% CI) 19 19 100.0 % -0.15 [ -0.79, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 3.92, df = 9 (P = 0.92), I2 =0.0%
-2 -1 0 1 2
Favours oxycodone Favours comparison
(1) CR oxycodone is ’oxycodone’ group, IR oxycodone is ’comparison’ group.
(2) CR oxycodone is ’oxycodone’ group, IR oxycodone is ’comparison’ group.
(3) CR oxycodone is ’oxycodone’ group, IR oxycodone is ’comparison’ group.
(4) SDs were not reported so we used SDs for overall per-protocol population (46 participants) including people with non-cancer pain.
(5) Week 4 data.
(6) Mean pain at its worst in past 24 hours (primary outcome); however, SDs not reported so we used SDs for same outcome measured at baseline in full analysis set
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Analysis 2.1. Comparison 2 Adverse events, Outcome 1 Any adverse events.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 1 Any adverse events
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Controlled-release (CR) oxycodone vs CR morphine
Mucci-LoRusso 1998 40/48 39/52 25.1 % 1.11 [ 0.91, 1.36 ]
Zecca 2016 77/91 79/94 52.1 % 1.01 [ 0.89, 1.14 ]
Zhang 2014 25/57 34/57 22.8 % 0.74 [ 0.51, 1.06 ]
Subtotal (95% CI) 196 203 100.0 % 0.97 [ 0.87, 1.09 ]
Total events: 142 (Oxycodone), 152 (Comparison)
Heterogeneity: Chi2 = 4.29, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
Analysis 2.2. Comparison 2 Adverse events, Outcome 2 Asthenia.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 2 Asthenia
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs immediate-release (IR) oxycodone
Kaplan 1998 (1) 3/78 8/82 88.6 % 0.39 [ 0.11, 1.43 ]
Salzman 1999 (2) 2/24 1/24 11.4 % 2.00 [ 0.19, 20.61 ]
Subtotal (95% CI) 102 106 100.0 % 0.58 [ 0.20, 1.68 ]
Total events: 5 (Oxycodone), 9 (Comparison)
Heterogeneity: Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
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(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
Analysis 2.3. Comparison 2 Adverse events, Outcome 3 Confusion.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 3 Confusion
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Parris 1998 (1) 0/54 2/55 55.3 % 0.20 [ 0.01, 4.15 ]
Salzman 1999 (2) 3/24 2/24 44.7 % 1.50 [ 0.27, 8.19 ]
Subtotal (95% CI) 78 79 100.0 % 0.78 [ 0.20, 3.02 ]
Total events: 3 (Oxycodone), 4 (Comparison)
Heterogeneity: Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 0.36 (P = 0.72)
2 CR oxycodone vs CR morphine
Corli 2016 55/129 59/129 80.9 % 0.93 [ 0.71, 1.23 ]
Riley 2015 7/81 2/72 2.9 % 3.11 [ 0.67, 14.50 ]
Zecca 2016 12/85 12/88 16.2 % 1.04 [ 0.49, 2.18 ]
Subtotal (95% CI) 295 289 100.0 % 1.01 [ 0.78, 1.31 ]
Total events: 74 (Oxycodone), 73 (Comparison)
Heterogeneity: Chi2 = 2.39, df = 2 (P = 0.30); I2 =16%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.71), I2 =0.0%
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.4. Comparison 2 Adverse events, Outcome 4 Constipation.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 4 Constipation
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 9/78 17/82 46.7 % 0.56 [ 0.26, 1.17 ]
Parris 1998 (2) 12/54 10/55 27.9 % 1.22 [ 0.58, 2.59 ]
Salzman 1999 (3) 4/24 9/24 25.4 % 0.44 [ 0.16, 1.25 ]
Subtotal (95% CI) 156 161 100.0 % 0.71 [ 0.45, 1.13 ]
Total events: 25 (Oxycodone), 36 (Comparison)
Heterogeneity: Chi2 = 3.21, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 1.43 (P = 0.15)
2 CR oxycodone vs CR morphine
Corli 2016 75/129 82/129 57.8 % 0.91 [ 0.75, 1.11 ]
Mucci-LoRusso 1998 10/48 10/52 6.8 % 1.08 [ 0.49, 2.37 ]
Riley 2015 18/81 24/72 17.9 % 0.67 [ 0.40, 1.12 ]
Zecca 2016 30/85 22/87 15.3 % 1.40 [ 0.88, 2.22 ]
Zhang 2014 6/57 3/57 2.1 % 2.00 [ 0.53, 7.61 ]
Subtotal (95% CI) 400 397 100.0 % 0.98 [ 0.82, 1.16 ]
Total events: 139 (Oxycodone), 141 (Comparison)
Heterogeneity: Chi2 = 5.96, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 0.25 (P = 0.80)
3 CR oxycodone vs transdermal (TD) fentanyl
Corli 2016 75/129 77/127 96.1 % 0.96 [ 0.78, 1.17 ]
Su 2015 13/42 3/38 3.9 % 3.92 [ 1.21, 12.71 ]
Subtotal (95% CI) 171 165 100.0 % 1.07 [ 0.88, 1.32 ]
Total events: 88 (Oxycodone), 80 (Comparison)
Heterogeneity: Chi2 = 5.86, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 2.57, df = 2 (P = 0.28), I2 =22%
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(3) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.5. Comparison 2 Adverse events, Outcome 5 Dizziness/lightheadedness.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 5 Dizziness/lightheadedness
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 5/78 11/82 50.7 % 0.48 [ 0.17, 1.31 ]
Parris 1998 (2) 8/54 10/55 46.9 % 0.81 [ 0.35, 1.91 ]
Salzman 1999 (3) 2/24 0/24 2.4 % 5.00 [ 0.25, 98.96 ]
Subtotal (95% CI) 156 161 100.0 % 0.74 [ 0.40, 1.37 ]
Total events: 15 (Oxycodone), 21 (Comparison)
Heterogeneity: Chi2 = 2.34, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 0.95 (P = 0.34)
2 CR oxycodone vs CR morphine
Mucci-LoRusso 1998 4/48 7/52 56.8 % 0.62 [ 0.19, 1.98 ]
Riley 2015 3/81 2/72 17.9 % 1.33 [ 0.23, 7.76 ]
Zhang 2014 2/57 3/57 25.3 % 0.67 [ 0.12, 3.84 ]
Subtotal (95% CI) 186 181 100.0 % 0.76 [ 0.33, 1.76 ]
Total events: 9 (Oxycodone), 12 (Comparison)
Heterogeneity: Chi2 = 0.53, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(3) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.6. Comparison 2 Adverse events, Outcome 6 Drowsiness/somnolence.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 6 Drowsiness/somnolence
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 14/78 17/82 46.7 % 0.87 [ 0.46, 1.64 ]
Parris 1998 (2) 13/54 12/55 33.5 % 1.10 [ 0.55, 2.20 ]
Salzman 1999 (3) 9/24 7/24 19.7 % 1.29 [ 0.57, 2.89 ]
Subtotal (95% CI) 156 161 100.0 % 1.03 [ 0.69, 1.54 ]
Total events: 36 (Oxycodone), 36 (Comparison)
Heterogeneity: Chi2 = 0.61, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 CR oxycodone vs CR morphine
Corli 2016 74/129 79/129 59.0 % 0.94 [ 0.77, 1.15 ]
Mucci-LoRusso 1998 7/48 10/52 7.2 % 0.76 [ 0.31, 1.83 ]
Riley 2015 12/81 13/72 10.3 % 0.82 [ 0.40, 1.68 ]
Zecca 2016 27/85 31/88 22.8 % 0.90 [ 0.59, 1.37 ]
Zhang 2014 1/57 1/57 0.7 % 1.00 [ 0.06, 15.60 ]
Subtotal (95% CI) 400 398 100.0 % 0.90 [ 0.75, 1.08 ]
Total events: 121 (Oxycodone), 134 (Comparison)
Heterogeneity: Chi2 = 0.34, df = 4 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 0.32, df = 1 (P = 0.57), I2 =0.0%
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(3) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.7. Comparison 2 Adverse events, Outcome 7 Dry mouth.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 7 Dry mouth
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 3/78 5/82 55.1 % 0.63 [ 0.16, 2.55 ]
Parris 1998 (2) 4/54 3/55 33.6 % 1.36 [ 0.32, 5.78 ]
Salzman 1999 (3) 3/24 1/24 11.3 % 3.00 [ 0.34, 26.84 ]
Subtotal (95% CI) 156 161 100.0 % 1.14 [ 0.48, 2.75 ]
Total events: 10 (Oxycodone), 9 (Comparison)
Heterogeneity: Chi2 = 1.49, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
2 CR oxycodone vs CR morphine
Corli 2016 66/129 66/129 74.5 % 1.00 [ 0.79, 1.27 ]
Mucci-LoRusso 1998 1/48 7/52 7.6 % 0.15 [ 0.02, 1.21 ]
Riley 2015 3/81 2/72 2.4 % 1.33 [ 0.23, 7.76 ]
Zecca 2016 19/85 14/88 15.5 % 1.41 [ 0.75, 2.62 ]
Subtotal (95% CI) 343 341 100.0 % 1.01 [ 0.80, 1.26 ]
Total events: 89 (Oxycodone), 89 (Comparison)
Heterogeneity: Chi2 = 4.38, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(3) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.8. Comparison 2 Adverse events, Outcome 8 Dysuria.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 8 Dysuria
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs CR morphine
Corli 2016 17/129 22/129 89.8 % 0.77 [ 0.43, 1.39 ]
Zhang 2014 0/57 2/57 10.2 % 0.20 [ 0.01, 4.08 ]
Subtotal (95% CI) 186 186 100.0 % 0.71 [ 0.40, 1.26 ]
Total events: 17 (Oxycodone), 24 (Comparison)
Heterogeneity: Chi2 = 0.75, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
2 CR oxycodone vs TD fentanyl
Corli 2016 17/129 13/127 80.6 % 1.29 [ 0.65, 2.54 ]
Su 2015 2/42 3/38 19.4 % 0.60 [ 0.11, 3.42 ]
Subtotal (95% CI) 171 165 100.0 % 1.15 [ 0.62, 2.16 ]
Total events: 19 (Oxycodone), 16 (Comparison)
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 1.24, df = 1 (P = 0.27), I2 =19%
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
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Analysis 2.9. Comparison 2 Adverse events, Outcome 9 Hallucinations.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 9 Hallucinations
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs CR morphine
Corli 2016 8/129 17/129 61.7 % 0.47 [ 0.21, 1.05 ]
Mucci-LoRusso 1998 0/48 2/52 8.7 % 0.22 [ 0.01, 4.39 ]
Riley 2015 3/81 4/72 15.4 % 0.67 [ 0.15, 2.88 ]
Zecca 2016 3/91 4/94 14.3 % 0.77 [ 0.18, 3.37 ]
Subtotal (95% CI) 349 347 100.0 % 0.52 [ 0.28, 0.97 ]
Total events: 14 (Oxycodone), 27 (Comparison)
Heterogeneity: Chi2 = 0.78, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.039)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
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Analysis 2.10. Comparison 2 Adverse events, Outcome 10 Headache.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 10 Headache
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 0/78 6/82 61.5 % 0.08 [ 0.00, 1.41 ]
Parris 1998 (2) 7/54 3/55 28.8 % 2.38 [ 0.65, 8.71 ]
Salzman 1999 (3) 1/24 1/24 9.7 % 1.00 [ 0.07, 15.08 ]
Subtotal (95% CI) 156 161 100.0 % 0.83 [ 0.34, 2.02 ]
Total events: 8 (Oxycodone), 10 (Comparison)
Heterogeneity: Chi2 = 5.08, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(3) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.11. Comparison 2 Adverse events, Outcome 11 Insomnia.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 11 Insomnia
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 2/78 4/82 79.7 % 0.53 [ 0.10, 2.79 ]
Parris 1998 (2) 3/54 1/55 20.3 % 3.06 [ 0.33, 28.47 ]
Subtotal (95% CI) 132 137 100.0 % 1.04 [ 0.31, 3.53 ]
Total events: 5 (Oxycodone), 5 (Comparison)
Heterogeneity: Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.12. Comparison 2 Adverse events, Outcome 12 Nausea.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 12 Nausea
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 14/78 21/82 53.4 % 0.70 [ 0.38, 1.28 ]
Parris 1998 (2) 11/54 13/55 33.6 % 0.86 [ 0.42, 1.75 ]
Salzman 1999 (3) 7/24 5/24 13.0 % 1.40 [ 0.52, 3.80 ]
Subtotal (95% CI) 156 161 100.0 % 0.85 [ 0.56, 1.28 ]
Total events: 32 (Oxycodone), 39 (Comparison)
Heterogeneity: Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
2 CR oxycodone vs CR morphine
Corli 2016 63/129 64/129 60.5 % 0.98 [ 0.77, 1.26 ]
Mucci-LoRusso 1998 6/48 8/52 7.3 % 0.81 [ 0.30, 2.17 ]
Riley 2015 10/81 6/72 6.0 % 1.48 [ 0.57, 3.87 ]
Zecca 2016 18/85 13/88 12.1 % 1.43 [ 0.75, 2.74 ]
Zhang 2014 11/57 15/57 14.2 % 0.73 [ 0.37, 1.46 ]
Subtotal (95% CI) 400 398 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 108 (Oxycodone), 106 (Comparison)
Heterogeneity: Chi2 = 2.81, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.85)
Test for subgroup differences: Chi2 = 0.62, df = 1 (P = 0.43), I2 =0.0%
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(3) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.13. Comparison 2 Adverse events, Outcome 13 Nervousness.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 13 Nervousness
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 3/78 5/82 54.9 % 0.63 [ 0.16, 2.55 ]
Salzman 1999 (2) 2/24 4/24 45.1 % 0.50 [ 0.10, 2.48 ]
Subtotal (95% CI) 102 106 100.0 % 0.57 [ 0.20, 1.64 ]
Total events: 5 (Oxycodone), 9 (Comparison)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.14. Comparison 2 Adverse events, Outcome 14 Pruritus.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 14 Pruritus
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 2/78 4/82 41.7 % 0.53 [ 0.10, 2.79 ]
Parris 1998 (2) 7/54 5/55 53.0 % 1.43 [ 0.48, 4.22 ]
Salzman 1999 (3) 4/24 0/24 5.3 % 9.00 [ 0.51, 158.52 ]
Subtotal (95% CI) 156 161 100.0 % 1.46 [ 0.65, 3.25 ]
Total events: 13 (Oxycodone), 9 (Comparison)
Heterogeneity: Chi2 = 2.98, df = 2 (P = 0.23); I2 =33%
Test for overall effect: Z = 0.92 (P = 0.36)
2 CR oxycodone vs CR morphine
Corli 2016 16/129 24/129 67.0 % 0.67 [ 0.37, 1.19 ]
Mucci-LoRusso 1998 4/48 5/52 13.4 % 0.87 [ 0.25, 3.04 ]
Riley 2015 3/81 2/72 5.9 % 1.33 [ 0.23, 7.76 ]
Zecca 2016 6/85 5/88 13.7 % 1.24 [ 0.39, 3.92 ]
Subtotal (95% CI) 343 341 100.0 % 0.81 [ 0.51, 1.29 ]
Total events: 29 (Oxycodone), 36 (Comparison)
Heterogeneity: Chi2 = 1.28, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 1.53, df = 1 (P = 0.22), I2 =35%
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(3) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.15. Comparison 2 Adverse events, Outcome 15 Sweating.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 15 Sweating
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 4/78 3/82 37.1 % 1.40 [ 0.32, 6.06 ]
Parris 1998 (2) 1/54 5/55 62.9 % 0.20 [ 0.02, 1.69 ]
Subtotal (95% CI) 132 137 100.0 % 0.65 [ 0.22, 1.93 ]
Total events: 5 (Oxycodone), 8 (Comparison)
Heterogeneity: Chi2 = 2.22, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.16. Comparison 2 Adverse events, Outcome 16 Vomiting.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 16 Vomiting
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 8/78 14/82 49.5 % 0.60 [ 0.27, 1.35 ]
Parris 1998 (2) 5/54 11/55 39.6 % 0.46 [ 0.17, 1.24 ]
Salzman 1999 (3) 5/24 3/24 10.9 % 1.67 [ 0.45, 6.21 ]
Subtotal (95% CI) 156 161 100.0 % 0.66 [ 0.38, 1.15 ]
Total events: 18 (Oxycodone), 28 (Comparison)
Heterogeneity: Chi2 = 2.45, df = 2 (P = 0.29); I2 =18%
Test for overall effect: Z = 1.46 (P = 0.14)
2 CR oxycodone vs CR morphine
Corli 2016 29/129 35/129 54.8 % 0.83 [ 0.54, 1.27 ]
Mucci-LoRusso 1998 6/48 5/52 7.5 % 1.30 [ 0.42, 3.98 ]
Riley 2015 9/81 4/72 6.6 % 2.00 [ 0.64, 6.22 ]
Zecca 2016 11/85 10/88 15.4 % 1.14 [ 0.51, 2.54 ]
Zhang 2014 5/57 10/57 15.7 % 0.50 [ 0.18, 1.37 ]
Subtotal (95% CI) 400 398 100.0 % 0.94 [ 0.68, 1.29 ]
Total events: 60 (Oxycodone), 64 (Comparison)
Heterogeneity: Chi2 = 4.08, df = 4 (P = 0.40); I2 =2%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 1.14, df = 1 (P = 0.29), I2 =12%
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(3) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
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Analysis 2.17. Comparison 2 Adverse events, Outcome 17 Discontinuation due to adverse events.
Review: Oxycodone for cancer-related pain
Comparison: 2 Adverse events
Outcome: 17 Discontinuation due to adverse events
Study or subgroup Oxycodone Comparison Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CR oxycodone vs IR oxycodone
Kaplan 1998 (1) 6/78 10/82 52.2 % 0.63 [ 0.24, 1.65 ]
Parris 1998 (2) 4/54 7/55 37.1 % 0.58 [ 0.18, 1.87 ]
Salzman 1999 (3) 1/24 2/24 10.7 % 0.50 [ 0.05, 5.15 ]
Subtotal (95% CI) 156 161 100.0 % 0.60 [ 0.29, 1.22 ]
Total events: 11 (Oxycodone), 19 (Comparison)
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
2 CR oxycodone vs CR morphine
Mucci-LoRusso 1998 3/48 6/52 66.1 % 0.54 [ 0.14, 2.05 ]
Zecca 2016 6/91 3/94 33.9 % 2.07 [ 0.53, 8.01 ]
Zhang 2014 0/57 0/57 Not estimable
Subtotal (95% CI) 196 203 100.0 % 1.06 [ 0.43, 2.60 ]
Total events: 9 (Oxycodone), 9 (Comparison)
Heterogeneity: Chi2 = 1.91, df = 1 (P = 0.17); I2 =48%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Chi2 = 0.95, df = 1 (P = 0.33), I2 =0.0%
0.01 0.1 1 10 100
Favours oxycodone Favours comparison
(1) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(3) Please note that CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
A D D I T I O N A L T A B L E S
Table 1. Controlled-release (CR) oxycodone versus immediate-release (IR) oxycodone: adverse events
Compari-
son
CR oxycodone versus IR oxycodone
Study Kaplan 1998 Parris 1998a Salzman 1999 Stambaugh 2001
Treatment CR IR CR IR CR IR CR IR
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Table 1. Controlled-release (CR) oxycodone versus immediate-release (IR) oxycodone: adverse events (Continued)
Any adverse
events
- - 38/54-55 38/54-55 - - 10/30 10/30
Total ad-
verse events
109 186 138 142 - - - -
Abdominal
pain
- - 3/54-55 1/54-55 - - - -
Anxiety 0/78 4/82 - - - - - -
Asthenia 3/78 8/82 - - 2/24 1/24 2/30 2/30
Confusion - - 0/54-55 2/54-55 3/24 2/24 - -
Constipa-
tion
9/78 17/82 12/54-55 10/54-55 4/24 9/24 1/30 1/30
Dizzi-
ness, light-
headedness
5/78 11/82 8/54-55 10/54-55 2/24 0/24 3/30 3/30
Drowsiness,
somnolence
14/78 17/82 13/54-55 12/54-55 9/24 7/24 3/30 2/30
Dry mouth 3/78 5/82 4/54-55 3/54-55 3/24 1/24 1/30 1/30
Headache 0/78 6/82 7/54-55 3/54-55 1/24 1/24 - -
Insomnia 2/78 4/82 3/54-55 1/54-55 - - - -
Nausea 14/78 21/82 11/54-55 13/54-55 7/24 5/24 4/30 3/30
Nervousness 3/78 5/82 - - 2/24 4/24 0/30 1/30
Postural hy-
potension
- - - - 5/24 4/24 - -
Pruritus 2/78 4/82 7/54-55 5/54-55 4/24 0/24 1/30 2/30
Sweating 4/78 3/82 1/54-55 5/54-55 - - 2/30 1/30
Vomiting 8/78 14/82 5/54-55 11/54-55 5/24 3/24 2/30 0/30
Discontinu-
ation due to
adverse
events
6/78 10/82 4/54-55 7/54-55 1/24 2/24 - -
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a Total number of participants for safety evaluation = 109. Not clear which group had 55 and 54 participants, respectively.
-: not reported; CR: controlled-release; IR: immediate-release.
Table 2. Controlled-release (CR) oxycodone versus CR morphine: adverse events
Com-
par-
i-
son
CR oxycodone versus CR morphine
Study
Bruera
1998
Corli
2016
Heiska-
nen 1997
Lauretti
2003
Mer-
cadante
2010a
Mucci-
LoRusso
1998
Riley
2014
Zhang 2014 Zecca
2016
Treat-
ment
Oxy Mor Oxy Mor Oxy Mor Oxy Mor Oxy Mor Oxy Mor Oxy Mor Oxy Mor
MS
Con-
tin
Oxy Mor
Any
ad-
verse
events
- - - - - - - - - - 40/
48
39/
52
- - 25/
57
34/
57
31/
57
77/
81
79/
94
Se-
vere/
mod-
er-
ate
ad-
verse
events
- - 48.
8%
58.
9%
- - - - - - - - - - - - - - -
Ab-
nor-
mal
dreams
- - - - - - - - - - - - 3/
81
1/
72
- - - - -
Anorexia,
ap-
petite
loss
- - - - 0/
27
1/
27
14/
22
13/
22
- - - - 1/
81
0/
72
- - - - -
Breath-
less-
ness
- se-
vere
- - 12/
129
3/
129
17/
129
4/
129
- - - - - - - - - - - - - - -
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Table 2. Controlled-release (CR) oxycodone versus CR morphine: adverse events (Continued)
Chills
- - - - 1/
27
0/
27
- - - - - - - - - - - - -
Con-
fu-
sion
- se-
ri-
ous
- - 55/
129
12/
129
59/
129
20/
129
- - - - 0.
37
(0.
49)
0.
25
(0.
44)
- - 7/
81
3/
81
2/
72
0/
72
- - - 12/
85
12/
88
Con-
sti-
pa-
tion
- se-
ri-
ous
- - 75/
129
40/
129
82/
129
50/
129
18/
27
14/
27
4/
22
5/
22
0.
63
(0.
68)
0.7
(0.
92)
10/
48
10/
52
18/
81
2/
81
24/
72
5/
72
6/
57
3/
57
5/
57
30/
85
22/
87
De-
creased
mo-
bil-
ity
- - - - - - - - - - - - 0/
81
2/
72
- - - - -
De-
pres-
sion
- - - - 1/
27
0/
27
- - - - - - - - - - - - -
Di-
ar-
rhoea
- - - - 2/
27
2/
27
- - - - - - - - - - - - -
Dizzi-
ness,
light-
head-
ed-
ness
- - - - 6/
27
6/
27
- - - - 4/
48
7/
52
3/
81
2/
72
2/
57
3/
57
4/
57
- -
Dou-
ble
vi-
sion
- - - - - - - - - - - - 0/
81
1/
72
- - - - -
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Table 2. Controlled-release (CR) oxycodone versus CR morphine: adverse events (Continued)
Drowsi-
ness,
som-
no-
lence
-
seri-
ous
(with/
with-
out
hal-
lu-
ci-
na-
tions)
- - 74/
129
34/
129
79/
129
38/
129
- - 7/
22
11/
22
0.
37
(0.
6)
0.
35
(0.
59)
7/
48
10/
52
12/
81
1/
81
13/
72
0/
72
1/
57
1/
57
1/
57
27/
85
31/
88
Drunken
feel-
ing
- - - - 1/
27
1/
27
- - - - - - - - - - - - -
Dry
mouth
- se-
vere
- - 66/
129
27/
129
66/
129
31/
129
12/
27
15/
27
3/
22
2/
22
0.
63
(0.
68)
0.6
(0.
68)
1/
48
7/
52
3/
81
2/
72
- - - 19/
85
14/
88
Dys-
p-
noea
- - - - 2/
27
2/
27
0/
22
0/
22
- - - - - - - - - - -
Dy-
suria
- se-
vere
- - 17/
129
4/
129
22/
129
2/
129
- - - - - - - - - - 0/
57
2/
57
1/
57
- -
Ex-
trasys-
toles
- - - - 1/
27
0/
27
- - - - - - - - - - - - -
Fae-
cal
in-
con-
ti-
nence
- - - - 1/
27
1/
27
- - - - - - - - - - - - -
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Table 2. Controlled-release (CR) oxycodone versus CR morphine: adverse events (Continued)
Fall - - - - - - - - - - - - 0/
81
3/
72
- - - - -
Feel-
ing
ab-
nor-
mal
- - - - - - - - - - - - 0/
81
1/
72
- - - - -
Fla-
tus
- - - - 0/
27
1/
27
- - - - - - - - - - - - -
Gas-
tral-
gia
- se-
vere
- - 21/
129
6/
129
24/
129
3/
129
- - - - - - - - - - - - - - -
Hal-
lu-
ci-
na-
tions
- se-
vere
- - 8/
129
1/
129
17/
129
6/
129
- - 0/
22
0/
22
- - 0/
48
2/
52
3/
81
4/
72
- - - 3/
91
4/
94
Hol-
low
feel-
ing
- - - - 1/
27
0/
27
- - - - - - - - - - - - -
Lethargy
- - - - - - - - - - - - 1/
81
0/
72
- - - - -
Mem-
ory
im-
pair-
ment
- - - - - - - - - - - - 1/
81
1/
72
- - - - -
Mus-
cle
twitches
- - - - 1/
27
1/
27
- - - - - - 0/
81
2/
72
- - - - -
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Table 2. Controlled-release (CR) oxycodone versus CR morphine: adverse events (Continued)
Mus-
cle
spasm
my-
oclonus
- se-
vere
- - 23/
129
0/
129
14/
129
6/
129
- - - - - - - - - - - - - - -
Nau-
sea
-
seri-
ous
(with
vom-
it-
ing)
/se-
vere
12.
3
13.
9
63/
129
22/
129
64/
129
19/
129
14/
27
16/
27
1/
22
8/
22
0.
84
(0.
9)
0.6
(0.
75)
6/
48
8/
52
10/
81
1/
81
6/
72
0/
72
11/
57
15/
57
14/
57
18/
85
13/
88
Night-
mares
- - - - 0/
27
3/
27
- - - - - - 2/
81
0/
72
- - - -
Pain
- - - - - - - - - - - - 0/
81
1/
72
- - - - -
Pares-
the-
sia
- - - - - - - - - - - - 1/
81
0/
72
- - - - -
Pru-
ri-
tus
- se-
vere
- - 16/
129
2/
129
24/
129
3/
129
10/
27
7/
27
1/
22
1/
22
- - 4/
48
5/
52
3/
81
2/
72
- - - 6/
85
5/
88
Se-
da-
tion
21.
4
25 - - 16/
27
18/
27
- - - - - - - - - - - - -
Sen-
sa-
tion
of
empty
- - - - - - 1/
22
0/
11
- - - - - - - - - - -
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Table 2. Controlled-release (CR) oxycodone versus CR morphine: adverse events (Continued)
head
Slow
speech
- - - - - - - - - - - - 1/
81
0/
72
- - - - -
Sweat-
ing,
hy-
per-
hidro-
sis
- - - - 12/
27
9/
27
- - - - - - 2/
81
0/
72
- - - - -
Se-
ri-
ous
tox-
icity
sec-
ondary
to
in-
fec-
tion
- - - - - - - - - - - - 1/
81
0/
72
- - - - -
Uri-
nary
hes-
ita-
tion
- - - - - - - - - - - - 0/
81
1/
72
- - - - -
Vi-
sual
im-
pair-
ment
- - - - - - - - - - - - 1/
81
0/
72
- - - - -
Vom-
it-
ing
- se-
vere
- - 29/
129
12/
129
35/
129
12/
129
5/
27
10/
27
0/
22
7/
22
- - 6/
48
5/
52
9/
81
4/
72
5/
57
10/
57
6/
57
11/
85
10/
88
Dis-
con-
tin-
ua-
tion
- - - - - - - - - - 3/
48
6/
52
- - 0/
57
0/
57
0/
57
6/
91
3/
94
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Table 2. Controlled-release (CR) oxycodone versus CR morphine: adverse events (Continued)
due
to
ad-
verse
events
Un-
ex-
pected
seri-
ous
ad-
verse
events
- - - - - - - - - - - - 2/
81
7/
72
- - - - -
a Mean (SD) ratings (out of 3) experienced during week 4.
-: not reported; CR: controlled release; Oxy: oxycodone; Mor: morphine.
Table 3. Single-study comparisons: adverse events
Com-
pari-
son
CR oxycodone
versus CR hy-
dromorphone
CR oxycodone
versus ER hy-
dromorphone
CR oxycodone
versus ER oxy-
morphone
CR oxycodone
versus ER
tapentadol
IV oxycodone
versus rectal
oxycodone
IV oxycodone followed by IR
oxycodone versus IV morphine
followed by IR morphine
Study Hagen 1997 Yu 2014 Gabrail 2004 Imanaka 2013 Leow 1995b Kalso 1990c
Treat-
ment
Oxy Hyd Oxy Hyd Oxy
Oxymo
Oxy Tap IV Rectal IV
oxy
IR
oxy
IV
mor
IR
mor
Any
ad-
verse
events
- - 117/
126
111/
128
- - 155/
172
147/
168
- - - - - -
To-
tal ad-
verse
events
- - - - - - - - 82 94 - - - -
Severe
ad-
verse
events
- - 30/
126
30/
128
- - - - - - - - - -
Seri-
ous
ad-
verse
- - 18/
126
11/
128
- - - - - - - - - -
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Table 3. Single-study comparisons: adverse events (Continued)
events
Ab-
domi-
nal
dis-
com-
fort
- - 7/126 4/128 - - - - - - - - - -
Ab-
domi-
nal
dis-
ten-
sion
- - 7/126 7/128 - - - - - - - - - -
Anaemia
- - 14/
126
14/
128
- - - - - - - - - -
Anorexia,
ap-
petite
loss
- - 21/
126
20/
128
- - 24/
172
23/
168
- - - - - -
Asthe-
nia
- - 9/126 11/
128
- - - - - - - - - -
Bone
mar-
row
failure
- - 9/126 9/128 - - - - - - - - - -
Chest
dis-
com-
fort
- - 6/126 9/128 - - - - - - - - - -
Con-
fusion
- - - - - - - - - - 0/19 1/19 0/19 1/19
Con-
stipa-
tion
- - 45/
126
43/
128
19/41 21/43 64/
172
51/
168
- - 6/19 6/19 8/19 8/19
Delir-
ium
- - - - - - 6/172 10/
168
- - - - - -
Diar-
rhoea
- - 9/126 12/
128
- - 19/
172
11/
168
- - - - - -
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Table 3. Single-study comparisons: adverse events (Continued)
Dizzi-
ness or
light-
head-
edness
- - 22/
126
21/
128
9/41 7/43 - - 0.54
(0.74)
0.71
(0.9)
- - - -
Drowsi-
ness,
som-
no-
lence
28/31 19/31 - - - - 36/
172
29/
168
0.68
(0.81)
0.79
(0.93)
7/19 4/19 4/19 5/19
Hallu-
cina-
tions
0/31 2/31 - - - - - - - - 0/19 0/19 2/19 3/19
Hy-
popro-
teinaemia
- - 5/126 9/128 - - - - - - - - - -
In-
som-
nia
- - - - - - 11/
172
9/168 - - - - - -
Nau-
sea
15 (3)
a
13 (3)
a
45/
126
43/
128
15/41 17/43 61/
172
48/
168
0.02
(0.15)
0.12
(0.45)
7/19 7/19 7/19 12/19
Neu-
trophil
count
de-
creased
- - 5/126 7/128 - - - - - - - - - -
Oedema,
pe-
riph-
eral
- - 6/126 11/
128
- - - - - - - - - -
Platelet
count
de-
creased
- - 7/126 8/128 - - - - - - - - - -
Pruri-
tus
- - - - 8/41 13/43 - - 0.05
(0.21)
0.05
(0.21)
3/19 1/19 3/19 2/19
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Table 3. Single-study comparisons: adverse events (Continued)
Pyrexia
- - 27/
126
24/
128
- - - - - - - - - -
Rash - - 4/126 7/128 - - - - - - - - -
Seda-
tion
24 (4)
a
18 (3)
a
- - 13/41 18/43 - - - - 12/19 13/19 12/19 14/19
Sweat-
ing or
hyper-
hidro-
sis
- - 8/126 3/128 9/41 12/43 - - 0.04
(0.19)
0.07
(0.3)
4/19 2/19 1/19 1/19
Uri-
nary
reten-
tion
- - - - - - - - - - 1/19 1/19 2/19 0/19
Uri-
nary
tract
infec-
tion
- - 7/126 4/128 - - - - - - - - - -
Vom-
iting
- - 47/
126
43/
128
7/41 5/43 41/
172
42/
168
0.01
(0.11)
0.01 (0.11) - - -
White
blood
cell
count
de-
creased
- - 17/
126
13/
128
- - - - - - - - - -
Dis-
con-
tinua-
tion
due to
ad-
verse
events
- - 18/
126
19/
128
- - 29/
172
22/
168
- - - - - -
Deaths
due to
study
drug
- - 0/126 0/128 - - - - - - - - - -
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Table 3. Single-study comparisons: adverse events (Continued)
treat-
ment
aMean (standard error) visual analogue scale across all days.
bMean (standard deviation) ratings (out of 3) experienced during the 24 hours of drug administration, apart from the total number of
adverse events which is read from the authors’ Figure 3.
cThe measure is the sum of positive responses after each study period: moderate = 1, severe = 2.
-: not reported; CR: controlled release; ER: extended release; Hyd: hydromorphone; IV: intravenous; Oxy: oxycodone; Oxymo:
oxymorphone; Mor: morphine; Tap: tapentadol.
Table 4. Controlled-release (CR) oxycodone versus transdermal fentanyl or buprenorphine
Comparison CR oxycodone versus TD fentanyl CR oxycodone versus TD buprenorphine
Study Corli 2016 Su 2015 Corli 2016
Treatment Oxy Fen Oxy Fen Oxy Bup
Severe/moderate
adverse events
48.8% 50.4% - - 48.8% 60%
Breathlessness 12/129 22/127 - - 12/129 30/130
Breathlessness,
severe
3/129 5/127 - - 3/129 6/130
Confusion 55/129 46/127 - - 55/129 61/130
Confusion,
severe
12/129 8/127 - - 12/129 12/130
Constipation 75/129 77/127 13/42 3/38 75/129 87/130
Constipation,
severe
40/129 36/127 - - 40/129 39/130
Dizziness - - 4/42 3/38 - -
Drowsiness 74/129 70/127 - - 74/129 81/130
Drowsiness, se-
vere
34/129 26/127 - - 34/129 40/130
Dry mouth 66/129 67/127 - - 66/129 73/130
Dry mouth, se-
vere
27/129 29/127 - - 27/129 30/130
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Table 4. Controlled-release (CR) oxycodone versus transdermal fentanyl or buprenorphine (Continued)
Dysuria 17/129 13/127 2/42 3/38 17/129 16/130
Dysuria, severe 4/129 4/127 - - 4/129 4/130
Gastralgia 21/129 26/127 - - 21/129 21/130
Gastralgia,
severe
6/129 4/127 - - 6/129 1/130
Hallucinations 8/129 3/127 - - 8/129 8/130
Hallucinations,
severe
1/129 0/127 - - 1/129 2/130
Itching 16/129 14/127 - - 16/129 21/130
Itching, severe 2/129 3/127 - - 2/129 1/130
Lethargy - - 3/42 2/38 - -
Muscle spasm
myoclonus
23/129 15/127 - - 23/129 24/130
Mus-
cle spasm my-
oclonus, severe
0/129 3/127 - - 0/129 1/130
Nausea and
vomiting
- - 11/42 2/38 - -
Nausea 63/129 57/127 - - 63/129 59/130
Nausea, severe 22/129 16/127 - - 22/129 18/130
Vomiting 29/129 29/127 - - 29/129 30/130
Vomiting, severe 12/129 10/127 - - 12/129 5/130
-: not reported; Bup: buprenorphine; CR: controlled release; Fen: fentanyl; Oxy: oxycodone; TD: transdermal.
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A P P E N D I C E S
Appendix 1. Search strategies
Original search run in March 2014
CENTRAL (the Cochrane Library)
#1 MeSH descriptor: [Oxycodone] explode all trees
#2 (ox?codon* or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid):ti,ab,kw (Word variations have been searched)
#3 (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon):ti,ab,kw (Word variations have been searched)
#4 (endocet or endocodone or endone or eu?odal or eubine):ti,ab,kw (Word variations have been searched)
#5 (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone):ti,ab,kw (Word
variations have been searched)
#6 (remoxy or roxicet or rox?codone or roxilox):ti,ab,kw (Word variations have been searched)
#7 (supeudol or thecodinum or theocodin or tylox):ti,ab,kw (Word variations have been searched)
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 MeSH descriptor: [Neoplasms] explode all trees
#10 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or
malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*):ti,ab,kw (Word variations have been searched)
#11 #9 or #10
#12 #8 and #11
MEDLINE and MEDLINE In-Process (Ovid)
1 Oxycodone/
2 (ox?codon$ or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid).tw.
3 (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon).tw.
4 (endocet or endocodone or endone or eu?odal or eubine).tw.
5 (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone).tw.
6 (remoxy or roxicet or rox?codone or roxilox).tw.
7 (supeudol or thecodinum or theocodin or tylox).tw.
8 or/1-7
9 exp Neoplasms/
10 (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
11 or/9-10
12 8 and 11
13 randomized controlled trial.pt.
14 controlled clinical trial.pt.
15 randomized.ab.
16 placebo.ab.
17 drug therapy.fs.
18 randomly.ab.
19 trial.ab.
20 or/13-19
21 exp animals/ not humans.sh.
22 20 not 21
23 12 and 22
Embase (Ovid)
1 Oxycodone/
2 (ox?codon$ or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid).tw.
3 (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon).tw.
4 (endocet or endocodone or endone or eu?odal or eubine).tw.
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5 (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone).tw.
6 (remoxy or roxicet or rox?codone or roxilox).tw.
7 (supeudol or thecodinum or theocodin or tylox).tw.
8 or/1-7
9 exp Neoplasms/
10 (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
11 or/9-10
12 8 and 11
13 random$.tw.
14 factorial$.tw.
15 crossover$.tw.
16 cross over$.tw.
17 cross-over$.tw.
18 placebo$.tw.
19 (doubl$ adj blind$).tw.
20 (singl$ adj blind$).tw.
21 assign$.tw.
22 allocat$.tw.
23 volunteer$.tw.
24 Crossover Procedure/
25 double-blind procedure.tw.
26 Randomized Controlled Trial/
27 Single Blind Procedure/
28 or/13-27
29 (animal/ or nonhuman/) not human/
30 28 not 29
31 12 and 30
Web of Science (ISI) SSCI and SCI
#22 #21 AND #9
#21 #20 OR #17 OR #16 OR #15 OR #14 OR #11 OR #10
#20 #19 AND #18
#19 TS=random* OR TI=random*
#18 TS=(allocate* OR assign*) OR TI=(allocate* OR assign*)
#17 TS=crossover* OR TI=crossover*
#16 TS=(mask* OR blind*) OR TI=(mask* OR blind*)
#15 TS=(singl* OR Doubl* OR Tripl* OR Trebl*) OR TI=(singl* OR Doubl* OR Tripl* OR Trebl*)
#14 #13 AND #12
#13 TS=trial* OR TI=trial*
#12 TI=clin* OR TS=clin*
#11 TI=randomi* OR TS=randomi*
#10 TS=Randomized clinical trial* OR TI=Randomized clinical trial*
#9 #8 AND #7
#8 Topic=((cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta*
or malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*))
#7 #6 OR #5 OR #4 OR #3 OR #2 OR #1
#6 Topic=((supeudol or thecodinum or theocodin or tylox))
#5 Topic=((remoxy or roxicet or rox?codone or roxilox))
#4 Topic=((“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone))
#3 Topic=((endocet or endocodone or endone or eu?odal or eubine))
#2 Topic=((dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon))
#1 Topic=((ox?codon* or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm
or oxynormoro or oxyrapid))
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BIOSIS (ISI)
#21 #20 AND #19 AND #12
#20 Topic=(((cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta*
or malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*)))
#19 #18 OR #17 OR #16 OR #15 OR #14 OR #13
#18 Topic=(((supeudol or thecodinum or theocodin or tylox)))
#17 Topic=(((remoxy or roxicet or rox?codone or roxilox)))
#16 Topic=(((“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone)))
#15 Topic=(((endocet or endocodone or endone or eu?odal or eubine)))
#14 Topic=(((dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon)))
#13 Topic=(((ox?codon* or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm
or oxynormoro or oxyrapid)))
#12 #11 OR #8 OR #7 OR #6 OR #5 OR #2 OR #1
#11 #10 AND #9
#10 DS=random* OR TS=random* OR TI=random*
#9 DS=(allocate* OR assign*) OR TS=(allocate* OR assign*) OR TI=(allocate* OR assign*)
#8 DS=crossover* OR TS=crossover* OR TI=crossover*
#7 DS=(mask* OR blind*) OR TS=(mask* OR blind*) OR TI=(mask* OR blind*)
#6 DS=(singl* OR Doubl* OR Tripl* OR Trebl*) OR TS=(singl* OR Doubl* OR Tripl* OR Trebl*) OR TI=(singl* OR Doubl* OR
Tripl* OR Trebl*)
#5 #4 AND #3
#4 DS=trial* OR TS=trial* OR TI=trial*
#3 DS=clin* OR TI=clin* OR TS=clin*
#2 DS=randomi* OR TI=randomi* OR TS=randomi*
#1MQ=Randomized clinical trial* ORDS=Randomized clinical trial* ORTS=Randomized clinical trial* ORTI=Randomized clinical
trial*
PsycINFO (Ovid)
1 (ox?codon$ or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid).tw.
2 (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon).tw.
3 (endocet or endocodone or endone or eu?odal or eubine).tw.
4 (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone).tw.
5 (remoxy or roxicet or rox?codone or roxilox).tw.
6 (supeudol or thecodinum or theocodin or tylox).tw.
7 exp Neoplasms/
8 (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
9 or/7-8
10 or/1-6
11 9 and 10
12 clinical trials/
13 (randomis* or randomiz*).tw.
14 (random$ adj3 (allocat$ or assign$)).tw.
15 ((clinic$ or control$) adj trial$).tw.
16 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
17 (crossover$ or “cross over$”).tw.
18 random sampling/
19 Experiment Controls/
20 Placebo/
21 placebo$.tw.
22 exp program evaluation/
23 treatment effectiveness evaluation/
24 ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw.
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25 or/12-24
26 11 and 25
PubMed
(((Oxycodone[MeSH Terms]) OR ((ox?codon* OR oxycontin OR oxycodeinon OR oxycone OR oxycdn OR ox?conum OR oxydose
ORoxyfastORoxygesicORoxynormORoxynormoroORoxyrapid))OR ((dazidoxORdihydrohydroxycodeinoneORdihydroneOR
dinarkon)) OR ((endocet OR endocodone OR endone OR eu?odal OR eubine)) OR ((“m oxy” OR oxecta OR oxydihydrocodeinonum
OR pancodine OR pavinal OR percocet OR percolone OR proladone)) OR ((remoxy OR roxicet OR rox?codone OR roxilox)) OR
((supeudol OR thecodinum OR theocodin OR tylox))) AND and AND ((Neoplasms[MeSH Terms]) OR ((cancer* OR neoplas*
OR tumo* OR carcinoma* OR hodgkin* OR nonhodgkin* OR adenocarcinoma* OR leuk?emia*1 OR metasta* OR malignan* OR
lymphoma* OR sarcoma* ORmelanoma* ORmyeloma* OR oncolog*)))) AND and AND (((randomized controlled trial[Publication
Type]) OR (controlled clinical trial[Publication Type]) OR (randomized[Title/Abstract]) OR (placebo[Title/Abstract]) OR (drug ther-
apy[Title/Abstract]) OR (randomly[Title/Abstract]) OR (trial[Title/Abstract]) OR (groups[Title/Abstract])) NOT ((animals[MeSH
Terms]) NOT humans[MeSH Terms]))
Update search run in November 2016
CENTRAL (the Cochrane Library)
#1 MeSH descriptor: [Oxycodone] explode all trees
#2 (ox?codon* or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid):ti,ab,kw (Word variations have been searched)
#3 (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon):ti,ab,kw (Word variations have been searched)
#4 (endocet or endocodone or endone or eu?odal or eubine):ti,ab,kw (Word variations have been searched)
#5 (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone):ti,ab,kw (Word
variations have been searched)
#6 (remoxy or roxicet or rox?codone or roxilox):ti,ab,kw (Word variations have been searched)
#7 (supeudol or thecodinum or theocodin or tylox):ti,ab,kw (Word variations have been searched)
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 MeSH descriptor: [Neoplasms] explode all trees
#10 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or
malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*):ti,ab,kw (Word variations have been searched)
#11 #9 or #10
#12 #8 and #11
MEDLINE and MEDLINE In-Process (Ovid)
1 Oxycodone/
2 (ox?codon$ or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid).tw.
3 (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon).tw.
4 (endocet or endocodone or endone or eu?odal or eubine).tw.
5 (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone).tw.
6 (remoxy or roxicet or rox?codone or roxilox).tw.
7 (supeudol or thecodinum or theocodin or tylox).tw.
8 or/1-7
9 exp Neoplasms/
10 (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
11 or/9-10
12 8 and 11
13 randomized controlled trial.pt.
14 controlled clinical trial.pt.
15 randomized.ab.
16 placebo.ab.
17 drug therapy.fs.
18 randomly.ab.
19 trial.ab.
20 or/13-19
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21 exp animals/ not humans.sh.
22 20 not 21
23 12 and 22
24 (201403* or 201404* or 201405* or 201406* or 201407* or 201408* or 201409* or 201410* or 201411* or 201412* or 2015*
or 2016*).ed.
25 23 and 24
Embase (Ovid)
1. Oxycodone/
2. (ox?codon$ or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid).tw.
3. (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon).tw.
4. (endocet or endocodone or endone or eu?odal or eubine).tw.
5. (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone).tw.
6. (remoxy or roxicet or rox?codone or roxilox).tw.
7. (supeudol or thecodinum or theocodin or tylox).tw.
8. or/1-7
9. exp Neoplasms/
10. (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
11. or/9-10
12. 8 and 11
13. random$.tw.
14. factorial$.tw.
15. crossover$.tw.
16. cross over$.tw.
17. cross-over$.tw.
18. placebo$.tw.
19. (doubl$ adj blind$).tw.
20. (singl$ adj blind$).tw.
21. assign$.tw.
22. allocat$.tw.
23. volunteer$.tw.
24. Crossover Procedure/
25. double-blind procedure.tw.
26. Randomized Controlled Trial/
27. Single Blind Procedure/
28. or/13-27
29. (animal/ or nonhuman/) not human/
30. 28 not 29
31. 12 and 30
32 (201403* or 201404* or 201405* or 201406* or 201407* or 201408* or 201409* or 201410* or 201411* or 201412* or 2015*
or 2016*).dd.
33 31 and 32
Web of Science (ISI) SSCI & SCI
#22 #21 AND #9
#21 #20 OR #17 OR #16 OR #15 OR #14 OR #11 OR #10
#20 #19 AND #18
#19 TS=random* OR TI=random*
#18 TS=(allocate* OR assign*) OR TI=(allocate* OR assign*)
#17 TS=crossover* OR TI=crossover*
#16 TS=(mask* OR blind*) OR TI=(mask* OR blind*)
#15 TS=(singl* OR Doubl* OR Tripl* OR Trebl*) OR TI=(singl* OR Doubl* OR Tripl* OR Trebl*)
#14 #13 AND #12
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#13 TS=trial* OR TI=trial*
#12 TI=clin* OR TS=clin*
#11 TI=randomi* OR TS=randomi*
#10 TS=Randomized clinical trial* OR TI=Randomized clinical trial*
#9 #8 AND #7
#8 Topic=((cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta*
or malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*))
#7 #6 OR #5 OR #4 OR #3 OR #2 OR #1
#6 Topic=((supeudol or thecodinum or theocodin or tylox))
#5 Topic=((remoxy or roxicet or rox?codone or roxilox))
#4 Topic=((“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone))
#3 Topic=((endocet or endocodone or endone or eu?odal or eubine))
#2 Topic=((dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon))
#1 Topic=((ox?codon* or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm
or oxynormoro or oxyrapid))
BIOSIS (ISI)
#21 #20 AND #19 AND #12
#20 Topic=(((cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta*
or malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*)))
#19 #18 OR #17 OR #16 OR #15 OR #14 OR #13
#18 Topic=(((supeudol or thecodinum or theocodin or tylox)))
#17 Topic=(((remoxy or roxicet or rox?codone or roxilox)))
#16 Topic=(((“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone)))
#15 Topic=(((endocet or endocodone or endone or eu?odal or eubine)))
#14 Topic=(((dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon)))
#13 Topic=(((ox?codon* or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm
or oxynormoro or oxyrapid)))
#12 #11 OR #8 OR #7 OR #6 OR #5 OR #2 OR #1
#11 #10 AND #9
#10 DS=random* OR TS=random* OR TI=random*
#9 DS=(allocate* OR assign*) OR TS=(allocate* OR assign*) OR TI=(allocate* OR assign*)
#8 DS=crossover* OR TS=crossover* OR TI=crossover*
#7 DS=(mask* OR blind*) OR TS=(mask* OR blind*) OR TI=(mask* OR blind*)
#6 DS=(singl* OR Doubl* OR Tripl* OR Trebl*) OR TS=(singl* OR Doubl* OR Tripl* OR Trebl*) OR TI=(singl* OR Doubl* OR
Tripl* OR Trebl*)
#5 #4 AND #3
#4 DS=trial* OR TS=trial* OR TI=trial*
#3 DS=clin* OR TI=clin* OR TS=clin*
#2 DS=randomi* OR TI=randomi* OR TS=randomi*
#1MQ=Randomized clinical trial* ORDS=Randomized clinical trial* ORTS=Randomized clinical trial* ORTI=Randomized clinical
trial*
PsycINFO (Ovid)
1. (ox?codon$ or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid).tw.
2. (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon).tw.
3. (endocet or endocodone or endone or eu?odal or eubine).tw.
4. (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone).tw.
5. (remoxy or roxicet or rox?codone or roxilox).tw.
6. (supeudol or thecodinum or theocodin or tylox).tw.
7. exp Neoplasms/
8. (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
9. or/7-8
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10. or/1-6
11. 9 and 10
12. clinical trials/
13. (randomis* or randomiz*).tw.
14. (random$ adj3 (allocat$ or assign$)).tw.
15. ((clinic$ or control$) adj trial$).tw.
16. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
17. (crossover$ or “cross over$”).tw.
18. random sampling/
19. Experiment Controls/
20. Placebo/
21. placebo$.tw.
22. exp program evaluation/
23. treatment effectiveness evaluation/
24. ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw.
25. or/12-24
26. 11 and 25
WH A T ’ S N E W
Last assessed as up-to-date: 29 November 2016.
Date Event Description
25 October 2017 Amended Minor correction to Discussion
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 2, 2015
Date Event Description
30 January 2017 New citation required but conclusions have not
changed
An update search run on 29 November 2016 iden-
tified 267 new records of which 6 new eligible stud-
ies (Corli 2016; Lux 2014; Su 2015; Yu 2014; Zecca
2016; Zhang 2014), have been included in this review.
The studies added a further 1258 participants to the
review and examined four new comparisons with oxy-
codone, namely transdermal (TD) fentanyl (2 stud-
ies), TD buprenorphine, extended-release (ER) oxy-
codone, and ER hydromorphone, and also contained
data to include in the original controlled-release (CR)
oxycodone versus CR morphine comparison. The ad-
ditional studies allowed us to meta-analyse the adverse
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(Continued)
event data (which were summarised narratively and in
tables in the original review), to examine the robust-
ness of our primary outcome pain intensity meta-anal-
yses in sensitivity analyses, and to include an additional
meta-analysis of pain intensity for the comparison of
CR oxycodone and TD fentanyl. None of the meta-
analyses of pain intensity and adverse events were sig-
nificant with two exceptions: 1) Pain intensity was sta-
tistically significantly, but not clinically significantly,
higher after treatment with CR oxycodone compared
toCRmorphine. Sensitivity analysis of this result how-
ever did not find a statistically significant difference
in pain intensity between the two treatments, and 2)
the risk ratio of experiencing hallucinations was signif-
icantly higher after treatment with CRmorphine than
CR oxycodone. Otherwise, the conclusions of the up-
dated review remain the same as that of the original
review. Previous readers of the review may enjoy re-
reading this update
18 January 2017 New search has been performed An update search run on 29 November 2016 revealed
6 new eligible studies. These have now been added
22 February 2013 New citation required and major changes This protocol has been significantly updated by new
authors. See Published notes.
11 February 2010 New citation required and major changes This protocol was originally published in Issue 4,
2002. As the authors were unable to commit time to
the completion of the full review it was then with-
drawn in January 2009. The original authors are now
able to work on completing the full review and plan
to do so by the end of 2010
13 January 2009 New citation required and major changes Withdrawn: the review group was unable to maintain
contactwith the contact author.Newauthors are being
sought to take over this protocol, please contact the
PaPaS Review Group if you are interested in working
on this review title
22 September 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
MSH and MIB conceived and designed the review and wrote the protocol.
SA devised and undertook the search strategy.
MSH, NB, and JSH screened the search results and performed the data extraction and ’risk of bias’ assessment of the included studies.
MSH devised and performed the analysis strategy, and wrote the first draft of the full review.
MIB interpreted the results and wrote the ’Authors conclusions’ section.
All the authors approved the final version of the review.
For the update
SA undertook the search strategy.
MSH and NB screened the search results and performed the data extraction and ’risk of bias’ assessment of the included studies.
MSH devised and performed the analysis strategy, and wrote the first draft of the updated review.
MIB interpreted the results and wrote the ’Authors conclusions’ section.
All the authors approved the final version of the review
D E C L A R A T I O N S O F I N T E R E S T
MSH: none known.
MIB is a specialist palliative medicine physician and manages people with cancer pain. MIB received lecture fees from Pfizer in 2016.
SA: none known.
NB: none known.
JSH: none known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
2015: In the ’risk of bias’ assessments, we also included an item that captured whether data were available for both time periods in
cross-over trials, in order to make explicit this potential source of bias. We reported treatment acceptability as a proxy for quality of life
as this outcome was rarely reported.
N O T E S
The protocol was originally published in 2002, Issue 4. As the authors were unable to commit time to the completion of the full review
it was then withdrawn in January 2009. The original authors intended to publish in 2010 (Reid 2010), but experienced further delays.
The current author team has completed the full review.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Analgesics, Opioid [administration & dosage; adverse effects; ∗therapeutic use]; Cancer Pain [∗drug therapy]; Constipation [chem-
ically induced]; Delayed-Action Preparations; Drug Administration Schedule; Morphine [administration & dosage; adverse effects;
therapeutic use]; Nausea [chemically induced]; Neoplasms [∗complications]; Oxycodone [administration & dosage; adverse effects;
∗therapeutic use]; Pain Measurement; Quality of Life; Randomized Controlled Trials as Topic; Sleep Stages; Vomiting [chemically
induced]
MeSH check words
Aged; Female; Humans; Male; Middle Aged
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